BFO 2 Reference: BFO does not claim to provide complete coverage of entities of all types. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning - coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation.
BFO 2 Reference: BFO's treatment of continuants and occurrents - as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality - earlier called the 'SNAP' and 'SPAN' perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science.
BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. 'Entity' is an example of a primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms.
Alan Ruttenberg
Albert Goldfain
Asiyah Yu Lin (CDRH, Food and Drug Administration)
Astghik Sargsyan (Fraunhofer SCAI)
Barry Smith
Bill Duncan
Bjoern Peters
Chris Mungall
David Osumi-Sutherland
Fabian Neuhaus
Geena Mariya Jose (Causality Biomodels)
Holger Stenzhorn
James A. Overton
Janna Hastings
Jie Zheng
Jonathan Bona
Larry Hunter
Leon Li (NIH)
Leonard Jacuzzo
Ludger Jansen
Mark Ressler
Mathias Brochhausen
Mauricio Almeida
Melanie Courtot
Oliver He (University of Michigan)
Pierre Grenon
Randall Dipert
Ron Rudnicki
Selja Seppälä
Shounak Baksi (Causality Biomodels)
Stefan Schulz
Thomas Bittner
Werner Ceusters
Yongqun "Oliver" He
The core Ontology of Clinical Trials (CTO) will serve as a structured resource integrating basic terms and concepts in the context of clinical trials. Thereby covering clinicaltrails.gov. CoreCTO will serve as a basic ontology to generate extended versions for specific applications such as annotation of variables in study documents from clinical trials.
Alpha Tom Kodamullil (Fraunhofer SCAI)
Johannes Darms (Fraunhofer SCAI)
Stephan Gebel (Fraunhofer SCAI)
Sumit Madan (Fraunhofer SCAI)
http://creativecommons.org/licenses/by/4.0/
http://creativecommons.org/licenses/by/4.0
CTO: Core Ontology of Clinical Trials
Please see the project site https://github.com/BFO-ontology/BFO, the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel, the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx. This ontology is generated from a specification at https://github.com/BFO-ontology/BFO/tree/master/src/ontology/owl-group/specification/ and with the code that generates the OWL version in https://github.com/BFO-ontology/BFO/tree/master/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif.
The BSD license on the BFO project site refers to code used to build BFO.
This BFO 2.0 version represents a major update to BFO and is not strictly backwards compatible with BFO 1.1. The previous OWL version of BFO, version 1.1.1 will remain available at http://ifomis.org/bfo/1.1 and will no longer be updated. The BFO 2.0 OWL is a classes-only specification. The incorporation of core relations has been held over for a later version.
http://purl.obolibrary.org/obo/bfo/dev/bfo.clif
https://github.com/BFO-ontology/BFO/tree/master/src/ontology/owl-group/specification/
http://groups.google.com/group/bfo-devel
http://groups.google.com/group/bfo-discuss
http://groups.google.com/group/bfo-owl-devel
http://purl.obolibrary.org/obo/bfo/dev/owl
https://github.com/BFO-ontology/BFO/tree/master/src/tools/
Version Release: 1.0.0
http://basic-formal-ontology.org/
http://ifomis.org/bfo
https://github.com/BFO-ontology/BFO
mailto:bfo-owl-devel@googlegroups.com
obo:BFO_0000001
entity
obo:BFO_0000001
Entity
obo:BFO_0000001
Julius Caesar
obo:BFO_0000001
Verdi’s Requiem
obo:BFO_0000001
the Second World War
obo:BFO_0000001
your body mass index
obo:BFO_0000001
BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81
http://purl.obolibrary.org/obo/bfo/axiom/0000004
per discussion with Barry Smith
http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf
obo:BFO_0000001
Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf
http://purl.obolibrary.org/obo/bfo/axiom/001-001
obo:BFO_0000001
An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])
obo:BFO_0000001
obo:bfo.owl
obo:BFO_0000001
entity
obo:BFO_0000002
continuant
obo:BFO_0000002
Continuant
obo:BFO_0000002
An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts.
obo:BFO_0000002
BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240
obo:BFO_0000002
Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants
http://purl.obolibrary.org/obo/bfo/axiom/0000007
obo:BFO_0000002
Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants
obo:BFO_0000002
obo:iao.owl
obo:BFO_0000002
A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])
http://purl.obolibrary.org/obo/bfo/axiom/008-002
obo:BFO_0000002
A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])
obo:BFO_0000002
if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])
http://purl.obolibrary.org/obo/bfo/axiom/126-001
obo:BFO_0000002
if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])
obo:BFO_0000002
if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])
http://purl.obolibrary.org/obo/bfo/axiom/009-002
obo:BFO_0000002
if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])
obo:BFO_0000002
if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])
http://purl.obolibrary.org/obo/bfo/axiom/011-002
obo:BFO_0000002
if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])
obo:BFO_0000002
(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002]
http://purl.obolibrary.org/obo/bfo/axiom/009-002
obo:BFO_0000002
(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002]
obo:BFO_0000002
(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001]
http://purl.obolibrary.org/obo/bfo/axiom/126-001
obo:BFO_0000002
(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001]
obo:BFO_0000002
(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002]
http://purl.obolibrary.org/obo/bfo/axiom/008-002
obo:BFO_0000002
(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002]
obo:BFO_0000002
(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002]
http://purl.obolibrary.org/obo/bfo/axiom/011-002
obo:BFO_0000002
(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002]
obo:BFO_0000002
obo:bfo.owl
obo:BFO_0000002
continuant
obo:BFO_0000003
occurrent
obo:BFO_0000003
Occurrent
obo:BFO_0000003
BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region
obo:BFO_0000003
BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players.
http://purl.obolibrary.org/obo/bfo/axiom/0000006
per discussion with Barry Smith
obo:BFO_0000003
Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process.
http://purl.obolibrary.org/obo/bfo/axiom/0000012
obo:BFO_0000003
Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame.
http://purl.obolibrary.org/obo/bfo/axiom/077-002
obo:BFO_0000003
An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])
http://purl.obolibrary.org/obo/bfo/axiom/108-001
obo:BFO_0000003
Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])
http://purl.obolibrary.org/obo/bfo/axiom/079-001
obo:BFO_0000003
b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])
http://purl.obolibrary.org/obo/bfo/axiom/108-001
obo:BFO_0000003
(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001]
http://purl.obolibrary.org/obo/bfo/axiom/079-001
obo:BFO_0000003
(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001]
obo:BFO_0000003
obo:bfo.owl
obo:BFO_0000003
occurrent
obo:BFO_0000004
ic
obo:BFO_0000004
IndependentContinuant
obo:BFO_0000004
a chair
obo:BFO_0000004
a heart
obo:BFO_0000004
a leg
obo:BFO_0000004
a molecule
obo:BFO_0000004
a spatial region
obo:BFO_0000004
an atom
obo:BFO_0000004
an orchestra.
obo:BFO_0000004
an organism
obo:BFO_0000004
the bottom right portion of a human torso
obo:BFO_0000004
the interior of your mouth
http://purl.obolibrary.org/obo/bfo/axiom/017-002
obo:BFO_0000004
b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])
http://purl.obolibrary.org/obo/bfo/axiom/134-001
obo:BFO_0000004
For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])
http://purl.obolibrary.org/obo/bfo/axiom/018-002
obo:BFO_0000004
For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])
http://purl.obolibrary.org/obo/bfo/axiom/134-001
obo:BFO_0000004
(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001]
http://purl.obolibrary.org/obo/bfo/axiom/018-002
obo:BFO_0000004
(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002]
http://purl.obolibrary.org/obo/bfo/axiom/017-002
obo:BFO_0000004
(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002]
obo:BFO_0000004
obo:bfo.owl
obo:BFO_0000004
independent continuant
obo:BFO_0000006
s-region
obo:BFO_0000006
SpatialRegion
obo:BFO_0000006
BFO 2 Reference: Spatial regions do not participate in processes.
http://purl.obolibrary.org/obo/bfo/axiom/0000002
per discussion with Barry Smith
obo:BFO_0000006
Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional.
http://purl.obolibrary.org/obo/bfo/axiom/035-001
obo:BFO_0000006
A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001])
http://purl.obolibrary.org/obo/bfo/axiom/036-001
obo:BFO_0000006
All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001])
http://purl.obolibrary.org/obo/bfo/axiom/036-001
obo:BFO_0000006
(forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001]
http://purl.obolibrary.org/obo/bfo/axiom/035-001
obo:BFO_0000006
(forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001]
obo:BFO_0000006
obo:bfo.owl
obo:BFO_0000006
spatial region
obo:BFO_0000008
t-region
obo:BFO_0000008
TemporalRegion
http://purl.obolibrary.org/obo/bfo/axiom/0000003
per discussion with Barry Smith
obo:BFO_0000008
Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional
http://purl.obolibrary.org/obo/bfo/axiom/100-001
obo:BFO_0000008
A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001])
http://purl.obolibrary.org/obo/bfo/axiom/101-001
obo:BFO_0000008
All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])
http://purl.obolibrary.org/obo/bfo/axiom/119-002
obo:BFO_0000008
Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])
http://purl.obolibrary.org/obo/bfo/axiom/119-002
obo:BFO_0000008
(forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002]
http://purl.obolibrary.org/obo/bfo/axiom/101-001
obo:BFO_0000008
(forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001]
http://purl.obolibrary.org/obo/bfo/axiom/100-001
obo:BFO_0000008
(forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001]
obo:BFO_0000008
obo:bfo.owl
obo:BFO_0000008
temporal region
obo:BFO_0000009
2d-s-region
obo:BFO_0000009
TwoDimensionalSpatialRegion
obo:BFO_0000009
an infinitely thin plane in space.
obo:BFO_0000009
the surface of a sphere-shaped part of space
http://purl.obolibrary.org/obo/bfo/axiom/039-001
obo:BFO_0000009
A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001])
http://purl.obolibrary.org/obo/bfo/axiom/039-001
obo:BFO_0000009
(forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001]
obo:BFO_0000009
obo:bfo.owl
obo:BFO_0000009
two-dimensional spatial region
obo:BFO_0000011
st-region
obo:BFO_0000011
SpatiotemporalRegion
obo:BFO_0000011
the spatiotemporal region occupied by a human life
obo:BFO_0000011
the spatiotemporal region occupied by a process of cellular meiosis.
obo:BFO_0000011
the spatiotemporal region occupied by the development of a cancer tumor
http://purl.obolibrary.org/obo/bfo/axiom/095-001
obo:BFO_0000011
A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001])
http://purl.obolibrary.org/obo/bfo/axiom/096-001
obo:BFO_0000011
All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])
http://purl.obolibrary.org/obo/bfo/axiom/099-001
obo:BFO_0000011
Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])
http://purl.obolibrary.org/obo/bfo/axiom/098-001
obo:BFO_0000011
Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])
obo:BFO_0000011
Every spatiotemporal region occupies_spatiotemporal_region itself.
http://purl.obolibrary.org/obo/bfo/axiom/107-002
obo:BFO_0000011
Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])
http://purl.obolibrary.org/obo/bfo/axiom/107-002
obo:BFO_0000011
(forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002]
http://purl.obolibrary.org/obo/bfo/axiom/099-001
obo:BFO_0000011
(forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001]
http://purl.obolibrary.org/obo/bfo/axiom/096-001
obo:BFO_0000011
(forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001]
http://purl.obolibrary.org/obo/bfo/axiom/095-001
obo:BFO_0000011
(forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001]
http://purl.obolibrary.org/obo/bfo/axiom/098-001
obo:BFO_0000011
(forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001]
obo:BFO_0000011
obo:bfo.owl
obo:BFO_0000011
spatiotemporal region
obo:BFO_0000015
process
obo:BFO_0000015
Process
obo:BFO_0000015
a process of cell-division, \ a beating of the heart
obo:BFO_0000015
a process of meiosis
obo:BFO_0000015
a process of sleeping
obo:BFO_0000015
the course of a disease
obo:BFO_0000015
the flight of a bird
obo:BFO_0000015
the life of an organism
obo:BFO_0000015
your process of aging.
obo:BFO_0000015
An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t.
obo:BFO_0000015
p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])
http://purl.obolibrary.org/obo/bfo/axiom/083-003
obo:BFO_0000015
p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])
obo:BFO_0000015
BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war)
obo:BFO_0000015
obo:bfo.owl
obo:BFO_0000015
obo:oae.owl
obo:BFO_0000015
obo:obi.owl
obo:BFO_0000015
obo:ro.owl
obo:BFO_0000015
(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003]
http://purl.obolibrary.org/obo/bfo/axiom/083-003
obo:BFO_0000015
(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003]
obo:BFO_0000015
obo:bfo.owl
obo:BFO_0000015
process
obo:BFO_0000016
disposition
obo:BFO_0000016
Disposition
obo:BFO_0000016
an atom of element X has the disposition to decay to an atom of element Y
obo:BFO_0000016
certain people have a predisposition to colon cancer
obo:BFO_0000016
children are innately disposed to categorize objects in certain ways.
obo:BFO_0000016
the cell wall is disposed to filter chemicals in endocytosis and exocytosis
obo:BFO_0000016
BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type.
obo:BFO_0000016
obo:ogms.owl
http://purl.obolibrary.org/obo/bfo/axiom/062-002
obo:BFO_0000016
b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])
http://purl.obolibrary.org/obo/bfo/axiom/063-002
obo:BFO_0000016
If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])
http://purl.obolibrary.org/obo/bfo/axiom/063-002
obo:BFO_0000016
(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002]
http://purl.obolibrary.org/obo/bfo/axiom/062-002
obo:BFO_0000016
(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002]
obo:BFO_0000016
obo:bfo.owl
obo:BFO_0000016
disposition
obo:BFO_0000017
realizable
obo:BFO_0000017
RealizableEntity
obo:BFO_0000017
the disposition of this piece of metal to conduct electricity.
obo:BFO_0000017
the disposition of your blood to coagulate
obo:BFO_0000017
the function of your reproductive organs
obo:BFO_0000017
the role of being a doctor
obo:BFO_0000017
the role of this boundary to delineate where Utah and Colorado meet
obo:BFO_0000017
A specifically dependent continuant that inheres in continuant entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances.
obo:BFO_0000017
obo:dron.owl
obo:BFO_0000017
obo:envo.owl
obo:BFO_0000017
obo:obi.owl
obo:BFO_0000017
obo:ogms.owl
obo:BFO_0000017
obo:omrse.owl
obo:BFO_0000017
obo:opmi.owl
obo:BFO_0000017
To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])
http://purl.obolibrary.org/obo/bfo/axiom/058-002
obo:BFO_0000017
To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])
obo:BFO_0000017
All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])
http://purl.obolibrary.org/obo/bfo/axiom/060-002
obo:BFO_0000017
All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])
obo:BFO_0000017
(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002]
http://purl.obolibrary.org/obo/bfo/axiom/060-002
obo:BFO_0000017
(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002]
obo:BFO_0000017
(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002]
http://purl.obolibrary.org/obo/bfo/axiom/058-002
obo:BFO_0000017
(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002]
obo:BFO_0000017
obo:bfo.owl
obo:BFO_0000017
realizable entity
obo:BFO_0000018
0d-s-region
obo:BFO_0000018
ZeroDimensionalSpatialRegion
http://purl.obolibrary.org/obo/bfo/axiom/037-001
obo:BFO_0000018
A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001])
http://purl.obolibrary.org/obo/bfo/axiom/037-001
obo:BFO_0000018
(forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001]
obo:BFO_0000018
obo:bfo.owl
obo:BFO_0000018
zero-dimensional spatial region
obo:BFO_0000019
quality
obo:BFO_0000019
Quality
obo:BFO_0000019
the ambient temperature of this portion of air
obo:BFO_0000019
the color of a tomato
obo:BFO_0000019
the length of the circumference of your waist
obo:BFO_0000019
the mass of this piece of gold.
obo:BFO_0000019
the shape of your nose
obo:BFO_0000019
the shape of your nostril
http://purl.obolibrary.org/obo/bfo/axiom/055-001
obo:BFO_0000019
a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])
http://purl.obolibrary.org/obo/bfo/axiom/105-001
obo:BFO_0000019
If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])
http://purl.obolibrary.org/obo/bfo/axiom/055-001
obo:BFO_0000019
(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001]
http://purl.obolibrary.org/obo/bfo/axiom/105-001
obo:BFO_0000019
(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001]
obo:BFO_0000019
obo:bfo.owl
obo:BFO_0000019
quality
obo:BFO_0000020
sdc
obo:BFO_0000020
SpecificallyDependentContinuant
obo:BFO_0000020
Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key
obo:BFO_0000020
of one-sided specifically dependent continuants: the mass of this tomato
obo:BFO_0000020
of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates.
obo:BFO_0000020
the disposition of this fish to decay
obo:BFO_0000020
the function of this heart: to pump blood
obo:BFO_0000020
the mutual dependence of proton donors and acceptors in chemical reactions [79
obo:BFO_0000020
the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction
obo:BFO_0000020
the pink color of a medium rare piece of grilled filet mignon at its center
obo:BFO_0000020
the role of being a doctor
obo:BFO_0000020
the shape of this hole.
obo:BFO_0000020
the smell of this portion of mozzarella
http://purl.obolibrary.org/obo/bfo/axiom/050-003
obo:BFO_0000020
b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])
http://purl.obolibrary.org/obo/bfo/axiom/0000005
per discussion with Barry Smith
obo:BFO_0000020
Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc.
http://purl.obolibrary.org/obo/bfo/axiom/050-003
obo:BFO_0000020
(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003]
obo:BFO_0000020
obo:bfo.owl
obo:BFO_0000020
specifically dependent continuant
obo:BFO_0000023
role
obo:BFO_0000023
Role
obo:BFO_0000023
John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.
obo:BFO_0000023
the priest role
obo:BFO_0000023
the role of a boundary to demarcate two neighboring administrative territories
obo:BFO_0000023
the role of a building in serving as a military target
obo:BFO_0000023
the role of a stone in marking a property boundary
obo:BFO_0000023
the role of subject in a clinical trial
obo:BFO_0000023
the student role
obo:BFO_0000023
A realizable entity the manifestation of which brings about some result or end that is not essential to a continuant in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant in some kinds of natural, social or institutional contexts.
obo:BFO_0000023
BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives.
obo:BFO_0000023
obo:dron.owl
obo:BFO_0000023
obo:obi.owl
obo:BFO_0000023
obo:omrse.owl
obo:BFO_0000023
obo:opmi.owl
obo:BFO_0000023
b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])
http://purl.obolibrary.org/obo/bfo/axiom/061-001
obo:BFO_0000023
b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])
obo:BFO_0000023
(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001]
http://purl.obolibrary.org/obo/bfo/axiom/061-001
obo:BFO_0000023
(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001]
obo:BFO_0000023
obo:bfo.owl
obo:BFO_0000023
role
obo:BFO_0000024
fiat-object-part
obo:BFO_0000024
FiatObjectPart
obo:BFO_0000024
or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29
obo:BFO_0000024
the FMA:regional parts of an intact human body.
obo:BFO_0000024
the Western hemisphere of the Earth
obo:BFO_0000024
the division of the brain into regions
obo:BFO_0000024
the division of the planet into hemispheres
obo:BFO_0000024
the dorsal and ventral surfaces of the body
obo:BFO_0000024
the upper and lower lobes of the left lung
obo:BFO_0000024
BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions
http://purl.obolibrary.org/obo/bfo/axiom/027-004
obo:BFO_0000024
b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])
http://purl.obolibrary.org/obo/bfo/axiom/027-004
obo:BFO_0000024
(forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004]
obo:BFO_0000024
obo:bfo.owl
obo:BFO_0000024
fiat object part
obo:BFO_0000026
1d-s-region
obo:BFO_0000026
OneDimensionalSpatialRegion
obo:BFO_0000026
an edge of a cube-shaped portion of space.
http://purl.obolibrary.org/obo/bfo/axiom/038-001
obo:BFO_0000026
A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001])
http://purl.obolibrary.org/obo/bfo/axiom/038-001
obo:BFO_0000026
(forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001]
obo:BFO_0000026
obo:bfo.owl
obo:BFO_0000026
one-dimensional spatial region
obo:BFO_0000027
object-aggregate
obo:BFO_0000027
ObjectAggregate
obo:BFO_0000027
a collection of cells in a blood biobank.
obo:BFO_0000027
a swarm of bees is an aggregate of members who are linked together through natural bonds
obo:BFO_0000027
a symphony orchestra
obo:BFO_0000027
an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team)
obo:BFO_0000027
defined by fiat: the aggregate of members of an organization
obo:BFO_0000027
defined through physical attachment: the aggregate of atoms in a lump of granite
obo:BFO_0000027
defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container
obo:BFO_0000027
defined via attributive delimitations such as: the patients in this hospital
obo:BFO_0000027
the aggregate of bearings in a constant velocity axle joint
obo:BFO_0000027
the aggregate of blood cells in your body
obo:BFO_0000027
the nitrogen atoms in the atmosphere
obo:BFO_0000027
the restaurants in Palo Alto
obo:BFO_0000027
your collection of Meissen ceramic plates.
http://purl.obolibrary.org/obo/bfo/axiom/0000011
obo:BFO_0000027
An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects
http://purl.obolibrary.org/obo/bfo/axiom/0000301
obo:BFO_0000027
An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects
obo:BFO_0000027
BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee).
http://purl.obolibrary.org/obo/bfo/axiom/0000300
obo:BFO_0000027
ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158.
http://purl.obolibrary.org/obo/bfo/axiom/025-004
obo:BFO_0000027
b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004])
http://purl.obolibrary.org/obo/bfo/axiom/025-004
obo:BFO_0000027
(forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004]
obo:BFO_0000027
obo:bfo.owl
obo:BFO_0000027
object aggregate
obo:BFO_0000028
3d-s-region
obo:BFO_0000028
ThreeDimensionalSpatialRegion
obo:BFO_0000028
a cube-shaped region of space
obo:BFO_0000028
a sphere-shaped region of space,
http://purl.obolibrary.org/obo/bfo/axiom/040-001
obo:BFO_0000028
A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001])
http://purl.obolibrary.org/obo/bfo/axiom/040-001
obo:BFO_0000028
(forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001]
obo:BFO_0000028
obo:bfo.owl
obo:BFO_0000028
three-dimensional spatial region
obo:BFO_0000029
site
obo:BFO_0000029
Site
obo:BFO_0000029
Manhattan Canyon)
obo:BFO_0000029
a hole in the interior of a portion of cheese
obo:BFO_0000029
a rabbit hole
obo:BFO_0000029
an air traffic control region defined in the airspace above an airport
obo:BFO_0000029
the Grand Canyon
obo:BFO_0000029
the Piazza San Marco
obo:BFO_0000029
the cockpit of an aircraft
obo:BFO_0000029
the hold of a ship
obo:BFO_0000029
the interior of a kangaroo pouch
obo:BFO_0000029
the interior of the trunk of your car
obo:BFO_0000029
the interior of your bedroom
obo:BFO_0000029
the interior of your office
obo:BFO_0000029
the interior of your refrigerator
obo:BFO_0000029
the lumen of your gut
obo:BFO_0000029
your left nostril (a fiat part – the opening – of your left nasal cavity)
http://purl.obolibrary.org/obo/bfo/axiom/034-002
obo:BFO_0000029
b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002])
http://purl.obolibrary.org/obo/bfo/axiom/034-002
obo:BFO_0000029
(forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002]
obo:BFO_0000029
obo:bfo.owl
obo:BFO_0000029
site
obo:BFO_0000030
object
obo:BFO_0000030
Object
obo:BFO_0000030
atom
obo:BFO_0000030
cell
obo:BFO_0000030
cells and organisms
obo:BFO_0000030
engineered artifacts
obo:BFO_0000030
grain of sand
obo:BFO_0000030
molecule
obo:BFO_0000030
organelle
obo:BFO_0000030
organism
obo:BFO_0000030
planet
obo:BFO_0000030
solid portions of matter
obo:BFO_0000030
star
obo:BFO_0000030
BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting.
obo:BFO_0000030
BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below).
obo:BFO_0000030
BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47
obo:BFO_0000030
BFO 2 Reference: an object is a maximal causally unified material entity
obo:BFO_0000030
BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74
obo:BFO_0000030
obo:dron.owl
obo:BFO_0000030
obo:envo.owl
obo:BFO_0000030
obo:opmi.owl
obo:BFO_0000030
b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])
http://purl.obolibrary.org/obo/bfo/axiom/024-001
obo:BFO_0000030
b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])
obo:BFO_0000030
obo:bfo.owl
obo:BFO_0000030
object
obo:BFO_0000031
gdc
obo:BFO_0000031
GenericallyDependentContinuant
obo:BFO_0000031
The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity.
obo:BFO_0000031
the pdf file on your laptop, the pdf file that is a copy thereof on my laptop
obo:BFO_0000031
the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule.
obo:BFO_0000031
A continuant that is dependent on one or other independent continuant bearers. For every instance of A requires some instance of (an independent continuant type) B but which instance of B serves can change from time to time.
obo:BFO_0000031
b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])
http://purl.obolibrary.org/obo/bfo/axiom/074-001
obo:BFO_0000031
b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])
obo:BFO_0000031
obo:iao.owl
obo:BFO_0000031
(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001]
http://purl.obolibrary.org/obo/bfo/axiom/074-001
obo:BFO_0000031
(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001]
obo:BFO_0000031
obo:bfo.owl
obo:BFO_0000031
generically dependent continuant
obo:BFO_0000034
function
obo:BFO_0000034
Function
obo:BFO_0000034
the function of a hammer to drive in nails
obo:BFO_0000034
the function of a heart pacemaker to regulate the beating of a heart through electricity
obo:BFO_0000034
the function of amylase in saliva to break down starch into sugar
obo:BFO_0000034
BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc.
http://purl.obolibrary.org/obo/bfo/axiom/064-001
obo:BFO_0000034
A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])
http://purl.obolibrary.org/obo/bfo/axiom/064-001
obo:BFO_0000034
(forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001]
obo:BFO_0000034
obo:bfo.owl
obo:BFO_0000034
function
obo:BFO_0000035
p-boundary
obo:BFO_0000035
ProcessBoundary
obo:BFO_0000035
the boundary between the 2nd and 3rd year of your life.
http://purl.obolibrary.org/obo/bfo/axiom/084-001
obo:BFO_0000035
p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])
http://purl.obolibrary.org/obo/bfo/axiom/085-002
obo:BFO_0000035
Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002])
http://purl.obolibrary.org/obo/bfo/axiom/085-002
obo:BFO_0000035
(forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002]
http://purl.obolibrary.org/obo/bfo/axiom/084-001
obo:BFO_0000035
(iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001]
obo:BFO_0000035
obo:bfo.owl
obo:BFO_0000035
process boundary
obo:BFO_0000038
1d-t-region
obo:BFO_0000038
OneDimensionalTemporalRegion
obo:BFO_0000038
the temporal region during which a process occurs.
obo:BFO_0000038
BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks).
http://purl.obolibrary.org/obo/bfo/axiom/103-001
obo:BFO_0000038
A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001])
http://purl.obolibrary.org/obo/bfo/axiom/103-001
obo:BFO_0000038
(forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001]
obo:BFO_0000038
obo:bfo.owl
obo:BFO_0000038
one-dimensional temporal region
obo:BFO_0000040
material
obo:BFO_0000040
MaterialEntity
obo:BFO_0000040
a flame
obo:BFO_0000040
a forest fire
obo:BFO_0000040
a human being
obo:BFO_0000040
a hurricane
obo:BFO_0000040
a photon
obo:BFO_0000040
a puff of smoke
obo:BFO_0000040
a sea wave
obo:BFO_0000040
a tornado
obo:BFO_0000040
an aggregate of human beings.
obo:BFO_0000040
an energy wave
obo:BFO_0000040
an epidemic
obo:BFO_0000040
the undetached arm of a human being
obo:BFO_0000040
An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time.
obo:BFO_0000040
BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60
obo:BFO_0000040
BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity.
obo:BFO_0000040
BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here.
obo:BFO_0000040
obo:bfo.owl
obo:BFO_0000040
obo:dron.owl
obo:BFO_0000040
obo:envo.owl
obo:BFO_0000040
obo:ero.owl
obo:BFO_0000040
obo:oae.owl
obo:BFO_0000040
obo:obi.owl
obo:BFO_0000040
obo:omrse.owl
obo:BFO_0000040
obo:opmi.owl
obo:BFO_0000040
A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])
http://purl.obolibrary.org/obo/bfo/axiom/019-002
obo:BFO_0000040
A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])
obo:BFO_0000040
Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])
http://purl.obolibrary.org/obo/bfo/axiom/020-002
obo:BFO_0000040
Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])
obo:BFO_0000040
every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])
http://purl.obolibrary.org/obo/bfo/axiom/021-002
obo:BFO_0000040
every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])
obo:BFO_0000040
(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002]
http://purl.obolibrary.org/obo/bfo/axiom/019-002
obo:BFO_0000040
(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002]
obo:BFO_0000040
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002]
http://purl.obolibrary.org/obo/bfo/axiom/021-002
obo:BFO_0000040
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002]
obo:BFO_0000040
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002]
http://purl.obolibrary.org/obo/bfo/axiom/020-002
obo:BFO_0000040
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002]
obo:BFO_0000040
obo:bfo.owl
obo:BFO_0000040
material entity
obo:BFO_0000040
material_entity
obo:BFO_0000051
has part
obo:BFO_0000055
realizes
obo:BFO_0000062
preceded by
obo:BFO_0000062
preceded_by
obo:BFO_0000140
cf-boundary
obo:BFO_0000140
ContinuantFiatBoundary
http://purl.obolibrary.org/obo/bfo/axiom/029-001
obo:BFO_0000140
b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])
obo:BFO_0000140
BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions.
obo:BFO_0000140
BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29
http://purl.obolibrary.org/obo/bfo/axiom/0000008
obo:BFO_0000140
Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions.
obo:BFO_0000140
Every continuant fiat boundary is located at some spatial region at every time at which it exists
http://purl.obolibrary.org/obo/bfo/axiom/029-001
obo:BFO_0000140
(iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001]
obo:BFO_0000140
obo:bfo.owl
obo:BFO_0000140
continuant fiat boundary
obo:BFO_0000141
immaterial
obo:BFO_0000141
ImmaterialEntity
obo:BFO_0000141
BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10
obo:BFO_0000141
obo:bfo.owl
obo:BFO_0000141
immaterial entity
obo:BFO_0000142
1d-cf-boundary
obo:BFO_0000142
OneDimensionalContinuantFiatBoundary
obo:BFO_0000142
The Equator
obo:BFO_0000142
all geopolitical boundaries
obo:BFO_0000142
all lines of latitude and longitude
obo:BFO_0000142
the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin.
obo:BFO_0000142
the median sulcus of your tongue
http://purl.obolibrary.org/obo/bfo/axiom/032-001
obo:BFO_0000142
a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001])
http://purl.obolibrary.org/obo/bfo/axiom/032-001
obo:BFO_0000142
(iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001]
obo:BFO_0000142
obo:bfo.owl
obo:BFO_0000142
one-dimensional continuant fiat boundary
obo:BFO_0000144
process-profile
obo:BFO_0000144
ProcessProfile
obo:BFO_0000144
On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels
obo:BFO_0000144
One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance.
obo:BFO_0000144
The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on.
http://purl.obolibrary.org/obo/bfo/axiom/093-002
obo:BFO_0000144
b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002])
http://purl.obolibrary.org/obo/bfo/axiom/094-005
obo:BFO_0000144
b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])
http://purl.obolibrary.org/obo/bfo/axiom/094-005
obo:BFO_0000144
(forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005]
http://purl.obolibrary.org/obo/bfo/axiom/093-002
obo:BFO_0000144
(iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002]
obo:BFO_0000144
obo:bfo.owl
obo:BFO_0000144
process profile
obo:BFO_0000145
r-quality
obo:BFO_0000145
RelationalQuality
obo:BFO_0000145
John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.
obo:BFO_0000145
a marriage bond, an instance of requited love, an obligation between one person and another.
http://purl.obolibrary.org/obo/bfo/axiom/057-001
obo:BFO_0000145
b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])
http://purl.obolibrary.org/obo/bfo/axiom/057-001
obo:BFO_0000145
(iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001]
obo:BFO_0000145
obo:bfo.owl
obo:BFO_0000145
relational quality
obo:BFO_0000146
2d-cf-boundary
obo:BFO_0000146
TwoDimensionalContinuantFiatBoundary
http://purl.obolibrary.org/obo/bfo/axiom/033-001
obo:BFO_0000146
a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001])
http://purl.obolibrary.org/obo/bfo/axiom/033-001
obo:BFO_0000146
(iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001]
obo:BFO_0000146
obo:bfo.owl
obo:BFO_0000146
two-dimensional continuant fiat boundary
obo:BFO_0000147
0d-cf-boundary
obo:BFO_0000147
ZeroDimensionalContinuantFiatBoundary
obo:BFO_0000147
the geographic North Pole
obo:BFO_0000147
the point of origin of some spatial coordinate system.
obo:BFO_0000147
the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet
http://purl.obolibrary.org/obo/bfo/axiom/0000001
requested by Melanie Courtot
https://groups.google.com/d/msg/bfo-owl-devel/s9Uug5QmAws/ZDRnpiIi_TUJ
obo:BFO_0000147
zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona.
http://purl.obolibrary.org/obo/bfo/axiom/031-001
obo:BFO_0000147
a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001])
http://purl.obolibrary.org/obo/bfo/axiom/031-001
obo:BFO_0000147
(iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001]
obo:BFO_0000147
obo:bfo.owl
obo:BFO_0000147
zero-dimensional continuant fiat boundary
obo:BFO_0000148
0d-t-region
obo:BFO_0000148
ZeroDimensionalTemporalRegion
obo:BFO_0000148
a temporal region that is occupied by a process boundary
obo:BFO_0000148
right now
obo:BFO_0000148
the moment at which a child is born
obo:BFO_0000148
the moment at which a finger is detached in an industrial accident
obo:BFO_0000148
the moment of death.
obo:BFO_0000148
temporal instant.
obo:BFO_0000148
obo:obi.owl
obo:BFO_0000148
obo:opmi.owl
obo:BFO_0000148
A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])
http://purl.obolibrary.org/obo/bfo/axiom/102-001
obo:BFO_0000148
A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])
obo:BFO_0000148
(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001]
http://purl.obolibrary.org/obo/bfo/axiom/102-001
obo:BFO_0000148
(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001]
obo:BFO_0000148
obo:bfo.owl
obo:BFO_0000148
zero-dimensional temporal region
obo:BFO_0000179
BFO OWL specification label
obo:BFO_0000179
Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification.
obo:BFO_0000179
Really of interest to developers only
obo:BFO_0000179
BFO OWL specification label
obo:BFO_0000179
BFO OWL specification label
obo:BFO_0000180
BFO CLIF specification label
obo:BFO_0000180
Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2
obo:BFO_0000180
Person:Alan Ruttenberg
obo:BFO_0000180
Really of interest to developers only
obo:BFO_0000180
BFO CLIF specification label
obo:BFO_0000180
BFO CLIF specification label
obo:BFO_0000182
history
obo:BFO_0000182
History
http://purl.obolibrary.org/obo/bfo/axiom/138-001
obo:BFO_0000182
A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001])
obo:BFO_0000182
obo:bfo.owl
obo:BFO_0000182
history
obo:CHEBI_23367
molecular entity
obo:CHEBI_23367
Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.
obo:CHEBI_23367
We are assuming that every molecular entity has to be completely connected by chemical bonds. This excludes protein complexes, which are comprised of minimally two separate molecular entities. We will follow up with Chebi to ensure this is their understanding as well
obo:CHEBI_23367
obo:chebi.owl
obo:CHEBI_23367
obo:dron.owl
obo:CHEBI_23367
obo:obi.owl
obo:CHEBI_23367
obo:opmi.owl
obo:CHEBI_23367
molecular entity
obo:CHEBI_23367
chebi_ontology
obo:CHEBI_23367
entidad molecular
obo:CHEBI_23367
entidades moleculares
obo:CHEBI_23367
entite moleculaire
obo:CHEBI_23367
molecular entities
obo:CHEBI_23367
molekulare Entitaet
obo:CHEBI_23367
CHEBI:23367
obo:CHEBI_23367
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/chebi#3_STAR
obo:CHEBI_23367
molecular entity
obo:CHEBI_24431
A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances.
obo:CHEBI_24431
obo:chebi.owl
obo:CHEBI_24431
obo:dron.owl
obo:CHEBI_24431
obo:opmi.owl
obo:CHEBI_24431
chemical entity
obo:CHEBI_24431
chebi_ontology
obo:CHEBI_24431
CHEBI:24431
obo:CHEBI_24431
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/chebi#3_STAR
obo:CHEBI_24431
chemical entity
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000001
An identifier(s) (ID), if any, other than the organization's Unique Protocol Identification Number or the NCT number that is assigned to the clinical study. This includes any unique clinical study identifiers assigned by other publicly available clinical trial registries. If the clinical study is funded in whole or in part by a U.S. Federal Government agency, the complete grant or contract number must be submitted as a Secondary ID.
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000001
Other identifiers besides the Trial Identifying Number allocated by the Primary Registry, if any.
obo:CTO_0000001
secondary identifier
obo:CTO_0000002
A centrally registered identifier that is assigned for a specific clinical trial registered in the Australian New Zealand clinical trials registry (ANZCTR). The format for the registry number is “ACTRN” followed by a 14-digit number, e.g., ACTRN12620000457943.
obo:CTO_0000002
ANZCTR identifier
obo:CTO_0000002
Australian New Zealand clinical trials registry identifier
obo:CTO_0000002
http://www.anzctr.org.au/
obo:CTO_0000002
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000003
Australian New Zealand Clinical Trials Registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000003
ANZCTR
obo:CTO_0000003
Australian New Zealand clinical trials registry
obo:CTO_0000003
http://www.anzctr.org.au/
obo:CTO_0000003
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000004
A centrally registered identifier that is assigned for a specific clinical trial registered in the Peruvian clinical trial registry (REPEC). The format for the registry number is “PER-” followed by a 3-digit number, followed by a hyphen, followed by a 2-digit number e.g., PER-010-20.
obo:CTO_0000004
REPEC identifier
obo:CTO_0000004
Peruvian clinical trial registry identifier
obo:CTO_0000004
https://ensayosclinicos-repec.ins.gob.pe/en/
obo:CTO_0000004
https://www.who.int/ictrp/network/primary/en/
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000005
The party or parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants.
obo:CTO_0000005
blinding
obo:CTO_0000005
masking
obo:CTO_0000005
masking design
obo:CTO_0000005
http://www.icmje.org/recommendations/
obo:CTO_0000005
http://www.who.int/ictrp/network/trds/en/index.html
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000006
Participants are expressly assigned to intervention groups through a non-random method, such as physician choice
obo:CTO_0000006
non-randomized
obo:CTO_0000006
nonrandomized
obo:CTO_0000006
non-random allocation
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000007
A study record that includes the summary results posted in the ClinicalTrials.gov results database. Summary results information includes participant flow, baseline characteristics, outcome measures, and adverse events (including serious adverse events).
obo:CTO_0000007
summary results
obo:CTO_0000007
study summary result
obo:CTO_0000007
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000008
A description of each secondary outcome measure (or for observational studies, specific secondary measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment).
Each secondary outcome measure information includes title, description and time frame.
obo:CTO_0000008
https://prsinfo.clinicaltrials.gov/definitions.html
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000008
key secondary outcome
obo:CTO_0000008
secondary outcome measure information
obo:CTO_0000008
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000009
The Iranian registry of clinical trials is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000009
IRCT
obo:CTO_0000009
Iranian registry of clinical trials
obo:CTO_0000009
http://www.irct.ir/
obo:CTO_0000009
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000010
Any other measurements, excluding post-hoc measures, that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study.
Each primary outcome measure information includes title, description and time frame.
obo:CTO_0000010
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000010
other pre-specified outcome measures
obo:CTO_0000010
other outcome measure information
obo:CTO_0000011
The Indian clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000011
CTRI
obo:CTO_0000011
clinical trials registry - India
obo:CTO_0000011
Indian clinical trials registry
obo:CTO_0000011
http://ctri.nic.in/
obo:CTO_0000011
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000012
The Netherlands national trial register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000012
NTR
obo:CTO_0000012
The Netherlands national trial register
obo:CTO_0000012
http://www.trialregister.nl/
obo:CTO_0000012
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000013
A centrally registered identifier that is assigned for a specific clinical trial registered in the Iranian registry of clinical trials (IRCT). The format for the registry number is “IRCT” followed by a 14-digit number, one letter and again one or two numbers, e.g., IRCT20100228003449N29.
obo:CTO_0000013
IRCT identifier
obo:CTO_0000013
Iranian registry of clinical trials identifier
obo:CTO_0000013
http://www.irct.ir/
obo:CTO_0000013
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000014
A centrally registered identifier that is assigned for a specific clinical trial registered in the German clinical trials register (DRKS). The format for the registry number is “DRKS” followed by a 8-digit number, e.g., DRKS00000494.
obo:CTO_0000014
DRKS identifier
obo:CTO_0000014
German clinical trials register identifier
obo:CTO_0000014
https://www.drks.de/drks_web/
obo:CTO_0000014
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000015
The Cuban public registry of clinical trials is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000015
RPCEC
obo:CTO_0000015
Cuban public registry of clinical trials
obo:CTO_0000015
http://registroclinico.sld.cu/en/home
obo:CTO_0000015
https://www.who.int/ictrp/network/primary/en/
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000016
For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
obo:CTO_0000016
outcome measure
obo:CTO_0000016
outcome measurement
obo:CTO_0000016
clinical trial outcome measurement
obo:CTO_0000017
The Pan African clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000017
PACTR
obo:CTO_0000017
Pan African clinical trial registry
obo:CTO_0000017
http://www.pactr.org/
obo:CTO_0000017
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000018
A centrally registered identifier that is assigned for a specific clinical trial registered in the The Netherlands national trial register (NTR). The format for the registry number is “NTR” followed by a 1 to 4-digit number, e.g., NL8498.
obo:CTO_0000018
NTR identifier
obo:CTO_0000018
The Netherlands national trial register identifier
obo:CTO_0000018
https://www.trialregister.nl/
obo:CTO_0000018
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000019
The JAPIC (Japan Pharmaceutical Information Center) clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000019
JapicCTI
obo:CTO_0000019
JAPIC clinical trials registry
obo:CTO_0000019
https://rctportal.niph.go.jp/en/
obo:CTO_0000019
https://www.japic.or.jp/
obo:CTO_0000019
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000020
A centrally registered identifier that is assigned for a specific clinical trial registered in the Pan African clinical trial register. The format for the registry number is “KCT” followed by a 15-digit number, e.g., PACTR202004893013257.
obo:CTO_0000020
PACTR identifier
obo:CTO_0000020
Pan African clinical trial registry identifier
obo:CTO_0000020
https://pactr.samrc.ac.za/
obo:CTO_0000020
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000022
A centrally registered identifier that is assigned for a specific clinical trial registered in the Chinese clinical trials register (ChiCTR). The format for the registry number is “ChiCTR” followed by a 10-digit number, e.g., ChiCTR2000031589.
obo:CTO_0000022
ChiCTR identifier
obo:CTO_0000022
Chinese Clinical Trial Register number
obo:CTO_0000022
Chinese clinical trail registry identifier
obo:CTO_0000022
http://www.chictr.org.cn/enIndex.aspx
obo:CTO_0000023
The Lebanese clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000023
LBCTR
obo:CTO_0000023
Lebanese clinical trials registry
obo:CTO_0000023
http://lbctr.emro.who.int/
obo:CTO_0000023
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000024
German clinical trials register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000024
DRKS
obo:CTO_0000024
German clinical trials register
obo:CTO_0000024
http://www.germanctr.de/
obo:CTO_0000024
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000025
The JMACCT (Japan Medical Association, Center for Clinical Trials) clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000025
JMACCT
obo:CTO_0000025
JMACCT clinical trials registry
obo:CTO_0000025
https://dbcentre3.jmacct.med.or.jp/jmactr/Default_Eng.aspx
obo:CTO_0000025
https://rctportal.niph.go.jp/en/
obo:CTO_0000026
adult (18-64)
obo:CTO_0000026
age_between_18_and_64
obo:CTO_0000026
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000028
The actual total number of participants that are enrolled in a clinical study
obo:CTO_0000028
https://prsinfo.clinicaltrials.gov/definitions.html
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000028
enrollment
http://www.who.int/ictrp/network/trds/en/index.html
obo:CTO_0000028
sample size
obo:CTO_0000028
number of participants
obo:CTO_0000028
http://www.icmje.org/recommendations/
obo:CTO_0000030
A centrally registered identifier that is assigned for a specific clinical trial registered in Brazilian Registry of Clinical Trials (ReBEC). The format for the ReBEC registry number is “RBR-” followed by 6 characters, e.g., RBR-4hb9qs.
obo:CTO_0000030
Brazilian Registry of Clinical Trials identifier
obo:CTO_0000030
ReBEC identifier
obo:CTO_0000030
Brazilian clinical trial registry identifier
obo:CTO_0000030
http://www.ensaiosclinicos.gov.br/
obo:CTO_0000031
Clinical trial phase that is a combination of phases 2 and 3.
obo:CTO_0000031
Phase 2/3
obo:CTO_0000031
Phase 2/Phase 3
obo:CTO_0000031
Phase I/II
obo:CTO_0000031
clinical trial phase 2/3
obo:CTO_0000031
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000032
data item ....
obo:CTO_0000032
study result
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000033
A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in that clinical study.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000033
Indication that participants who do not have a disease or condition, or related conditions or symptoms, under study in the clinical study are permitted to participate in the clinical study.
obo:CTO_0000033
accepts healthy volunteers
obo:CTO_0000033
healthy volunteer criterion
obo:CTO_0000033
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000034
child (birth-17)
obo:CTO_0000034
age_between_birth_and_17_years
obo:CTO_0000035
A description of each primary outcome measure (or for observational studies, specific key measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment).
Each primary outcome measure information includes title, description and time frame.
obo:CTO_0000035
https://prsinfo.clinicaltrials.gov/definitions.html
https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf
obo:CTO_0000035
primary end point
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000035
primary outcome(s)
obo:CTO_0000035
primary outcome measure information
obo:CTO_0000035
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000036
The EU clinical trials register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000036
EU-CTR
obo:CTO_0000036
EU clinical trials register
obo:CTO_0000036
https://eudract.ema.europa.eu/
obo:CTO_0000036
https://www.clinicaltrialsregister.eu
obo:CTO_0000036
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000037
The UMIN (University Hospital Medical Information Network Center) clinical trials registry is a Japanese primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000037
UMIN CTR
obo:CTO_0000037
UMIN clinical trials registry
obo:CTO_0000037
https://rctportal.niph.go.jp/en/
obo:CTO_0000037
https://www.umin.ac.jp/ctr/
obo:CTO_0000037
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000038
older adult (65+)
obo:CTO_0000038
age_older_than_64
obo:CTO_0000038
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000039
Data generated from measurement of experimental variables in a study, or for observational studies, from descriptions of patterns of diseases or traits or associations with exposures, risk factors or treatment.
obo:CTO_0000039
outcome measure result
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000040
Indicate whether a clinical study has been reviewed and approved by at least one human subjects protection review board or such review is not required per applicable law (for example, 21 CFR Part 56, 45 CFR Part 46, or other applicable regulation).
obo:CTO_0000040
human subjects protection review board status
obo:CTO_0000041
ClinicalTrials.gov is a registry of clinical trials.
obo:CTO_0000041
The Korean clinical trials registry (Clinical Research Information Service (CRiS), Republic of Korea) is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000041
CRiS
obo:CTO_0000041
Clinical Research Information Service, Republic of Korea
obo:CTO_0000041
Korean clinical trials registry
obo:CTO_0000041
http://cris.nih.go.kr/cris/en/use_guide/cris_introduce.jsp
obo:CTO_0000041
https://www.who.int/ictrp/network/primary/en/
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000043
Trials without phases (for example, studies of devices or behavioral interventions).
obo:CTO_0000043
N/A
obo:CTO_0000043
phase not applicable
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000044
Look back using observations collected predominantly prior to subject selection and enrollment
obo:CTO_0000044
retrospective study design
obo:CTO_0000045
A centrally registered identifier that is assigned for a specific clinical trial registered in the international standard randomised controlled trial register (ISRCT). The format for the registry number is “ISRCTN” followed by a 8-digit number, e.g., ISRCTN14966673.
obo:CTO_0000045
ISRCTN
obo:CTO_0000045
International Standard Randomised Controlled Trial Number
obo:CTO_0000045
International standard randomised controlled trial register identifier
obo:CTO_0000045
http://www.isrctn.com/
obo:CTO_0000045
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000046
Clinical trial phase that is a combination of phases 1 and 2.
obo:CTO_0000046
Phase 1/2
obo:CTO_0000046
Phase 1/Phase 2
obo:CTO_0000046
Phase I/II
obo:CTO_0000046
clinical trial phase 1/2
obo:CTO_0000046
https://prsinfo.clinicaltrials.gov/definitions.html
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000047
Look forward using periodic observations collected predominantly following subject enrollment
obo:CTO_0000047
prospective study design
obo:CTO_0000048
A centrally registered identifier that is assigned for a specific clinical trial registered in the Thai clinical trials registry (TCTR). The format for the registry number is “TCTR” followed by a 11-digit number, e.g., TCTR20200405001
obo:CTO_0000048
TCTR identifier
obo:CTO_0000048
Thai clinical trials registry identifier
obo:CTO_0000048
http://www.clinicaltrials.in.th/
obo:CTO_0000048
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000049
The Chinese clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000049
ChiCTR
obo:CTO_0000049
Chinese clinical trial registry
obo:CTO_0000049
http://www.chictr.org.cn/
obo:CTO_0000049
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000050
The Thai clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000050
TCTR
obo:CTO_0000050
Thai clinical trials registry
obo:CTO_0000050
http://www.clinicaltrials.in.th/
obo:CTO_0000050
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000051
A description of the outcome measure in an interventional study or for observational studies, specific key measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment.
obo:CTO_0000051
outcome specification
obo:CTO_0000051
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:CTO_0000052
A centrally registered identifier that is assigned for a specific clinical trial registered in the Indian clinical trial register. The format for the registry number is “CRTI/” followed by a 4-digit number, followed by a slash, followed a 2-digit number, followed by a slash, followed a 6-digit number, e.g., CTRI/2020/03/024402.
obo:CTO_0000052
CRTI identifier
obo:CTO_0000052
Clinical Trials Registry - India identifier
obo:CTO_0000052
Indian clinical trial registry identifier
obo:CTO_0000052
http://ctri.nic.in/Clinicaltrials/login.php
obo:CTO_0000052
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000053
The Brazilian clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000053
ReBec
obo:CTO_0000053
Brazilian clinical trials registry
obo:CTO_0000053
http://www.ensaiosclinicos.gov.br/
obo:CTO_0000053
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000054
A centrally registered identifier that is assigned for a specific clinical trial registered in the Japan Registry of Clinical Trials (jRCT). The format for the registry number is “jRCTs” followed by a 9-digit number, e.g., JPRN-jRCTs031190227
obo:CTO_0000054
Japan registry of clinical trials identifier
obo:CTO_0000054
jRCT clinical trial identifier
obo:CTO_0000054
https://jrct.niph.go.jp/
obo:CTO_0000054
https://rctportal.niph.go.jp/en/
obo:CTO_0000054
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000055
A centrally registered identifier that is assigned for a specific clinical trial registered in the Cuban public registry of clinical trials (RPCEC). The format for the registry number is “RPCEC” followed by a 8-digit number, e.g., RPCEC00000306.
obo:CTO_0000055
RPCEC identifier
obo:CTO_0000055
Cuban public registry of clinical trials identifier
obo:CTO_0000055
http://registroclinico.sld.cu/en/home
obo:CTO_0000055
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000056
A centrally registered identifier that is assigned for a specific clinical trial registered in the Lebanese clinical trials registry (LBCTR). The format for the registry number is “LBCTR” followed by a 10-digit number, e.g., LBCTR2020043459.
obo:CTO_0000056
Lebanese clinical trials registry identifier
obo:CTO_0000056
LBCTR identifier
obo:CTO_0000056
http://lbctr.emro.who.int/
obo:CTO_0000056
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000073
A primary registry is clinical trial registry in the WHO registry network that meet specific criteria for content, quality and validity, accessibility, unique identification, technical capacity and administration. Primary registries also meet the requirements of the International Clinical Trials Registry Platform (ICMJE).
obo:CTO_0000073
primary registry
obo:CTO_0000073
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000074
The Peruvian clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000074
REPEC
obo:CTO_0000074
Peruvian clinical trial registry
obo:CTO_0000074
https://ensayosclinicos-repec.ins.gob.pe/en/
obo:CTO_0000074
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000075
The Sri Lanka clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000075
SLCTR
obo:CTO_0000075
Sri Lanka clinical trials registry
obo:CTO_0000075
http://www.slctr.lk/
obo:CTO_0000075
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000076
ClinicalTrials.gov is a registry for clinical trials funded and maintained by NIH/NLM in US.
obo:CTO_0000076
ClinicalTrials.gov
obo:CTO_0000076
US ClinicalTrial.gov registry
obo:CTO_0000076
https://clinicaltrials.gov/
obo:CTO_0000077
A clinical trials registry organization is an organization that enables the registration and documentation of clinical trials.
obo:CTO_0000077
clinical trials registry
obo:CTO_0000077
clinical trials registry organization
obo:CTO_0000099
clinical trial enrollment
obo:CTO_0000100
clinical trial participant
obo:CTO_0000101
healthy enrollee
obo:CTO_0000102
enrolled patient
obo:CTO_0000103
placebo medical intervention
obo:CTO_0000104
outcome measurement datum
obo:CTO_0000105
primary outcome measurement datum
obo:CTO_0000106
secondary outcome measurement datum
obo:CTO_0000107
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000107
2021-06-10T13:15:41Z
obo:CTO_0000107
investigational molecular entity administration
obo:CTO_0000108
investigational molecular entity
obo:CTO_0000109
A clinical trial investigate some molecular entity which either will be a new drug or is already an approved drug but looking for new indications or new populations that are not stated in the drug label.
obo:CTO_0000109
Asiyah Yu Lin
obo:CTO_0000109
drug clinical trial
obo:CTO_0000110
a sponsor role that ties to a clinical trial.
obo:CTO_0000110
Asiyah Yu Lin
obo:CTO_0000110
clinical trial sponsor role
obo:CTO_0000111
procedure clinical trIal
obo:CTO_0000112
a study design in which neither the subjects nor the investigators are permitted to know which subject is receiving which treatment
obo:CTO_0000112
double-blind
obo:CTO_0000112
double-blinded
obo:CTO_0000112
double blinded design
obo:CTO_0000113
a study design in which only the investigators are permitted to know which subject is receiving which treatment
obo:CTO_0000113
double blind
obo:CTO_0000113
double blinded
obo:CTO_0000113
single blinded design
obo:CTO_0000114
a study design in which the subjects and the investigators are permitted to know which subject is receiving which treatment
obo:CTO_0000114
open blind
obo:CTO_0000114
open label
obo:CTO_0000114
open blinded design
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000115
Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies
obo:CTO_0000115
sequential design
obo:CTO_0000116
study design with a single group (arm)
obo:CTO_0000116
sinlge arm
obo:CTO_0000116
single arm design
obo:CTO_0000117
primary outcome measurement
obo:CTO_0000118
secondary outcome measurement
obo:CTO_0000119
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000119
2021-06-10T13:15:58Z
obo:CTO_0000119
investigational drug administration
obo:CTO_0000120
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000120
2021-06-10T13:16:26Z
obo:CTO_0000120
investigational supplement administration
obo:CTO_0000121
Corresponding to CT.gov XML tag "official_title"
<xs:element name="clinical_study">
<xs:complexType>
<xs:sequence>
...
<xs:element name="official_title" type="xs:string" minOccurs="0"/>
...
obo:CTO_0000121
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000121
2021-06-10T13:26:41Z
obo:CTO_0000121
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000121
hasOfficialTitle
obo:CTO_0000122
Corresponding to CT.gov XML tag "brief_title"
<xs:element name="clinical_study">
<xs:complexType>
<xs:sequence>
...
<xs:element name="brief_title" type="xs:string"/>
...
obo:CTO_0000122
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000122
2021-06-10T13:32:02Z
obo:CTO_0000122
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000122
hasBriefTitle
obo:CTO_0000123
Corresponding to CT.gov XML tag "primary completion date" with flag "Actual"
<xs:element name="clinical_study">
<xs:complexType>
<xs:sequence>
...
<xs:element name="primary_completion_date" type="variable_date_struct" minOccurs="0"/>
...
obo:CTO_0000123
Asiyah Yu Lin,
obo:CTO_0000123
2021-06-10T13:33:12Z
obo:CTO_0000123
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000123
hasCompletionDate
obo:CTO_0000124
Corresponding to CT.gov XML tag "start_date" with flag "Actual".
<xs:element name="clinical_study">
<xs:complexType>
<xs:sequence>
...
<xs:element name="start_date" type="variable_date_struct" minOccurs="0"/>
obo:CTO_0000124
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000124
2021-06-10T13:35:06Z
obo:CTO_0000124
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000124
hasStartDate
obo:CTO_0000125
Corresponding to CT.gov XML tag "phase":
<xs:simpleType name="phase_enum">
<xs:restriction base="xs:string">
<xs:enumeration value="N/A"/>
<xs:enumeration value="Early Phase 1"/>
<xs:enumeration value="Phase 1"/>
<xs:enumeration value="Phase 1/Phase 2"/>
<xs:enumeration value="Phase 2"/>
<xs:enumeration value="Phase 2/Phase 3"/>
<xs:enumeration value="Phase 3"/>
<xs:enumeration value="Phase 4"/>
</xs:restriction>
</xs:simpleType>
obo:CTO_0000125
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000125
2021-06-10T13:36:18Z
obo:CTO_0000125
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000125
hasPhase
obo:CTO_0000126
Corresponding to CT.gov XML tag "Principal Investigator", a type of "responsible party"
<xs:simpleType name="role_enum">
<xs:restriction base="xs:string">
<xs:enumeration value="Principal Investigator"/>
<xs:enumeration value="Sub-Investigator"/>
<xs:enumeration value="Study Chair"/>
<xs:enumeration value="Study Director"/>
</xs:restriction>
</xs:simpleType>
obo:CTO_0000126
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000126
2021-06-10T13:42:36Z
obo:CTO_0000126
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000126
has investigator
obo:CTO_0000127
Corresponding to CT.gov XML tag "collaborator", a type of "sponsors"
<!-- === Sponsors ==================================================== -->
<xs:complexType name="sponsors_struct">
<xs:sequence>
<xs:element name="lead_sponsor" type="sponsor_struct"/>
<xs:element name="collaborator" type="sponsor_struct" minOccurs="0" maxOccurs="unbounded"/>
</xs:sequence>
</xs:complexType>
obo:CTO_0000127
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000127
2021-06-10T13:45:21Z
obo:CTO_0000127
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000127
has collaborator
obo:CTO_0000128
Corresponding to CT.gov XML tag: "overall_contact"
<xs:element name="clinical_study">
<xs:complexType>
<xs:sequence>
...
<xs:element name="overall_contact" type="contact_struct" minOccurs="0"/>
...
obo:CTO_0000128
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000128
2021-06-10T13:46:58Z
obo:CTO_0000128
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000128
has contact
obo:CTO_0000129
Corresponding to CT.gov XML tag : "location_countries"
<xs:element name="clinical_study">
<xs:complexType>
<xs:sequence>
...
<xs:element name="location_countries" type="countries_struct" minOccurs="0"/>
...
obo:CTO_0000129
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000129
2021-06-10T13:47:26Z
obo:CTO_0000129
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000129
has clinical trial site
obo:CTO_0000130
Corresponding to CT.gov XML tag "lead_sponsor", a type of "sponsors"
<!-- === Sponsors ==================================================== -->
<xs:complexType name="sponsors_struct">
<xs:sequence>
<xs:element name="lead_sponsor" type="sponsor_struct"/>
<xs:element name="collaborator" type="sponsor_struct" minOccurs="0" maxOccurs="unbounded"/>
</xs:sequence>
</xs:complexType>
obo:CTO_0000130
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000130
2021-06-10T13:47:47Z
obo:CTO_0000130
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000130
has primary sponsor
obo:CTO_0000131
Corresponding to CT.gov XML tag "agency"
<!-- === Sponsor ===================================================== -->
<xs:simpleType name="agency_class_enum">
<xs:restriction base="xs:string">
<xs:enumeration value="NIH"/>
<xs:enumeration value="U.S. Fed"/>
<xs:enumeration value="Industry"/>
<xs:enumeration value="Other"/>
</xs:restriction>
</xs:simpleType>
<xs:complexType name="sponsor_struct">
<xs:sequence>
<xs:element name="agency" type="xs:string"/>
<xs:element name="agency_class" type="agency_class_enum" minOccurs="0"/>
</xs:sequence>
</xs:complexType>
obo:CTO_0000131
Asiyah Yu Lin, Qingliang "Leon" Li
obo:CTO_0000131
2021-06-10T13:48:23Z
obo:CTO_0000131
https://clinicaltrials.gov/ct2/html/images/info/public.xsd
obo:CTO_0000131
has funding agency
obo:CTO_0000132
A clinical trial is conducted for the purpose of demonstrating the efficacy of a new drug in order to obtain its marketing approval by regulatory authorities (e.g. FDA in the United States and EMA in Europe). The pivotal clinical trial usually is a Phase III clinical trial, but exceptionally phase 2 studies could also be utilized as pivotal trials.
obo:CTO_0000132
This is the same terms as the pre-version of this ontology: Clinical Trials Ontology - Neurodegenerative Diseases: http://www.co-ode.org/ontologies/ont.owl#Pivotal_trial
obo:CTO_0000132
pivotal trial
obo:CTO_0000132
https://en.wikipedia.org/wiki/Pivotal_trial
obo:CTO_0000132
https://www.sofpromed.com/pivotal-clinical-trials-frequently-asked-questions/
obo:CTO_0000132
Asiyah Yu Lin
obo:CTO_0000132
2021-06-10T16:49:17Z
obo:CTO_0000132
pivotal clinical trial
obo:CTO_0000200
The main objective of the intervention(s) being evaluated by the clinical trial.
obo:CTO_0000200
primary purpose of clinical trial
obo:CTO_0000200
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000200
clinical trial primary purpose specification
obo:CTO_0000201
The quality of a clinical trial that studies a drug or biological product. The phase is based on the study's objective, the number of participants, and other characteristics. According to USA FDA, there are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4.
obo:CTO_0000201
Leon Li, Asiyah Lin, Oliver He
obo:CTO_0000201
clinical trial stage
obo:CTO_0000201
https://www.clinicaltrials.gov/ct2/help/glossary/phase
obo:CTO_0000201
phase
obo:CTO_0000201
clinical trial phase
obo:CTO_0000201
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000202
A clinical trial phase that is designed to use an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited. [def-source: NCI]
obo:CTO_0000202
Leon Li, Asiyah Lin, Oliver He
obo:CTO_0000202
obo:CTO_0000202
Early Phase 1
obo:CTO_0000202
Pre-Clinical Phase
obo:CTO_0000202
clinical trial phase 0
obo:CTO_0000202
http://purl.obolibrary.org/obo/NCIT_C54721
obo:CTO_0000202
https://en.wikipedia.org/wiki/Clinical_trial
obo:CTO_0000202
C1882358
obo:CTO_0000202
C54721
obo:CTO_0000202
clinical trial early phase 1
obo:CTO_0000203
A clinical trial phase that represents the first-in-man trial, which tests within a small group of people (typically 20-80) to evaluate safety, determine safe dosage ranges, and begin to identify side effects. A drug's side effects could be subtle or long term, or may only happen with a few people, so phase 1 trials are not expected to identify all side effects.
obo:CTO_0000203
Leon Li, Asiyah Lin, Oliver He
obo:CTO_0000203
Phase 1
obo:CTO_0000203
Phase I
obo:CTO_0000203
http://purl.obolibrary.org/obo/NCIT_C15600
obo:CTO_0000203
https://en.wikipedia.org/wiki/Clinical_trial
obo:CTO_0000203
C0920321
obo:CTO_0000203
C15600
obo:CTO_0000203
clinical trial phase 1
obo:CTO_0000204
A clinical trial phase that is designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention. [def-source: NCI]
obo:CTO_0000204
Leon Li, Asiyah Lin, Oliver He
obo:CTO_0000204
Phase II
obo:CTO_0000204
http://purl.obolibrary.org/obo/NCIT_C15601
obo:CTO_0000204
https://en.wikipedia.org/wiki/Clinical_trial
obo:CTO_0000204
C0282460
obo:CTO_0000204
C15601
obo:CTO_0000204
clinical trial phase 2
obo:CTO_0000205
A clinical trial phase that is designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo. [def-source: NCI]
obo:CTO_0000205
Leon Li, Asiyah Lin, Oliver He
obo:CTO_0000205
Phase III
obo:CTO_0000205
http://purl.obolibrary.org/obo/NCIT_C15602
obo:CTO_0000205
https://en.wikipedia.org/wiki/Clinical_trial
obo:CTO_0000205
C0282461
obo:CTO_0000205
C15602
obo:CTO_0000205
clinical trial phase 3
obo:CTO_0000206
A clinical trial phase that is designed for a randomized, controlled trial to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed. [def-source: NCI]
obo:CTO_0000206
Leon Li, Asiyah Lin, Oliver He
obo:CTO_0000206
Phase IV
obo:CTO_0000206
https://en.wikipedia.org/wiki/Clinical_trial
obo:CTO_0000206
C0282462
obo:CTO_0000206
C15603
obo:CTO_0000206
clinical trial phase 4
obo:CTO_0000207
A clinical trial that is at Early Phase 1 or Phase 0
obo:CTO_0000207
A clinical trial that is at an Early Phase i or Phase 0, which is designed to use an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited. [def-source: NCI]
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000207
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). (Formerly listed as "Phase 0")
obo:CTO_0000207
Leon Li, Asiyah Lin, Oliver He
obo:CTO_0000207
Phase 0 clinical trial
obo:CTO_0000207
Phase 0 trial
obo:CTO_0000207
Pre-Clinical Trial
obo:CTO_0000207
http://purl.obolibrary.org/obo/NCIT_C54721
obo:CTO_0000207
https://en.wikipedia.org/wiki/Clinical_trial
obo:CTO_0000207
Early Phase 1 clinical trial
obo:CTO_0000208
EudraCT Number: 2007-002422-29
obo:CTO_0000208
Qingliang Leon Li, Asiyah Yu Lin, Oliver He
obo:CTO_0000208
EudraCT identifier
obo:CTO_0000208
https://en.wikipedia.org/wiki/EudraCT
obo:CTO_0000208
https://www.clinicaltrialsregister.eu/ctr-search/search
obo:CTO_0000208
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract
obo:CTO_0000208
European clinical trial registry identifier
obo:CTO_0000208
https://www.who.int/ictrp/network/primary/en/
obo:CTO_0000209
Qingliang Leon Li, Asiyah Yu Lin, Oliver He
obo:CTO_0000209
https://pubchem.ncbi.nlm.nih.gov/source/NIPH%20Clinical%20Trials%20Search%20of%20Japan
obo:CTO_0000209
https://rctportal.niph.go.jp/en/
obo:CTO_0000209
Japan clinical trial identifier
obo:CTO_0000209
https://www.who.int/ictrp/network/jprn2/en/
obo:CTO_0000210
Qingliang Leon Li, Asiyah Yu Lin, Oliver He
obo:CTO_0000210
JapicCTI
obo:CTO_0000210
https://rctportal.niph.go.jp/en/
obo:CTO_0000210
JAPIC clinical trial identifier
obo:CTO_0000211
A centrally registered identifier that is assigned for a specific clinical trial registered in JMACCT. The format for the JMACCT registry number is “JMA-IIA” followed by a 5-digit number, e.g., JMA-IIA00391.
obo:CTO_0000211
Qingliang Leon Li, Asiyah Yu Lin, Oliver He
obo:CTO_0000211
JMACCT
obo:CTO_0000211
https://rctportal.niph.go.jp/en/
obo:CTO_0000211
JMACCT clinical trial identifier
obo:CTO_0000212
A Japan clinical trial identifier provided by the University Hospital Medical Information Network Center (UMIN-CTR)
obo:CTO_0000212
Qingliang Leon Li, Asiyah Yu Lin, Oliver He
obo:CTO_0000212
UMIN
obo:CTO_0000212
https://rctportal.niph.go.jp/en/
obo:CTO_0000212
UMIN-CTR clinical trial identifier
obo:CTO_0000213
A centrally registered identifier that is assigned for a specific clinical trial registered in the ClinicalTrials.gov. The format for the ClinicalTrials.gov registry number is “NCT” followed by an 8-digit number, e.g.: NCT00000419.
obo:CTO_0000213
Qingliang Leon Li, Asiyah Yu Lin, Oliver He
obo:CTO_0000213
NCT identifier
obo:CTO_0000213
NCT number
obo:CTO_0000213
National Clinical Trial identifier
obo:CTO_0000213
https://clinicaltrials.gov/ct2/about-site/link-to
obo:CTO_0000213
https://www.nlm.nih.gov/bsd/policy/clin_trials.html
obo:CTO_0000213
USA National Clinical Trial identifier
obo:CTO_0000214
The date on which a study starts
obo:CTO_0000214
study start date
obo:CTO_0000215
The date that the final participant was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical study concluded according to the pre-specified protocol or was terminated. In the case of clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all of the primary outcomes.
obo:CTO_0000215
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000215
primary completion
obo:CTO_0000215
clinical trial primary completion date
obo:CTO_0000216
The date the final participant was examined or received an intervention for purposes of final collection of data for the primary and secondary outcome measures and adverse events (for example, last participant’s last visit), whether the clinical study concluded according to the pre-specified protocol or was terminated.
obo:CTO_0000216
https://prsinfo.clinicaltrials.gov/definitions.html
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:CTO_0000216
completion date
obo:CTO_0000216
clinical trial study completion date
obo:CTO_0000217
A textual entity that is the title of a clinical trial
obo:CTO_0000217
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000217
title of clinical trial
obo:CTO_0000218
A title of clinical trial that is meant for lay people understanding
obo:CTO_0000218
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000218
brief title
obo:CTO_0000218
lay title
obo:CTO_0000218
public title
obo:CTO_0000218
lay title of clinical trial
obo:CTO_0000218
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000219
A title of clinical trial that is recorded as official
obo:CTO_0000219
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000219
full title
obo:CTO_0000219
scientific title
obo:CTO_0000219
official title of clinical trial
obo:CTO_0000219
https://www.who.int/ictrp/network/trds/en/
obo:CTO_0000220
a clinical trial is a medical interventional study where participants are assigned prospectively to an intervention or interventions according to a protocol to evaluate the safety and efficacy of the intervention(s) on biomedical or other health related outcomes. The Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioral treatments, process-of-care changes, preventive care, etc.
obo:CTO_0000220
Oliver He, Asiyah Yu Lin, Qingliang Li
obo:CTO_0000220
interventional trial
obo:CTO_0000220
https://clinicaltrials.gov/ct2/search/map
obo:CTO_0000220
https://en.wikipedia.org/wiki/Clinical_trial
obo:CTO_0000220
https://prsinfo.clinicaltrials.gov/definitions.html
obo:CTO_0000220
https://www.who.int/ictrp/en/
obo:CTO_0000220
clinical trial
obo:DRON_00000005
a material entity (1) containing at least one scattered molecular aggregate as part that is the bearer of an active ingredient role and (2) that is itself the bearer of a clinical drug role
obo:DRON_00000005
William Hogan
obo:DRON_00000005
obo:dron.owl
obo:DRON_00000005
William Hogan
obo:DRON_00000005
drug product
obo:ERO_0000017
epidemiological study
obo:ERO_0000017
A study of the populations and demographic of the avian flu.
obo:ERO_0000017
obo:IAO_0000120
obo:ERO_0000017
A human study of diseases in populations of humans or other animals, specifically how, when and where they occur. Epidemiological studies can never prove causation, epidemiological evidence can only show that this risk factor is correlated with a higher incidence of disease in the population exposed to that risk factor. The higher the correlation the more certain the association, but it cannot prove the causation.
obo:ERO_0000017
PERSON: Karen Corday
obo:ERO_0000017
http://pmep.cce.cornell.edu/profiles/extoxnet/TIB/epidemiology.html
obo:ERO_0000017
obo:ero.owl
obo:ERO_0000017
epidemiological study
https://prsinfo.clinicaltrials.gov/definitions.html
obo:ERO_0000348
single group of individuals with specific characteristics.
obo:ERO_0001092
A blood pressure monitor is a medical device.
obo:ERO_0001092
obo:IAO_0000120
obo:ERO_0001092
An instrument used in the diagnosis of disease or other conditions or for use in the care, treatment, or prevention of disease that does not achieve any of its primary intended purposes by chemical action or by being metabolized.
obo:ERO_0001092
PERSON: Nicole Vasilevsky
obo:ERO_0001092
http://medical-dictionary.thefreedictionary.com/medical+device
obo:ERO_0001092
obo:ero.owl
obo:ERO_0001092
medical device
obo:ERO_0001402
obo:IAO_0000123
obo:ERO_0001402
A preliminary study to determine the practicability of a proposed health program or procedure or of a larger study and to appraise the factors that may influence its practicability. A feasibility study aims to discover those things which may affect successful study conduct on a larger scale.
obo:ERO_0001402
PERSON: Melanie Wilson
obo:ERO_0001402
Dictionary of Epidemiology, 5th edition.
obo:ERO_0001402
obo:ero.owl
obo:ERO_0001402
feasibility study
obo:ERO_0001843
obo:IAO_0000123
obo:ERO_0001843
An organization dedicated to the collection, storage and dissemination of a set of scientific or clinical data.
obo:ERO_0001843
PERSON: Nicole Vasilevsky
obo:ERO_0001843
PERSON: Scott Hoffmann
obo:ERO_0001843
obo:ero.owl
obo:ERO_0001843
registry
obo:ERO_0001843
https://www.who.int/ictrp/network/trds/en/
obo:IAO_0000005
objective specification
obo:IAO_0000005
In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction.
obo:IAO_0000005
obo:IAO_0000122
obo:IAO_0000005
A directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved.
obo:IAO_0000005
2009-03-16: original definition when imported from OBI read: "objective is an non realizable information entity which can serve as that proper part of a plan towards which the realization of the plan is directed."
obo:IAO_0000005
2014-03-31: In the example of usage ("In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction") there is a protocol which is the ChIP assay protocol. In addition to being concretized on paper, the protocol can be concretized as a realizable entity, such as a plan that inheres in a person. The objective specification is the part that says that some protein and DNA interactions are identified. This is a specification of a process endpoint: the boundary in the process before which they are not identified and after which they are. During the realization of the plan, the goal is to get to the point of having the interactions, and participants in the realization of the plan try to do that.
obo:IAO_0000005
Answers the question, why did you do this experiment?
obo:IAO_0000005
PERSON: Alan Ruttenberg
obo:IAO_0000005
PERSON: Barry Smith
obo:IAO_0000005
PERSON: Bjoern Peters
obo:IAO_0000005
PERSON: Jennifer Fostel
obo:IAO_0000005
goal specification
obo:IAO_0000005
OBI Plan and Planned Process/Roles Branch
obo:IAO_0000005
OBI_0000217
obo:IAO_0000005
obo:iao.owl
obo:IAO_0000005
objective specification
obo:IAO_0000007
Pour the contents of flask 1 into flask 2
obo:IAO_0000007
obo:IAO_0000122
obo:IAO_0000007
A directive information entity that describes an action the bearer will take.
obo:IAO_0000007
Alan Ruttenberg
obo:IAO_0000007
OBI Plan and Planned Process branch
obo:IAO_0000007
obo:iao.owl
obo:IAO_0000007
action specification
obo:IAO_0000027
data item
obo:IAO_0000027
Data items include counts of things, analyte concentrations, and statistical summaries.
obo:IAO_0000027
obo:IAO_0000125
obo:IAO_0000027
a data item is an information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements.
obo:IAO_0000027
a data item that is about the outcome measured by a clinical trial.
obo:IAO_0000027
2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers.
obo:IAO_0000027
2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum.
obo:IAO_0000027
2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym.
obo:IAO_0000027
2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/
obo:IAO_0000027
JAR: datum -- well, this will be very tricky to define, but maybe some
information-like stuff that might be put into a computer and that is
meant, by someone, to denote and/or to be interpreted by some
process... I would include lists, tables, sentences... I think I might
defer to Barry, or to Brian Cantwell Smith
JAR: A data item is an approximately justified approximately true approximate belief
obo:IAO_0000027
PERSON: Alan Ruttenberg
obo:IAO_0000027
PERSON: Chris Stoeckert
obo:IAO_0000027
PERSON: Jonathan Rees
obo:IAO_0000027
data
obo:IAO_0000027
obo:iao.owl
obo:IAO_0000027
obo:ogms.owl
obo:IAO_0000027
data item
obo:IAO_0000030
information content entity
obo:IAO_0000030
Examples of information content entites include journal articles, data, graphical layouts, and graphs.
obo:IAO_0000030
obo:IAO_0000122
obo:IAO_0000030
A generically dependent continuant that is about some thing.
obo:IAO_0000030
An information content entity is an entity that is generically dependent on some artifact and stands in relation of aboutness to some entity
obo:IAO_0000030
2014-03-10: The use of "thing" is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ).
obo:IAO_0000030
information_content_entity 'is_encoded_in' some digital_entity in obi before split (040907). information_content_entity 'is_encoded_in' some physical_document in obi before split (040907).
Previous. An information content entity is a non-realizable information entity that 'is encoded in' some digital or physical entity.
obo:IAO_0000030
PERSON: Chris Stoeckert
obo:IAO_0000030
OBI_0000142
obo:IAO_0000030
obo:dron.owl
obo:IAO_0000030
obo:envo.owl
obo:IAO_0000030
obo:iao.owl
obo:IAO_0000030
obo:ico.owl
obo:IAO_0000030
obo:obi.owl
obo:IAO_0000030
obo:ogms.owl
obo:IAO_0000030
obo:omrse.owl
obo:IAO_0000030
obo:ontoneo.owl
obo:IAO_0000030
obo:opmi.owl
obo:IAO_0000030
obo:pdro.owl
obo:IAO_0000030
information content entity
obo:IAO_0000030
information content entity
obo:IAO_0000033
obo:IAO_0000122
obo:IAO_0000033
An information content entity whose concretizations indicate to their bearer how to realize them in a process.
obo:IAO_0000033
2009-03-16: provenance: a term realizable information entity was proposed for OBI (OBI_0000337) , edited by the PlanAndPlannedProcess branch. Original definition was "is the specification of a process that can be concretized and realized by an actor" with alternative term "instruction".It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.
obo:IAO_0000033
2013-05-30 Alan Ruttenberg: What differentiates a directive information entity from an information concretization is that it can have concretizations that are either qualities or realizable entities. The concretizations that are realizable entities are created when an individual chooses to take up the direction, i.e. has the intention to (try to) realize it.
obo:IAO_0000033
8/6/2009 Alan Ruttenberg: Changed label from "information entity about a realizable" after discussions at ICBO
obo:IAO_0000033
Werner pushed back on calling it realizable information entity as it isn't realizable. However this name isn't right either. An example would be a recipe. The realizable entity would be a plan, but the information entity isn't about the plan, it, once concretized, *is* the plan. -Alan
obo:IAO_0000033
PERSON: Alan Ruttenberg
obo:IAO_0000033
PERSON: Bjoern Peters
obo:IAO_0000033
obo:iao.owl
obo:IAO_0000033
obo:obi.owl
obo:IAO_0000033
directive information entity
obo:IAO_0000078
curation status specification
obo:IAO_0000078
obo:IAO_0000125
obo:IAO_0000078
The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value.
obo:IAO_0000078
Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting)
obo:IAO_0000078
PERSON:Bill Bug
obo:IAO_0000078
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000078
OBI_0000266
obo:IAO_0000078
obo:iao.owl
obo:IAO_0000078
curation status specification
obo:IAO_0000088
report
obo:IAO_0000088
Examples of reports are gene lists and investigation reports. These are not published (journal) articles but may be included in a journal article.
obo:IAO_0000088
obo:IAO_0000125
obo:IAO_0000088
a document assembled by an author for the purpose of providing information for the audience. A report is the output of a documenting process and has the objective to be consumed by a specific audience. Topic of the report is on something that has completed. A report is not a single figure. Examples of reports are journal article, patent application, grant progress report, case report (not patient record)
obo:IAO_0000088
2009-03-16: comment from Darren Natale: I am slightly uneasy with the sentence "Topic of the report is on
something that has completed." Should it be restricted to those things
that are completed? For example, a progress report is (usually) about
something that definitely has *not* been completed, or may include
(only) projections. I think the definition would not suffer if the
whole sentence is deleted.
obo:IAO_0000088
2009-03-16: this was report of results with definition: A report is a narrative object that is a formal statement of the results of an investigation, or of any matter on which definite information is required, made by some person or body instructed or required to do so.
obo:IAO_0000088
2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI.
obo:IAO_0000088
2009-08-10 Alan Ruttenberg: Larry Hunter suggests that this be obsoleted and replaced by 'document'. Alan restored as there are OBI dependencies and this merits further discussion
obo:IAO_0000088
disagreement about where reports go. alan: only some gene lists are reports. Is a report all the content of some document? The example of usage suggests that a report may be part of some article. Term needs clarification
obo:IAO_0000088
PERSON: Alan Ruttenberg
obo:IAO_0000088
PERSON: Melanie Courtot
obo:IAO_0000088
PERSON:Chris Stoeckert
obo:IAO_0000088
GROUP: OBI
obo:IAO_0000088
OBI_0000099
obo:IAO_0000088
obo:iao.owl
obo:IAO_0000088
report
obo:IAO_0000102
data about an ontology part is a data item about a part of an ontology, for example a term
obo:IAO_0000102
Person:Alan Ruttenberg
obo:IAO_0000102
obo:iao.owl
obo:IAO_0000102
data about an ontology part
obo:IAO_0000104
plan specification
obo:IAO_0000104
PMID: 18323827.Nat Med. 2008 Mar;14(3):226.New plan proposed to help resolve conflicting medical advice.
obo:IAO_0000104
obo:IAO_0000122
obo:IAO_0000104
A directive information entity with action specifications and objective specifications as parts that, when concretized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified.
obo:IAO_0000104
2009-03-16: provenance: a term a plan was proposed for OBI (OBI_0000344) , edited by the PlanAndPlannedProcess branch. Original definition was " a plan is a specification of a process that is realized by an actor to achieve the objective specified as part of the plan". It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.
obo:IAO_0000104
2014-03-31: A plan specification can have other parts, such as conditional specifications.
obo:IAO_0000104
Alternative previous definition: a plan is a set of instructions that specify how an objective should be achieved
obo:IAO_0000104
Alan Ruttenberg
obo:IAO_0000104
OBI Plan and Planned Process branch
obo:IAO_0000104
OBI_0000344
obo:IAO_0000104
obo:obi.owl
obo:IAO_0000104
2/3/2009 Comment from OBI review.
Action specification not well enough specified.
Conditional specification not well enough specified.
Question whether all plan specifications have objective specifications.
Request that IAO either clarify these or change definitions not to use them
obo:IAO_0000104
plan specification
obo:IAO_0000111
editor preferred label
obo:IAO_0000111
editor preferred label
obo:IAO_0000111
editor preferred term
obo:IAO_0000111
editor preferred term
obo:IAO_0000111
editor preferred term~editor preferred label
obo:IAO_0000111
obo:IAO_0000122
obo:IAO_0000111
The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English)
obo:IAO_0000111
PERSON:Daniel Schober
obo:IAO_0000111
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000111
obo:iao.owl
obo:IAO_0000111
editor preferred label
obo:IAO_0000111
editor preferred label
obo:IAO_0000111
editor preferred term
obo:IAO_0000111
editor preferred term
obo:IAO_0000111
editor preferred term~editor preferred label
obo:IAO_0000112
example
obo:IAO_0000112
example of usage
obo:IAO_0000112
obo:IAO_0000122
obo:IAO_0000112
A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not
obo:IAO_0000112
A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold.
obo:IAO_0000112
PERSON:Daniel Schober
obo:IAO_0000112
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000112
obo:iao.owl
obo:IAO_0000112
example of usage
obo:IAO_0000112
example of usage
obo:IAO_0000114
has curation status
obo:IAO_0000114
PERSON:Alan Ruttenberg
obo:IAO_0000114
PERSON:Bill Bug
obo:IAO_0000114
PERSON:Melanie Courtot
obo:IAO_0000114
OBI_0000281
obo:IAO_0000114
has curation status
obo:IAO_0000114
has curation status
obo:IAO_0000115
definition
obo:IAO_0000115
definition
obo:IAO_0000115
textual definition
obo:IAO_0000115
obo:IAO_0000122
obo:IAO_0000115
A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software.
obo:IAO_0000115
English language definitions of what NCI means by the concept. These are limited to 1024 characters. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software.
obo:IAO_0000115
The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.
obo:IAO_0000115
The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.
obo:IAO_0000115
2012-04-05:
Barry Smith
The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible.
Can you fix to something like:
A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property.
Alan Ruttenberg
Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria.
On the specifics of the proposed definition:
We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition.
Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable.
We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with.
obo:IAO_0000115
2012-04-05:
Barry Smith
The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible.
Can you fix to something like:
A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property.
Alan Ruttenberg
Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria.
On the specifics of the proposed definition:
We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition.
Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable.
We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with.
obo:IAO_0000115
PERSON:Daniel Schober
obo:IAO_0000115
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000115
DEFINITION
obo:IAO_0000115
obo:iao.owl
obo:IAO_0000115
definition
obo:IAO_0000115
definition
obo:IAO_0000115
textual definition
obo:IAO_0000116
editor note
obo:IAO_0000116
obo:IAO_0000122
obo:IAO_0000116
An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology.
obo:IAO_0000116
PERSON:Daniel Schober
obo:IAO_0000116
GROUP:OBI:<http://purl.obfoundry.org/obo/obi>
obo:IAO_0000116
GROUP:OBI:<http://purl.obofoundry.org/obo/obi>
obo:IAO_0000116
IAO:0000116
obo:IAO_0000116
uberon
obo:IAO_0000116
editor_note
obo:IAO_0000116
1
obo:IAO_0000116
editor_note
obo:IAO_0000116
obo:iao.owl
obo:IAO_0000116
editor note
obo:IAO_0000116
editor note
obo:IAO_0000117
definition editor
obo:IAO_0000117
term editor
obo:IAO_0000117
obo:IAO_0000122
obo:IAO_0000117
Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people
obo:IAO_0000117
Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people
obo:IAO_0000117
20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115.
obo:IAO_0000117
20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115.
obo:IAO_0000117
PERSON:Daniel Schober
obo:IAO_0000117
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000117
obo:iao.owl
obo:IAO_0000117
definition editor
obo:IAO_0000117
definition editor
obo:IAO_0000117
term editor
obo:IAO_0000117
term editor
obo:IAO_0000118
alternative term
obo:IAO_0000118
obo:IAO_0000125
obo:IAO_0000118
An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent)
obo:IAO_0000118
PERSON:Daniel Schober
obo:IAO_0000118
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000118
obo:iao.owl
obo:IAO_0000118
alternative term
obo:IAO_0000118
alternative term
obo:IAO_0000119
definition source
obo:IAO_0000119
obo:IAO_0000122
obo:IAO_0000119
Formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007
obo:IAO_0000119
formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007
obo:IAO_0000119
PERSON:Daniel Schober
obo:IAO_0000119
Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w
obo:IAO_0000119
Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w
obo:IAO_0000119
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000119
obo:iao.owl
obo:IAO_0000119
definition source
obo:IAO_0000119
definition source
obo:IAO_0000122
ready for release
obo:IAO_0000123
metadata incomplete
obo:IAO_0000125
pending final vetting
obo:IAO_0000136
is about
obo:IAO_0000232
curator note
obo:IAO_0000232
obo:IAO_0000122
obo:IAO_0000232
An administrative note of use for a curator but of no use for a user
obo:IAO_0000232
PERSON:Alan Ruttenberg
obo:IAO_0000232
IAO:0000232
obo:IAO_0000232
uberon
obo:IAO_0000232
curator_notes
obo:IAO_0000232
1
obo:IAO_0000232
curator_notes
obo:IAO_0000232
obo:iao.owl
obo:IAO_0000232
curator note
obo:IAO_0000232
curator note
obo:IAO_0000232
curator notes
obo:IAO_0000233
term tracker item
obo:IAO_0000233
the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/
obo:IAO_0000233
obo:IAO_0000125
obo:IAO_0000233
An IRI or similar locator for a request or discussion of an ontology term.
obo:IAO_0000233
Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg
obo:IAO_0000233
Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg
obo:IAO_0000233
The 'tracker item' can associate a tracker with a specific ontology term.
obo:IAO_0000233
term tracker item
obo:IAO_0000300
textual entity
obo:IAO_0000300
Words, sentences, paragraphs, and the written (non-figure) parts of publications are all textual entities
obo:IAO_0000300
obo:IAO_0000123
obo:IAO_0000300
A textual entity is a part of a manifestation (FRBR sense), a generically dependent continuant whose concretizations are patterns of glyphs intended to be interpreted as words, formulas, etc.
obo:IAO_0000300
AR, (IAO call 2009-09-01): a document as a whole is not typically a textual entity, because it has pictures in it - rather there are parts of it that are textual entities. Examples: The title, paragraph 2 sentence 7, etc.
obo:IAO_0000300
MC, 2009-09-14 (following IAO call 2009-09-01): textual entities live at the FRBR (http://en.wikipedia.org/wiki/Functional_Requirements_for_Bibliographic_Records) manifestation level. Everything is significant: line break, pdf and html versions of same document are different textual entities.
obo:IAO_0000300
PERSON: Lawrence Hunter
obo:IAO_0000300
text
obo:IAO_0000300
obo:obi.owl
obo:IAO_0000300
textual entity
obo:IAO_0000310
document
obo:IAO_0000310
A journal article, patent application, laboratory notebook, or a book
obo:IAO_0000310
obo:IAO_0000120
obo:IAO_0000310
A collection of information content entities intended to be understood together as a whole
obo:IAO_0000310
PERSON: Lawrence Hunter
obo:IAO_0000310
obo:iao.owl
obo:IAO_0000310
document
obo:IAO_0000412
imported from
obo:IAO_0000412
obo:IAO_0000125
obo:IAO_0000412
For external terms/classes, the ontology from which the term was imported
obo:IAO_0000412
PERSON:Alan Ruttenberg
obo:IAO_0000412
PERSON:Melanie Courtot
obo:IAO_0000412
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
obo:IAO_0000412
obo:iao.owl
obo:IAO_0000412
imported from
obo:IAO_0000412
imported from
obo:IAO_0000422
obo:IAO_0000123
obo:IAO_0000422
A textual entity that is used as directive to deliver something to a person, or organization
obo:IAO_0000422
2010-05-24 Alan Ruttenberg. Use label for the string representation. See issue https://github.com/information-artifact-ontology/IAO/issues/59
obo:IAO_0000422
obo:obi.owl
obo:IAO_0000422
postal address
obo:IAO_0000429
email address
obo:IAO_0000429
obo:IAO_0000123
obo:IAO_0000429
Alan Ruttenberg 1/3/2012 - Provisional id, see issue at https://github.com/information-artifact-ontology/IAO/issues/130&thanks=130&ts=1325636583
obo:IAO_0000429
Person:Alan Ruttenberg
obo:IAO_0000429
Person:Chris Stoeckart
obo:IAO_0000429
obo:obi.owl
obo:IAO_0000429
email address
obo:IAO_0000578
The sentence "The article has Pubmed ID 12345." contains a CRID that has two parts: one part is the CRID symbol, which is '12345'; the other part denotes the CRID registry, which is Pubmed.
obo:IAO_0000578
obo:IAO_0000120
obo:IAO_0000578
An information content entity that consists of a CRID symbol and additional information about the CRID registry to which it belongs.
obo:IAO_0000578
2014-05-05: In defining this term we take no position on what the CRID denotes. In particular do not assume it denotes a *record* in the CRID registry (since the registry might not have 'records').
obo:IAO_0000578
Alan, IAO call 20101124: potentially the CRID denotes the instance it was associated with during creation.
obo:IAO_0000578
Note, IAO call 20101124: URIs are not always CRID, as not centrally registered. We acknowledge that CRID is a subset of a larger identifier class, but this subset fulfills our current needs. OBI PURLs are CRID as they are registered with OCLC. UPCs (Universal Product Codes from AC Nielsen)are not CRID as they are not centrally registered.
obo:IAO_0000578
PERSON: Alan Ruttenberg
obo:IAO_0000578
PERSON: Bill Hogan
obo:IAO_0000578
PERSON: Bjoern Peters
obo:IAO_0000578
PERSON: Melanie Courtot
obo:IAO_0000578
CRID
obo:IAO_0000578
Original proposal from Bjoern, discussions at IAO calls
obo:IAO_0000578
obo:iao.owl
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:IAO_0000578
Primary Registry and Trial Identifying Number
obo:IAO_0000578
centrally registered identifier
obo:IAO_0000600
elucidation
obo:IAO_0000600
person:Alan Ruttenberg
obo:IAO_0000600
Person:Barry Smith
obo:IAO_0000600
Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms
obo:IAO_0000600
obo:iao.owl
obo:IAO_0000600
elucidation
obo:IAO_0000600
elucidation
obo:IAO_0000601
has associated axiom(nl)
obo:IAO_0000601
Person:Alan Ruttenberg
obo:IAO_0000601
Person:Alan Ruttenberg
obo:IAO_0000601
An axiom associated with a term expressed using natural language
obo:IAO_0000601
obo:iao.owl
obo:IAO_0000601
has associated axiom(nl)
obo:IAO_0000601
has associated axiom(nl)
obo:IAO_0000602
has associated axiom(fol)
obo:IAO_0000602
Person:Alan Ruttenberg
obo:IAO_0000602
Person:Alan Ruttenberg
obo:IAO_0000602
An axiom expressed in first order logic using CLIF syntax
obo:IAO_0000602
obo:iao.owl
obo:IAO_0000602
has associated axiom(fol)
obo:IAO_0000602
has associated axiom(fol)
obo:IAO_0010000
obo:iao.owl
obo:IAO_0010000
has axiom label
obo:MS_1000590
Home institution of the contact person.
obo:MS_1000590
obo:ms.owl
obo:MS_1000590
value-type:xsd:string
obo:MS_1000590
MS
obo:MS_1000590
MS:1000590
obo:MS_1000590
contact affiliation
obo:NCBITaxon_1
obo:ncbitaxon.owl
obo:NCBITaxon_1
GC_ID:1
obo:NCBITaxon_1
ncbi_taxonomy
obo:NCBITaxon_1
all
obo:NCBITaxon_1
root
obo:NCBITaxon_131567
obo:ncbitaxon.owl
obo:NCBITaxon_131567
GC_ID:1
obo:NCBITaxon_131567
ncbi_taxonomy
obo:NCBITaxon_131567
biota
obo:NCBITaxon_131567
cellular organisms
obo:NCBITaxon_2759
obo:ncbitaxon.owl
obo:NCBITaxon_2759
obo:NCBITaxon_superkingdom
obo:NCBITaxon_2759
GC_ID:1
obo:NCBITaxon_2759
PMID:23020233
obo:NCBITaxon_2759
PMID:30257078
obo:NCBITaxon_2759
eucaryotes
obo:NCBITaxon_2759
eukaryotes
obo:NCBITaxon_2759
ncbi_taxonomy
obo:NCBITaxon_2759
Eucarya
obo:NCBITaxon_2759
Eucaryotae
obo:NCBITaxon_2759
Eukarya
obo:NCBITaxon_2759
Eukaryotae
obo:NCBITaxon_2759
eukaryotes
obo:NCBITaxon_2759
Eukaryota
obo:NCBITaxon_40674
obo:ncbitaxon.owl
obo:NCBITaxon_40674
obo:NCBITaxon_class
obo:NCBITaxon_40674
GC_ID:1
obo:NCBITaxon_40674
mammals
obo:NCBITaxon_40674
ncbi_taxonomy
obo:NCBITaxon_40674
mammals
obo:NCBITaxon_40674
Mammalia
obo:NCBITaxon_7742
obo:ncbitaxon.owl
obo:NCBITaxon_7742
GC_ID:1
obo:NCBITaxon_7742
Vertebrata
obo:NCBITaxon_7742
vertebrates
obo:NCBITaxon_7742
ncbi_taxonomy
obo:NCBITaxon_7742
vertebrates
obo:NCBITaxon_7742
Vertebrata <vertebrates>
obo:NCBITaxon_9606
Homo sapiens
obo:NCBITaxon_9606
Homo sapiens
obo:NCBITaxon_9606
human
obo:NCBITaxon_9606
human being
obo:NCBITaxon_9606
man
obo:NCBITaxon_9606
person
obo:NCBITaxon_9606
obo:envo.owl
obo:NCBITaxon_9606
obo:ncbitaxon.owl
obo:NCBITaxon_9606
obo:obi.owl
obo:NCBITaxon_9606
obo:omrse.owl
obo:NCBITaxon_9606
obo:opmi.owl
obo:NCBITaxon_9606
obo:NCBITaxon_species
obo:NCBITaxon_9606
GC_ID:1
obo:NCBITaxon_9606
human
obo:NCBITaxon_9606
man
obo:NCBITaxon_9606
ncbi_taxonomy
obo:NCBITaxon_9606
Home sapiens
obo:NCBITaxon_9606
Homo sampiens
obo:NCBITaxon_9606
Homo sapeins
obo:NCBITaxon_9606
Homo sapian
obo:NCBITaxon_9606
Homo sapians
obo:NCBITaxon_9606
Homo sapien
obo:NCBITaxon_9606
Homo sapience
obo:NCBITaxon_9606
Homo sapiense
obo:NCBITaxon_9606
Homo sapients
obo:NCBITaxon_9606
Homo sapines
obo:NCBITaxon_9606
Homo spaiens
obo:NCBITaxon_9606
Homo spiens
obo:NCBITaxon_9606
Humo sapiens
obo:NCBITaxon_9606
humans
obo:NCBITaxon_9606
Homo sapiens
obo:NCBITaxon_9606
Homo sapiens
obo:NCIT_A11
A property created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source.
obo:NCIT_A11
An association created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are a contributing source.
obo:NCIT_A11
A11
obo:NCIT_A11
Conceptual Entity
obo:NCIT_A11
Has_NICHD_Parent
obo:NCIT_A11
Has_NICHD_Parent
obo:NCIT_A11
Has_NICHD_Parent
obo:NCIT_C115575
Records containing any interim or final results, as well as clinical and statistical descriptions, presentations, analyses and interpretations of any therapeutic, prophylactic, or diagnostic agent used in human subjects in a clinical trial.
obo:NCIT_C115575
obo:ncit.owl
obo:NCIT_C115575
C115575
obo:NCIT_C115575
Intellectual Product
obo:NCIT_C115575
Clinical Trial Final Report
obo:NCIT_C115575
C3889645
obo:NCIT_C115575
CDISC-GLOSS
obo:NCIT_C115575
CareLex
obo:NCIT_C115575
A written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report. [ICH E3]
obo:NCIT_C115575
Subcategory name for the eTMF domain used to classify clinical study report documents.
obo:NCIT_C115575
CTrial Fin Rept Subcat
obo:NCIT_C115575
Central Trial Final Reports Subcategory
obo:NCIT_C115575
Clinical Trial Final Report
obo:NCIT_C115575
Reports
obo:NCIT_C115575
final report
obo:NCIT_C115575
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548
obo:NCIT_C115575
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C115575
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C115575
Clinical Trial Final Report
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C129000
An observational study that is also considered to be a Patient Registry. This type of study should only be registered once in the Protocol Registration and Results System (PRS), by the sponsor responsible for the primary data collection and analysis.
obo:NCIT_C129000
Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)
obo:NCIT_C129000
obo:ncit.owl
obo:NCIT_C129000
C129000
obo:NCIT_C129000
Research Activity
obo:NCIT_C129000
Patient Registry Study
obo:NCIT_C129000
C0920631
obo:NCIT_C129000
CDISC
obo:NCIT_C129000
Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)
obo:NCIT_C129000
PATIENT REGISTRY
obo:NCIT_C129000
Patient Registry Study
obo:NCIT_C129000
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C129000
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C129000
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C129000
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077
obo:NCIT_C129000
Patient Registry Study
obo:NCIT_C139174
An intervention of a device product is being evaluated to determine the feasibility of the product or to test a prototype device and not health outcomes. Such studies are conducted to confirm the design and operating specifications of a device before beginning a full clinical trial. (ClinicalTrials.gov)
obo:NCIT_C139174
obo:ncit.owl
obo:NCIT_C139174
C139174
obo:NCIT_C139174
Research Activity
obo:NCIT_C139174
Device Feasibility Study
obo:NCIT_C139174
CL526612
obo:NCIT_C139174
CDISC
obo:NCIT_C139174
An intervention of a device product is being evaluated to determine the feasibility of the product or to test a prototype device and not health outcomes. Such studies are conducted to confirm the design and operating specifications of a device before beginning a full clinical trial. (ClinicalTrials.gov)
obo:NCIT_C139174
DEVICE FEASIBILITY
obo:NCIT_C139174
Device Feasibility
obo:NCIT_C139174
Device Feasibility Study
obo:NCIT_C139174
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C139174
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067
obo:NCIT_C139174
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C139174
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C139174
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C139174
Device Feasibility Study
obo:NCIT_C142175
The nature of the investigation or the investigational use for which clinical study is being done.
obo:NCIT_C142175
obo:ncit.owl
obo:NCIT_C142175
C142175
obo:NCIT_C142175
Research Activity
obo:NCIT_C142175
Study Type
obo:NCIT_C142175
CL540168
obo:NCIT_C142175
CDISC
obo:NCIT_C142175
Describes the role the study plays in determining the interventions a subject receives.
obo:NCIT_C142175
STYPE
obo:NCIT_C142175
Study Type
obo:NCIT_C142175
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C142175
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C142191
obo:NCIT_C142175
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C142175
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738
obo:NCIT_C142175
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C142175
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152
obo:NCIT_C142175
Study Type
obo:NCIT_C142175
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C142175
https://www.who.int/ictrp/network/trds/en/
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C142660
Participants are assigned to intervention groups by chance
obo:NCIT_C142660
The process of resource distribution that is done by chance.
obo:NCIT_C142660
obo:ncit.owl
obo:NCIT_C142660
C142660
obo:NCIT_C142660
Activity
obo:NCIT_C142660
Random Allocation
obo:NCIT_C142660
CL540611
obo:NCIT_C142660
CDISC-GLOSS
obo:NCIT_C142660
Assignment of subjects to treatment (or control) groups in an unpredictable way. NOTE: in a blinded study, assignment sequences are concealed, but available for disclosure in the event a subject has an adverse experience.
obo:NCIT_C142660
Random Allocation
obo:NCIT_C142660
random allocation
obo:NCIT_C142660
randomized
obo:NCIT_C142660
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C142660
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C142660
Random Allocation
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C147141
The main objective of the intervention(s) being evaluated by the clinical trial.
obo:NCIT_C147141
The principal reason or intention for the execution of an interventional or non-interventional clinical study.
obo:NCIT_C147141
obo:ncit.owl
obo:NCIT_C147141
C147141
obo:NCIT_C147141
Idea or Concept
obo:NCIT_C147141
Study Primary Purpose
obo:NCIT_C147141
CL545057
obo:NCIT_C147141
CDISC
obo:NCIT_C147141
The principal reason or intention for the execution of an interventional or non-interventional clinical study. (NCI)
obo:NCIT_C147141
Study Primary Purpose
obo:NCIT_C147141
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C147141
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066
obo:NCIT_C147141
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C147141
Study Primary Purpose
obo:NCIT_C147141
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:NCIT_C15238
Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.
obo:NCIT_C15238
obo:ncit.owl
obo:NCIT_C15238
C15238
obo:NCIT_C15238
Therapeutic or Preventive Procedure
obo:NCIT_C15238
Gene Therapy
obo:NCIT_C15238
Gene Therapy
obo:NCIT_C15238
C0017296
obo:NCIT_C15238
CDISC
obo:NCIT_C15238
CTRP
obo:NCIT_C15238
Application of genetic material into cells in order to correct an inherited or acquired disease.
obo:NCIT_C15238
Treatment of human disease by gene transfer.
obo:NCIT_C15238
Treatment that alters a gene. In studies of gene therapy for cancer, researchers are trying to improve the body's natural ability to fight the disease or to make the cancer cells more sensitive to other kinds of therapy.
obo:NCIT_C15238
Gene_Therapy
obo:NCIT_C15238
Gene therapy techniques attempt to replace a faulty or missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.
obo:NCIT_C15238
DNA Therapy
obo:NCIT_C15238
GENETIC
obo:NCIT_C15238
Gene Therapy
obo:NCIT_C15238
Gene Transfer Procedure
obo:NCIT_C15238
Gene transfer
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15238
Genetic
obo:NCIT_C15238
Intervention, Genetic
obo:NCIT_C15238
Molecular Biology, Gene Therapy
obo:NCIT_C15238
gene therapy
obo:NCIT_C15238
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977
obo:NCIT_C15238
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169
obo:NCIT_C15238
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15238
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15238
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99078
obo:NCIT_C15238
Gene Therapy
obo:NCIT_C15245
A multidisciplinary field of inquiry that examines the costs, quality, accessibility, delivery, organization, financing, and outcomes of health care services.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15245
One or more interventions for evaluating the delivery, processes, management, organization, or financing of healthcare.
obo:NCIT_C15245
obo:ncit.owl
obo:NCIT_C15245
C15245
obo:NCIT_C15245
Research Activity
obo:NCIT_C15245
Health Services Research
obo:NCIT_C15245
C0018757
obo:NCIT_C15245
CDISC
obo:NCIT_C15245
A type of study designed to evaluate the delivery, processes, management, organization or financing of health care. (ClinicalTrials.gov)
obo:NCIT_C15245
Health_Services_Research
obo:NCIT_C15245
HEALTH SERVICES RESEARCH
obo:NCIT_C15245
Health Services Research
obo:NCIT_C15245
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15245
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067
obo:NCIT_C15245
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15245
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C15245
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15245
Health Services Research
obo:NCIT_C15329
A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.
obo:NCIT_C15329
obo:ncit.owl
obo:NCIT_C15329
obo:NCIT_C25218
obo:NCIT_C15329
C15329
obo:NCIT_C15329
Health Care Activity
obo:NCIT_C15329
Surgical Procedure
obo:NCIT_C15329
Surgical Procedure
obo:NCIT_C15329
C0543467
obo:NCIT_C15329
CPTAC
obo:NCIT_C15329
CTRP
obo:NCIT_C15329
NICHD
obo:NCIT_C15329
A procedure to remove or repair a part of the body or to find out whether disease is present. An operation.
obo:NCIT_C15329
Surgical_Procedure
obo:NCIT_C15329
Surgical Procedure
obo:NCIT_C15329
Surgery
obo:NCIT_C15329
Surgically Treated
obo:NCIT_C15329
Operation
obo:NCIT_C15329
Surgery
obo:NCIT_C15329
Surgical
obo:NCIT_C15329
Surgical Interventions
obo:NCIT_C15329
Surgical Procedure
obo:NCIT_C15329
Surgical Procedures
obo:NCIT_C15329
Surgically
obo:NCIT_C15329
Type of Surgery
obo:NCIT_C15329
surgery
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156952
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156953
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156954
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157524
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157526
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157527
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157528
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157529
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157530
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157532
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157533
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157534
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159412
obo:NCIT_C15329
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90259
obo:NCIT_C15329
Surgical Procedure
obo:NCIT_C15329
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15600
A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15600
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
obo:NCIT_C15600
obo:ncit.owl
obo:NCIT_C15600
C15600
obo:NCIT_C15600
Research Activity
obo:NCIT_C15600
Phase I Trial
obo:NCIT_C15600
C0920321
obo:NCIT_C15600
CDISC
obo:NCIT_C15600
CDISC-GLOSS
obo:NCIT_C15600
The first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, phase I trials usually include only a small number of patients who have not been helped by other treatments.
obo:NCIT_C15600
The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [after FDA CDER handbook, ICH E8]
obo:NCIT_C15600
The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase I studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [After FDA CDER Handbook, ICH E8] (CDISC glossary)
obo:NCIT_C15600
Phase_I_Trial
obo:NCIT_C15600
1
obo:NCIT_C15600
Clinical Trials, Phase I
obo:NCIT_C15600
Early-Stage Clinical Trials
obo:NCIT_C15600
PHASE I TRIAL
obo:NCIT_C15600
Phase 1 Study
obo:NCIT_C15600
Phase I Clinical Trials
obo:NCIT_C15600
Phase I Protocol
obo:NCIT_C15600
Phase I Study
obo:NCIT_C15600
Phase I Trial
obo:NCIT_C15600
Trial Phase 1
obo:NCIT_C15600
phase 1
obo:NCIT_C15600
phase I trial
obo:NCIT_C15600
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15600
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15600
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737
obo:NCIT_C15600
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15600
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C15600
Phase I Trial
obo:NCIT_C15601
A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15601
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
obo:NCIT_C15601
obo:ncit.owl
obo:NCIT_C15601
C15601
obo:NCIT_C15601
Research Activity
obo:NCIT_C15601
Phase II Trial
obo:NCIT_C15601
C0282460
obo:NCIT_C15601
CDISC
obo:NCIT_C15601
CDISC-GLOSS
obo:NCIT_C15601
A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.
obo:NCIT_C15601
Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [after FDA CDER handbook, ICH E8]
obo:NCIT_C15601
Phase 2. Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary)
obo:NCIT_C15601
Phase_II_Trial
obo:NCIT_C15601
2
obo:NCIT_C15601
Clinical Trials, Phase II
obo:NCIT_C15601
PHASE II TRIAL
obo:NCIT_C15601
Phase 2 Study
obo:NCIT_C15601
Phase II Clinical Trial
obo:NCIT_C15601
Phase II Protocol
obo:NCIT_C15601
Phase II Study
obo:NCIT_C15601
Phase II Trial
obo:NCIT_C15601
Trial Phase 2
obo:NCIT_C15601
phase 2
obo:NCIT_C15601
phase II trial
obo:NCIT_C15601
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15601
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15601
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737
obo:NCIT_C15601
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15601
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C15601
Phase II Trial
obo:NCIT_C15602
A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15602
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
obo:NCIT_C15602
obo:ncit.owl
obo:NCIT_C15602
C15602
obo:NCIT_C15602
Research Activity
obo:NCIT_C15602
Phase III Trial
obo:NCIT_C15602
C0282461
obo:NCIT_C15602
CDISC
obo:NCIT_C15602
CDISC-GLOSS
obo:NCIT_C15602
A study to compare the results of people taking a new treatment with the results of people taking the standard treatment (for example, which group has better survival rates or fewer side effects). In most cases, studies move into phase III only after a treatment seems to work in phases I and II. Phase III trials may include hundreds of people.
obo:NCIT_C15602
Phase 3. Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary)
obo:NCIT_C15602
Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [after FDA CDER handbook, ICH E8]
obo:NCIT_C15602
Phase_III_Trial
obo:NCIT_C15602
3
obo:NCIT_C15602
Clinical Trials, Phase III
obo:NCIT_C15602
PHASE III TRIAL
obo:NCIT_C15602
Phase 3 Study
obo:NCIT_C15602
Phase III Clinical Trial
obo:NCIT_C15602
Phase III Protocol
obo:NCIT_C15602
Phase III Study
obo:NCIT_C15602
Phase III Trial
obo:NCIT_C15602
Phase III Trials
obo:NCIT_C15602
Trial Phase 3
obo:NCIT_C15602
phase 3
obo:NCIT_C15602
phase III trial
obo:NCIT_C15602
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15602
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15602
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737
obo:NCIT_C15602
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15602
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C15602
Phase III Trial
obo:NCIT_C15603
A randomized, controlled trial that is designed to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15603
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
obo:NCIT_C15603
obo:ncit.owl
obo:NCIT_C15603
C15603
obo:NCIT_C15603
Research Activity
obo:NCIT_C15603
Phase IV Trial
obo:NCIT_C15603
C0282462
obo:NCIT_C15603
CDISC
obo:NCIT_C15603
CDISC-GLOSS
obo:NCIT_C15603
After a treatment has been approved and is being marketed, it is studied in a phase IV trial to evaluate side effects that were not apparent in the phase III trial. Thousands of people are involved in a phase IV trial.
obo:NCIT_C15603
Phase 4. Postmarketing (Phase 4) studies to delineate additional information about the drug's risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [After FDA CDER Handbook, ICH E8] (CDISC glossary)
obo:NCIT_C15603
Post approval studies to delineate additional information about the drug's risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [after FDA CDER handbook, ICH E8]
obo:NCIT_C15603
Phase_IV_Trial
obo:NCIT_C15603
4
obo:NCIT_C15603
Clinical Trials, Phase IV
obo:NCIT_C15603
PHASE IV TRIAL
obo:NCIT_C15603
Phase 4 Study
obo:NCIT_C15603
Phase IV Clinical Trials
obo:NCIT_C15603
Phase IV Study
obo:NCIT_C15603
Phase IV Trial
obo:NCIT_C15603
Trial Phase 4
obo:NCIT_C15603
phase 4
obo:NCIT_C15603
phase IV trial
obo:NCIT_C15603
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15603
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15603
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737
obo:NCIT_C15603
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15603
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C15603
Phase IV Trial
obo:NCIT_C15693
A clinical research protocol designed to study the safety, dosage levels and response to new treatment. Phase I/II trials combine a Phase I and a Phase II trial of the same treatment into a single protocol.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15693
Trials that are a combination of phases 1 and 2.
obo:NCIT_C15693
obo:ncit.owl
obo:NCIT_C15693
C15693
obo:NCIT_C15693
Research Activity
obo:NCIT_C15693
Phase I/II Trial
obo:NCIT_C15693
C1519043
obo:NCIT_C15693
CDISC
obo:NCIT_C15693
A class of clinical study that combines elements characteristic of traditional Phase I and Phase II trials. See also Phase I, Phase II.
obo:NCIT_C15693
A trial to study the safety, dosage levels, and response to a new treatment.
obo:NCIT_C15693
Phase_I_II_Trial
obo:NCIT_C15693
1-2
obo:NCIT_C15693
PHASE I/II TRIAL
obo:NCIT_C15693
Phase I/II Trial
obo:NCIT_C15693
Phase I/II trial
obo:NCIT_C15693
Trial Phase 1-2
obo:NCIT_C15693
Trial Phase 1/2
obo:NCIT_C15693
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15693
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15693
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737
obo:NCIT_C15693
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15693
Phase I/II Trial
obo:NCIT_C15694
A type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15694
Trials that are a combination of phases 2 and 3.
obo:NCIT_C15694
obo:ncit.owl
obo:NCIT_C15694
C15694
obo:NCIT_C15694
Research Activity
obo:NCIT_C15694
Phase II/III Trial
obo:NCIT_C15694
C1519042
obo:NCIT_C15694
CDISC
obo:NCIT_C15694
A class of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.
obo:NCIT_C15694
A trial to study response to a new treatment and the effectiveness of the treatment compared with the standard treatment regimen.
obo:NCIT_C15694
Phase_II_III_Trial
obo:NCIT_C15694
2-3
obo:NCIT_C15694
PHASE II/III TRIAL
obo:NCIT_C15694
Phase II/III Trial
obo:NCIT_C15694
Trial Phase 2-3
obo:NCIT_C15694
Trial Phase 2/3
obo:NCIT_C15694
phase II/III trial
obo:NCIT_C15694
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15694
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15694
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737
obo:NCIT_C15694
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15694
Phase II/III Trial
obo:NCIT_C15714
Fundamental research designed to obtain or increase general scientific knowledge.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C15714
One or more interventions for examining the basic mechanism of action (for example, physiology or biomechanics of an intervention).
obo:NCIT_C15714
obo:ncit.owl
obo:NCIT_C15714
C15714
obo:NCIT_C15714
Research Activity
obo:NCIT_C15714
Basic Research
obo:NCIT_C15714
C0681833
obo:NCIT_C15714
CDISC
obo:NCIT_C15714
A type of study designed to examine the basic mechanism of action (e.g., physiology, biomechanics) of an intervention. (ClinicalTrials.gov)
obo:NCIT_C15714
Basic_Science
obo:NCIT_C15714
BASIC SCIENCE
obo:NCIT_C15714
Basic Research
obo:NCIT_C15714
Basic Science
obo:NCIT_C15714
Basic Science Research
obo:NCIT_C15714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C15714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067
obo:NCIT_C15714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C15714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C15714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C15714
Basic Research
obo:NCIT_C16084
Studies among cancer patients and healthy populations that involve no intervention or alteration in the status of the participants.
obo:NCIT_C16084
obo:ncit.owl
obo:NCIT_C16084
C16084
obo:NCIT_C16084
Research Activity
obo:NCIT_C16084
Observational Study
obo:NCIT_C16084
C1518527
obo:NCIT_C16084
CDISC
obo:NCIT_C16084
A type of study in which individuals are observed or certain outcomes are measured. No attempt is made to affect the outcome (for example, no treatment is given).
obo:NCIT_C16084
Studies in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
obo:NCIT_C16084
Observational_Study
obo:NCIT_C16084
OBSERVATIONAL
obo:NCIT_C16084
Observational Study
obo:NCIT_C16084
Observational Trial
obo:NCIT_C16084
observational study
obo:NCIT_C16084
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C16084
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C16084
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C16084
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077
obo:NCIT_C16084
Observational Study
obo:NCIT_C161319
Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:NCIT_C161319
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C161319
The name(s) of the disease(s) or condition(s) studied in the clinical study, or the focus of the clinical study. Use, if available, appropriate descriptors from NLM's Medical Subject Headings (MeSH)-controlled vocabulary thesaurus or terms from another vocabulary, such as the Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT), that has been mapped to MeSH within the Unified Medical Language System (UMLS) Metathesaurus.
obo:NCIT_C161319
obo:ncit.owl
obo:NCIT_C161319
C161319
obo:NCIT_C161319
Qualitative Concept
obo:NCIT_C161319
Condition or Disease under Study
obo:NCIT_C161319
CDISC
obo:NCIT_C161319
Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)
obo:NCIT_C161319
Condition or Disease under Study
obo:NCIT_C161319
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
https://www.who.int/ictrp/network/trds/en/
obo:NCIT_C161319
health condition(s) or problem(s) studied
obo:NCIT_C161319
target disease
obo:NCIT_C161319
condition
obo:NCIT_C161319
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C161319
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C160921
obo:NCIT_C161319
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C161319
Condition or Disease under Study
obo:NCIT_C19332
The distinguishing qualities or prominent aspects of an individual person.
obo:NCIT_C19332
obo:ncit.owl
obo:NCIT_C19332
obo:opmi.owl
obo:NCIT_C19332
C19332
obo:NCIT_C19332
Organism Attribute
obo:NCIT_C19332
Personal Attribute
obo:NCIT_C19332
C0681884
obo:NCIT_C19332
Personal_Attribute
obo:NCIT_C19332
Personal
obo:NCIT_C19332
Personal Attribute
obo:NCIT_C19332
Subject Characteristics
obo:NCIT_C19332
Personal Attribute
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:NCIT_C25150
A type of eligibility criteria that indicates the age a person must be to participate in a clinical study.
obo:NCIT_C25150
How long something has existed; elapsed time since birth.
obo:NCIT_C25150
obo:ncit.owl
obo:NCIT_C25150
obo:opmi.owl
obo:NCIT_C25150
obo:NCIT_C89335
obo:NCIT_C25150
C25150
obo:NCIT_C25150
Organism Attribute
obo:NCIT_C25150
Age
obo:NCIT_C25150
C0001779
obo:NCIT_C25150
CDISC
obo:NCIT_C25150
FDA
obo:NCIT_C25150
NICHD
obo:NCIT_C25150
How long something has existed; elapsed time since birth. (NCI)
obo:NCIT_C25150
The time elapsed since birth.
obo:NCIT_C25150
Age
obo:NCIT_C25150
Chronological Age
obo:NCIT_C25150
AGE
obo:NCIT_C25150
Age
obo:NCIT_C25150
Aged
obo:NCIT_C25150
Chronological Age
obo:NCIT_C25150
Postnatal Age
obo:NCIT_C25150
age
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C118466
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C19752
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C54447
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C61410
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C77526
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C83187
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C83188
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90007
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90009
obo:NCIT_C25150
http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90259
obo:NCIT_C25150
Age
obo:NCIT_C25320
A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents.
obo:NCIT_C25320
obo:ncit.owl
obo:NCIT_C25320
C25320
obo:NCIT_C25320
Intellectual Product
obo:NCIT_C25320
Clinical Study Protocol
obo:NCIT_C25320
C1507394
obo:NCIT_C25320
BRIDG
obo:NCIT_C25320
CDISC-GLOSS
obo:NCIT_C25320
CareLex
obo:NCIT_C25320
A detailed plan of a scientific or medical experiment, treatment, or procedure. In clinical trials, it states what the study will do, how it will be done, and why it is being done. It explains how many people will be in the study, who is eligible to take part in it, what study drugs or other interventions will be given, what tests will be done and how often, and what information will be collected.
obo:NCIT_C25320
A discrete, structured plan (that persists over time) of a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. NOTE(S): The term "protocol" is somewhat overloaded and must be qualified to provide semantic context. Therefore the term "study protocol" was chosen to disambiguate it from other protocols. In previous versions of BRIDG, there was one class for StudyProtocol. However this too represented multiple distinct aspects of the semantics of study protocol, each of which have now been split into separate classes:- The StudyProtocol class represents the content of the study protocol and can exist even before the information is put into document form. - The details of the structured plan for the study protocol are represented by the StudyProtocolVersion, so named because any aspect of the definition can change from version to version. These details include, but are not limited to, the characteristics, specifications, objective(s), background, the pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization).- The protocol and its versions can each be represented in document form, respectively StudyProtocolDocument and StudyProtocolDocumentVersion. A StudyProtocolDocument groups the various document versions (StudyProtocolDocumentVersions).- The conduct of a study based on a study protocol definition is represented by the StudyExecution class.
obo:NCIT_C25320
A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. [NCI]
obo:NCIT_C25320
See protocol.
obo:NCIT_C25320
Protocol
obo:NCIT_C25320
Clinical Study Protocol
obo:NCIT_C25320
Clinical Trial Protocol
obo:NCIT_C25320
Full Protocol
obo:NCIT_C25320
Prot
obo:NCIT_C25320
Protocol
obo:NCIT_C25320
Protocol Amendment
obo:NCIT_C25320
Study Protocol
obo:NCIT_C25320
StudyProtocol
obo:NCIT_C25320
Trial Protocol
obo:NCIT_C25320
clinical protocol
obo:NCIT_C25320
protocol
obo:NCIT_C25320
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548
obo:NCIT_C25320
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159501
obo:NCIT_C25320
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159503
obo:NCIT_C25320
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C25320
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C25320
Clinical Study Protocol
obo:NCIT_C48355
A person or organization that supports or champions something.
obo:NCIT_C48355
obo:ncit.owl
obo:NCIT_C48355
C48355
obo:NCIT_C48355
Human
obo:NCIT_C48355
Sponsor
obo:NCIT_C48355
C1711305
obo:NCIT_C48355
Sponsor
obo:NCIT_C48355
Applicant
obo:NCIT_C48355
Sponsor
obo:NCIT_C48355
Sponsor
obo:NCIT_C49653
A type of study designed to evaluate method(s) aimed at identifying a disease or condition.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C49653
One or more interventions are being evaluated for identifying a disease or health condition.
obo:NCIT_C49653
obo:ncit.owl
obo:NCIT_C49653
C49653
obo:NCIT_C49653
Research Activity
obo:NCIT_C49653
Diagnosis Study
obo:NCIT_C49653
C1704656
obo:NCIT_C49653
CDISC
obo:NCIT_C49653
A type of study designed to evaluate intervention(s) aimed at identifying a disease or condition.
obo:NCIT_C49653
Diagnosis_Study
obo:NCIT_C49653
DIAGNOSIS
obo:NCIT_C49653
Diagnosis Study
obo:NCIT_C49653
Diagnostic Study
obo:NCIT_C49653
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C49653
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C49653
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C49653
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739
obo:NCIT_C49653
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C49653
Diagnosis Study
obo:NCIT_C49656
A type of study protocol designed to evaluate intervention(s) for disease treatment.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C49656
One or more interventions are being evaluated for treating a disease, syndrome, or condition.
obo:NCIT_C49656
obo:ncit.owl
obo:NCIT_C49656
C49656
obo:NCIT_C49656
Research Activity
obo:NCIT_C49656
Treatment Study
obo:NCIT_C49656
C3161471
obo:NCIT_C49656
CDISC
obo:NCIT_C49656
A type of study designed to evaluate intervention(s) for treatment of disease, syndrome or condition.
obo:NCIT_C49656
Treatment_Study
obo:NCIT_C49656
TREATMENT
obo:NCIT_C49656
Therapy Trial
obo:NCIT_C49656
Treatment Study
obo:NCIT_C49656
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C49656
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C49656
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C49656
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739
obo:NCIT_C49656
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C49656
Treatment Study
obo:NCIT_C49657
A type of study protocol designed to evaluate intervention(s) for disease prevention.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C49657
One or more interventions are being assessed for preventing the development of a specific disease or health condition.
obo:NCIT_C49657
obo:ncit.owl
obo:NCIT_C49657
C49657
obo:NCIT_C49657
Research Activity
obo:NCIT_C49657
Prevention Study
obo:NCIT_C49657
C1706420
obo:NCIT_C49657
CDISC
obo:NCIT_C49657
A type of study designed to identify actions necessary to permanently eliminate or reduce the long-term risk to human life as a result of a particular medication or treatment regimen.
obo:NCIT_C49657
Prevention_Study
obo:NCIT_C49657
PREVENTION
obo:NCIT_C49657
Prevention Study
obo:NCIT_C49657
Preventive Clinical Trial
obo:NCIT_C49657
Prophylaxis Study
obo:NCIT_C49657
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C49657
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C49657
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C49657
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739
obo:NCIT_C49657
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C49657
Prevention Study
obo:NCIT_C49692
The number of subjects entered in a clinical trial.
obo:NCIT_C49692
obo:ncit.owl
obo:NCIT_C49692
C49692
obo:NCIT_C49692
Group Attribute
obo:NCIT_C49692
Planned Subject Number
obo:NCIT_C49692
C1709561
obo:NCIT_C49692
CDISC
obo:NCIT_C49692
CDISC-GLOSS
obo:NCIT_C49692
The number of subjects in a class or group (including the total for the entire trial) intended to be enrolled in a trial to reach the planned sample size. Target enrollments are set so that statistical and scientific objectives of a trial will have a likelihood of being met as determined by agreement, algorithm, or other specified process.
obo:NCIT_C49692
The planned number of subjects to be entered in a clinical trial. (NCI)
obo:NCIT_C49692
Planned_Subject_Number
obo:NCIT_C49692
Anticipated Enrollment
obo:NCIT_C49692
PLANSUB
obo:NCIT_C49692
Planned Enrollment
obo:NCIT_C49692
Planned Number of Subjects
obo:NCIT_C49692
Planned Subject Number
obo:NCIT_C49692
Target Enrollment
obo:NCIT_C49692
target enrollment
obo:NCIT_C49692
target number
obo:NCIT_C49692
target size
obo:NCIT_C49692
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C49692
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066
obo:NCIT_C49692
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C49692
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738
obo:NCIT_C49692
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C49692
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152
obo:NCIT_C49692
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C49692
Planned Subject Number
obo:NCIT_C49692
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C49692
https://www.who.int/ictrp/network/trds/en/
obo:NCIT_C52580
The distribution of resources over various time periods, products, operations, or investments.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C52580
The method by which participants are assigned to arms in a clinical trial.
obo:NCIT_C52580
obo:ncit.owl
obo:NCIT_C52580
C52580
obo:NCIT_C52580
Activity
obo:NCIT_C52580
Allocation
obo:NCIT_C52580
C1706778
obo:NCIT_C52580
CDISC
obo:NCIT_C52580
The process of assigning subjects to particular treatment groups or cohorts in a clinical study.
obo:NCIT_C52580
Allocation
obo:NCIT_C52580
Allocation
obo:NCIT_C52580
Subject Allocation
obo:NCIT_C52580
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C52580
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066
obo:NCIT_C52580
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C52580
Allocation
obo:NCIT_C52580
https://www.clinicaltrials.gov/ct2/about-studies/glossary
obo:NCIT_C60776
Information regarding the means of contacting a person or group.
obo:NCIT_C60776
obo:ncit.owl
obo:NCIT_C60776
C60776
obo:NCIT_C60776
Conceptual Entity
obo:NCIT_C60776
Contact Information
obo:NCIT_C60776
C1880174
obo:NCIT_C60776
Contact_Information
obo:NCIT_C60776
Contact Info
obo:NCIT_C60776
Contact Information
obo:NCIT_C60776
Contact Information
obo:NCIT_C70793
An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]
obo:NCIT_C70793
obo:ncit.owl
obo:NCIT_C70793
C70793
obo:NCIT_C70793
Health Care Related Organization
obo:NCIT_C70793
Clinical Study Sponsor
obo:NCIT_C70793
C2347796
obo:NCIT_C70793
CDISC
obo:NCIT_C70793
CDISC-GLOSS
obo:NCIT_C70793
CareLex
obo:NCIT_C70793
An entity that is responsible for the initiation, management, and/or financing of a clinical study.
obo:NCIT_C70793
An entity that is responsible for the initiation, management, and/or financing of a clinical study.[NCI]
obo:NCIT_C70793
An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. NOTE: If there is also a secondary sponsor, the responsible entity would be considered the primary sponsor. A corporation or agency whose employees conduct the investigation is considered a sponsor and the employees are considered investigators. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP] See also secondary sponsor.
obo:NCIT_C70793
Clinical_Study_Sponsor
obo:NCIT_C70793
CLINICAL STUDY SPONSOR
obo:NCIT_C70793
Clinical Study Sponsor
obo:NCIT_C70793
SPONSOR
obo:NCIT_C70793
Sponsor
obo:NCIT_C70793
Study Sponsor
obo:NCIT_C70793
sponsor
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C154681
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C78735
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C83187
obo:NCIT_C70793
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C83188
obo:NCIT_C70793
Clinical Study Sponsor
obo:NCIT_C70817
The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.
https://prsinfo.clinicaltrials.gov/results_definitions.html
obo:NCIT_C70817
The written description of the clinical study, including objective(s), design, and methods. It may also include relevant scientific background and statistical considerations (if the protocol document includes the statistical analysis plan, use "Study Protocol with SAP and/or ICF" option). Note: All amendments approved by a human subjects protection review board (if applicable), before the time of submission and that apply to all clinical trial Facility Locations must be included.
obo:NCIT_C70817
obo:ncit.owl
obo:NCIT_C70817
C70817
obo:NCIT_C70817
Intellectual Product
obo:NCIT_C70817
Study Protocol
obo:NCIT_C70817
C2348563
obo:NCIT_C70817
CDISC
obo:NCIT_C70817
The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study, intervention description, and method of data analysis.
obo:NCIT_C70817
Study_Protocol
obo:NCIT_C70817
Protocol
obo:NCIT_C70817
Study Protocol
obo:NCIT_C70817
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C70817
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132310
obo:NCIT_C70817
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C70817
Study Protocol
obo:NCIT_C70817
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C70840
A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).
obo:NCIT_C70840
obo:ncit.owl
obo:NCIT_C70840
C70840
obo:NCIT_C70840
Research Activity
obo:NCIT_C70840
Blinded Clinical Study
obo:NCIT_C70840
C2347038
obo:NCIT_C70840
CDISC-GLOSS
obo:NCIT_C70840
A study in which the subject, the investigator, or anyone assessing the outcome is unaware of the treatment assignment(s). NOTE: Blinding is used to reduce the potential for bias. [Modified ICH E6 Glossary] See also blinding/masking, double-blind study, single-blind study, triple-blind study; contrast with open-label or unblinded study.
obo:NCIT_C70840
A type of study in which the patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given. The opposite of a blinded study is an open label study.
obo:NCIT_C70840
Blinded_Clinical_Study
obo:NCIT_C70840
Blind Clinical Study
obo:NCIT_C70840
Blinded Clinical Study
obo:NCIT_C70840
Blinded Clinical Trial
obo:NCIT_C70840
Masked Clinical Study
obo:NCIT_C70840
blinded study
obo:NCIT_C70840
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C70840
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C70840
Blinded Clinical Study
obo:NCIT_C71485
Clinical studies testing the efficacy of devices, techniques, procedures, or tests for the purpose of detecting the presence of disease, usually before there are any symptoms.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C71485
One or more interventions are assessed or examined for identifying a condition, or risk factors for a condition, in people who are not yet known to have the condition or risk factor.
obo:NCIT_C71485
obo:ncit.owl
obo:NCIT_C71485
C71485
obo:NCIT_C71485
Research Activity
obo:NCIT_C71485
Screening Study
obo:NCIT_C71485
C2348164
obo:NCIT_C71485
CDISC
obo:NCIT_C71485
CDISC-GLOSS
obo:NCIT_C71485
A type of study designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor). (Clinicaltrials.gov)
obo:NCIT_C71485
Trials conducted to detect persons with early, mild, and asymptomatic disease.
obo:NCIT_C71485
Screening_Study
obo:NCIT_C71485
SCREENING
obo:NCIT_C71485
Screening Study
obo:NCIT_C71485
Screening Trial
obo:NCIT_C71485
screening trials
obo:NCIT_C71485
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C71485
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C71485
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C71485
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C71485
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C71485
Screening Study
obo:NCIT_C71486
Clinical studies intended to improve the comfort and quality of life for the patient using drugs, nutritional, dietary, behavioral or other interventions.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C71486
One or more interventions are evaluated for maximizing comfort, minimizing side effects, or mitigating against a decline in the participant's health or function.
obo:NCIT_C71486
obo:ncit.owl
obo:NCIT_C71486
C71486
obo:NCIT_C71486
Research Activity
obo:NCIT_C71486
Supportive Care Study
obo:NCIT_C71486
C2348611
obo:NCIT_C71486
CDISC
obo:NCIT_C71486
A type of study designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease. (ClinicalTrials.gov)
obo:NCIT_C71486
Supportive_Care_Study
obo:NCIT_C71486
SUPPORTIVE CARE
obo:NCIT_C71486
Supportive Care Study
obo:NCIT_C71486
Supportive Care Trial
obo:NCIT_C71486
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C71486
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C71486
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736
obo:NCIT_C71486
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C71486
Supportive Care Study
obo:NCIT_C82638
A type of clinical study in which two or more treatments are given alone and in combination, such that all possible combinations are represented across the treatment arms, and are compared in parallel against the study control group.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C82638
Two or more interventions, each alone and in combination, are evaluated in parallel against a control group
obo:NCIT_C82638
obo:ncit.owl
obo:NCIT_C82638
C82638
obo:NCIT_C82638
Research Activity
obo:NCIT_C82638
Factorial Study
obo:NCIT_C82638
C2826344
obo:NCIT_C82638
CDISC
obo:NCIT_C82638
Two or more interventions, each alone or in combination, are evaluated in parallel against a control group. This study design allows for the comparison of active drug to placebo, presence of drug-drug interactions, and comparison of active drugs against each other.
obo:NCIT_C82638
Factorial_Study
obo:NCIT_C82638
FACTORIAL
obo:NCIT_C82638
Factorial Study
obo:NCIT_C82638
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C82638
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C82638
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C82638
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526
obo:NCIT_C82638
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C89967
obo:NCIT_C82638
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99076
obo:NCIT_C82638
Factorial Study
obo:NCIT_C84336
Any of two or more parties working jointly towards a common goal.
obo:NCIT_C84336
obo:ncit.owl
obo:NCIT_C84336
C84336
obo:NCIT_C84336
Conceptual Entity
obo:NCIT_C84336
Collaborator
obo:NCIT_C84336
C2827395
obo:NCIT_C84336
Collaborator
obo:NCIT_C84336
Collaborator
obo:NCIT_C90467
The country in which the test is conducted.
obo:NCIT_C90467
obo:ncit.owl
obo:NCIT_C90467
C90467
obo:NCIT_C90467
Geographic Area
obo:NCIT_C90467
Test Facility Country
obo:NCIT_C90467
C2983675
obo:NCIT_C90467
CDISC
obo:NCIT_C90467
The country of the place in which a nonclinical laboratory study takes place, i.e., actually uses the test article in a test system. Testing facility includes any establishment required to register under section 510 of the act that conducts nonclinical laboratory studies and any consulting laboratory described in section 704 of the act that conducts such studies. Testing facility encompasses only those operational units that are being or have been used to conduct nonclinical laboratory studies. (FDA)
obo:NCIT_C90467
TFCNTRY
obo:NCIT_C90467
Test Facility Country
obo:NCIT_C90467
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C90467
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526
obo:NCIT_C90467
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90007
obo:NCIT_C90467
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90009
obo:NCIT_C90467
Test Facility Country
obo:NCIT_C90469
The name of the place in which a test is conducted.
obo:NCIT_C90469
obo:ncit.owl
obo:NCIT_C90469
C90469
obo:NCIT_C90469
Intellectual Product
obo:NCIT_C90469
Test Facility Name
obo:NCIT_C90469
C2983677
obo:NCIT_C90469
CDISC
obo:NCIT_C90469
The name of the place in which a nonclinical laboratory study takes place, i.e., actually uses the test article in a test system. Testing facility includes any establishment required to register under section 510 of the act that conducts nonclinical laboratory studies and any consulting laboratory described in section 704 of the act that conducts such studies. Testing facility encompasses only those operational units that are being or have been used to conduct nonclinical laboratory studies. (FDA)
obo:NCIT_C90469
TSTFNAM
obo:NCIT_C90469
Test Facility Name
obo:NCIT_C90469
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C90469
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526
obo:NCIT_C90469
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90007
obo:NCIT_C90469
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90009
obo:NCIT_C90469
Test Facility Name
obo:NCIT_C93360
A condition that is a focus of the study.
obo:NCIT_C93360
obo:ncit.owl
obo:NCIT_C93360
C93360
obo:NCIT_C93360
Qualitative Concept
obo:NCIT_C93360
Study Condition
obo:NCIT_C93360
C2985574
obo:NCIT_C93360
BRIDG
obo:NCIT_C93360
A condition that is a focus of the study.
obo:NCIT_C93360
Study Condition
obo:NCIT_C93360
StudyCondition
obo:NCIT_C93360
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159501
obo:NCIT_C93360
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159503
obo:NCIT_C93360
Study Condition
obo:NCIT_C98388
Studies in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed.
obo:NCIT_C98388
obo:ncit.owl
obo:NCIT_C98388
C98388
obo:NCIT_C98388
Research Activity
obo:NCIT_C98388
Interventional Study
obo:NCIT_C98388
C3274035
obo:NCIT_C98388
CDISC
obo:NCIT_C98388
CDISC-GLOSS
obo:NCIT_C98388
A trial which intervenes with the inviolability of the trial subject for the purpose of the investigation. For example, the administration of an investigational medical product to the trial subject or use of some extra means of intervention (i.e., samples, tests, or questionnaires) that would not otherwise be used. [Clinical Trial Directive EC/20/2001 definitions]
obo:NCIT_C98388
Studies in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed.
obo:NCIT_C98388
INTERVENTIONAL
obo:NCIT_C98388
Interventional Study
obo:NCIT_C98388
interventional clinical trial
obo:NCIT_C98388
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C98388
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C98388
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C98388
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497
obo:NCIT_C98388
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077
obo:NCIT_C98388
Interventional Study
obo:NCIT_C98714
A sequence of letters, numbers, or other characters that uniquely identifies a clinical trial within a clinical trial registry.
obo:NCIT_C98714
obo:ncit.owl
obo:NCIT_C98714
C98714
obo:NCIT_C98714
Intellectual Product
obo:NCIT_C98714
Clinical Trial Registry Identifier
obo:NCIT_C98714
C3274381
obo:NCIT_C98714
CDISC
obo:NCIT_C98714
Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries.
obo:NCIT_C98714
Clinical Trial Registry Identifier
obo:NCIT_C98714
REGID
obo:NCIT_C98714
Registry Identifier
obo:NCIT_C98714
Trial Identifying Number
obo:NCIT_C98714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C98714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738
obo:NCIT_C98714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C98714
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152
obo:NCIT_C98714
Clinical Trial Registry Identifier
obo:NCIT_C98714
https://www.who.int/ictrp/network/trds/en/
obo:NCIT_C98722
Studies that provide a means for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet the eligibility criteria for enrollment, or who are otherwise unable to participate in another clinical study. Expanded Access studies include individual-patient IND, treatment IND, compassionate use, emergency use or continued access.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C98722
An investigational drug product (including biological product) available through expanded access for patients who do not qualify for enrollment in a clinical trial. Expanded Access includes all expanded access types under section 561 of the Federal Food, Drug, and Cosmetic Act: (1) for individual patients, including emergency use; (2) for intermediate-size patient populations; and (3) under a treatment IND or treatment protocol.
obo:NCIT_C98722
obo:ncit.owl
obo:NCIT_C98722
C98722
obo:NCIT_C98722
Research Activity
obo:NCIT_C98722
Expanded Access Study
obo:NCIT_C98722
C3274389
obo:NCIT_C98722
CDISC
obo:NCIT_C98722
Studies that provide a means for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet the eligibility criteria for enrollment, or who are otherwise unable to participate in another clinical study. Expanded Access studies include individual-patient IND, treatment IND, compassionate use, emergency use or continued access.
obo:NCIT_C98722
EXPANDED ACCESS
obo:NCIT_C98722
Expanded Access Study
obo:NCIT_C98722
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298
obo:NCIT_C98722
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C98722
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C98722
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077
obo:NCIT_C98722
Expanded Access Study
obo:NCIT_C98722
https://prsinfo.clinicaltrials.gov/expanded_access_definitions.html
https://prsinfo.clinicaltrials.gov/definitions.html
obo:NCIT_C98747
For each intervention studied in the clinical study, the general type of intervention.
obo:NCIT_C98747
The kind of product or procedure studied in a trial.
obo:NCIT_C98747
obo:ncit.owl
obo:NCIT_C98747
C98747
obo:NCIT_C98747
Functional Concept
obo:NCIT_C98747
Intervention Type
obo:NCIT_C98747
C3274412
obo:NCIT_C98747
CDISC
obo:NCIT_C98747
The kind of product or procedure studied in a trial.
obo:NCIT_C98747
INTTYPE
obo:NCIT_C98747
Intervention Type
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:NCIT_C98747
intervention
obo:NCIT_C98747
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C98747
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738
obo:NCIT_C98747
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C98747
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152
obo:NCIT_C98747
Intervention Type
obo:NCIT_C98772
The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).
obo:NCIT_C98772
obo:ncit.owl
obo:NCIT_C98772
C98772
obo:NCIT_C98772
Intellectual Product
obo:NCIT_C98772
Primary Outcome Measure
obo:NCIT_C98772
C3274433
obo:NCIT_C98772
CDISC
obo:NCIT_C98772
The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).
obo:NCIT_C98772
OUTMSPRI
obo:NCIT_C98772
PRIMARY OUTCOME MEASURE
obo:NCIT_C98772
Primary Outcome Measure
obo:NCIT_C98772
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C117745
obo:NCIT_C98772
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C98772
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738
obo:NCIT_C98772
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C98772
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152
obo:NCIT_C98772
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C81222
obo:NCIT_C98772
Primary Outcome Measure
obo:NCIT_C98781
Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).
obo:NCIT_C98781
obo:ncit.owl
obo:NCIT_C98781
C98781
obo:NCIT_C98781
Intellectual Product
obo:NCIT_C98781
Secondary Outcome Measure
obo:NCIT_C98781
C3274440
obo:NCIT_C98781
CDISC
obo:NCIT_C98781
Secondary measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).
obo:NCIT_C98781
OUTMSSEC
obo:NCIT_C98781
SECONDARY OUTCOME MEASURE
obo:NCIT_C98781
Secondary Outcome Measure
obo:NCIT_C98781
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C117745
obo:NCIT_C98781
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410
obo:NCIT_C98781
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738
obo:NCIT_C98781
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830
obo:NCIT_C98781
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152
obo:NCIT_C98781
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C81222
obo:NCIT_C98781
Secondary Outcome Measure
obo:NCIT_NHC0
true
obo:NCIT_NHC0
A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Thesaurus.
obo:NCIT_NHC0
NHC0
obo:NCIT_NHC0
code
obo:NCIT_NHC0
code
obo:NCIT_NHC0
code
obo:NCIT_P106
A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.
obo:NCIT_P106
The semantic type describes the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.
obo:NCIT_P106
P106
obo:NCIT_P106
Conceptual Entity
obo:NCIT_P106
Semantic Type
obo:NCIT_P106
Semantic_Type
obo:NCIT_P106
In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned. We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS.
obo:NCIT_P106
Semantic_Type
obo:NCIT_P106
Semantic_Type
obo:NCIT_P107
A property representing an alternative Preferred Name for use in some NCI systems.
obo:NCIT_P107
Provides an alternative Preferred Name for use in some NCI systems.
obo:NCIT_P107
P107
obo:NCIT_P107
Conceptual Entity
obo:NCIT_P107
Display Name
obo:NCIT_P107
Display_Name
obo:NCIT_P107
Display Name
obo:NCIT_P107
Display_Name
obo:NCIT_P107
Display_Name
obo:NCIT_P108
A property representing the word or phrase that NCI uses by preference to refer to the concept.
obo:NCIT_P108
The word or phrase that NCI uses by preference to refer to the concept.
obo:NCIT_P108
P108
obo:NCIT_P108
Conceptual Entity
obo:NCIT_P108
Preferred Name
obo:NCIT_P108
Preferred_Name
obo:NCIT_P108
Preferred Name
obo:NCIT_P108
Preferred Term
obo:NCIT_P108
Preferred_Name
obo:NCIT_P108
Preferred_Name
obo:NCIT_P207
A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept.
obo:NCIT_P207
Concept Unique Identifiers, or CUIs, are concept numbers assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept.
obo:NCIT_P207
P207
obo:NCIT_P207
Conceptual Entity
obo:NCIT_P207
UMLS CUI
obo:NCIT_P207
UMLS_CUI
obo:NCIT_P207
UMLS_CUI
obo:NCIT_P207
UMLS_CUI
obo:NCIT_P208
A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS).
obo:NCIT_P208
P208
obo:NCIT_P208
Conceptual Entity
obo:NCIT_P208
NCI Metathesaurus CUI
obo:NCIT_P208
NCI_META_CUI
obo:NCIT_P208
NCI_META_CUI
obo:NCIT_P208
NCI_META_CUI
obo:NCIT_P322
A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake.
obo:NCIT_P322
This property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake.
obo:NCIT_P322
P322
obo:NCIT_P322
Conceptual Entity
obo:NCIT_P322
Contributing Source
obo:NCIT_P322
Contributing_Source
obo:NCIT_P322
Contributing_Source
obo:NCIT_P322
Contributing_Source
obo:NCIT_P325
A property representing the English language definition of a concept from a source other than NCI.
obo:NCIT_P325
English language definitions of what a source other than NCI means by the concept. These are limited to 1024 characters. They include information about the definition's source in a form that can easily be interpreted by software.
obo:NCIT_P325
P325
obo:NCIT_P325
Conceptual Entity
obo:NCIT_P325
[source] Definition
obo:NCIT_P325
ALT_DEFINITION
obo:NCIT_P325
ALT_DEFINITION
obo:NCIT_P325
ALT_DEFINITION
obo:NCIT_P366
true
obo:NCIT_P366
A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding.
obo:NCIT_P366
A retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding.
obo:NCIT_P366
P366
obo:NCIT_P366
Conceptual Entity
obo:NCIT_P366
Legacy Concept Name
obo:NCIT_P366
Legacy Concept Name
obo:NCIT_P366
Legacy_Concept_Name
obo:NCIT_P371
A property representing a term chosen by NICHD to be used in the representation of the NICHD hierarchy.
obo:NCIT_P371
P371
obo:NCIT_P371
Conceptual Entity
obo:NCIT_P371
NICHD_Hierarchy_Term
obo:NCIT_P371
NICHD
obo:NCIT_P371
NICHD_Hierarchy_Term
obo:NCIT_P371
NICHD_Hierarchy_Term
obo:NCIT_P375
A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms.
obo:NCIT_P375
P375
obo:NCIT_P375
Conceptual Entity
obo:NCIT_P375
Maps_To
obo:NCIT_P375
Maps_To
obo:NCIT_P375
Maps_To
obo:NCIT_P98
A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept.
obo:NCIT_P98
Design notes are notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept.
obo:NCIT_P98
P98
obo:NCIT_P98
Conceptual Entity
obo:NCIT_P98
DesignNote
obo:NCIT_P98
DesignNote
obo:NCIT_P98
DesignNote
obo:NCIT_P98
DesignNote
https://prsinfo.clinicaltrials.gov/results_definitions.html
obo:OAE_0000001
Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant’s participation in the research, whether or not considered related to the participant’s participation in the research
obo:OAE_0000001
a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event.
obo:OAE_0000001
Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'.
obo:OAE_0000001
YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device.
obo:OAE_0000001
YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention.
obo:OAE_0000001
YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action).
Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623.
obo:OAE_0000001
YH: The current term 'adverse event' is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper.
We made the name changing in order to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term 'adverse event' is stil under the OGMS:pathological bodily process.
The 'adverse event' defined in the above paper has now been changed to a new term: 'causal adverse event'. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29 doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740.
obo:OAE_0000001
YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events.
obo:OAE_0000001
YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'.
obo:OAE_0000001
Yongqun He
obo:OAE_0000001
AE
obo:OAE_0000001
adverse reaction
obo:OAE_0000001
WEB: http://en.wikipedia.org/wiki/Adverse_event
obo:OAE_0000001
WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm
obo:OAE_0000001
WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068
obo:OAE_0000001
obo:oae.owl
obo:OAE_0000001
The OAE official website is: http://www.oae-ontology.org/.
obo:OAE_0000001
adverse event
https://www.clinicaltrials.gov/ct2/about-studies/glossary
obo:OAE_0000002
A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
obo:OAE_0000002
medical intervention is a planned process that has the goal of diagnosing, preventing or relieving illness or injury.
obo:OAE_0000002
The act of intervening, interfering or interceding with the intent of modifying the outcome. In medicine, an intervention is usually undertaken to help treat or cure a condition. For example, "Acupuncture as a therapeutic intervention is widely practiced in the United States,"
Reference:
http://www.medterms.com/script/main/art.asp?articlekey=34214 . Some interventions can be used for diagnosis.
obo:OAE_0000002
The act of intervening, interfering or interceding with the intent of modifying the outcome. In medicine, an intervention is usually undertaken to help treat or cure a condition. For example, "Acupuncture as a therapeutic intervention is widely practiced in the United States,"
Reference:
http://www.medterms.com/script/main/art.asp?articlekey=34214 . Some interventions can be used for diagnosis.
obo:OAE_0000002
YH
obo:OAE_0000002
WEB: http://wiki.answers.com/Q/What_is_medical_intervention
obo:OAE_0000002
obo:oae.owl
obo:OAE_0000002
obo:omrse.owl
obo:OAE_0000002
obo:opmi.owl
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:OAE_0000002
Intervention(s)
obo:OAE_0000002
medical intervention
obo:OAE_0000002
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OAE_0000011
a medical intervention where a patient is administered with a drug
obo:OAE_0000011
YH
obo:OAE_0000011
obo:oae.owl
obo:OAE_0000011
drug administration
obo:OAE_0000094
a medical intervention that is used for therapeutic purpose
obo:OAE_0000094
YH
obo:OAE_0000094
obo:oae.owl
obo:OAE_0000094
therapeutic intervention
obo:OAE_0002807
a medical intervention that refers to any series of pre-defined steps that should be followed to achieve a desired result.
obo:OAE_0002807
YH, SS
obo:OAE_0002807
WEB: http://www.wisegeekhealth.com/what-is-the-difference-between-a-surgery-and-a-procedure.htm
obo:OAE_0002807
obo:oae.owl
obo:OAE_0002807
medical procedure
obo:OBI_0000011
planned process
obo:OBI_0000011
planned process
obo:OBI_0000011
Injecting mice with a vaccine in order to test its efficacy
obo:OBI_0000011
obo:IAO_0000122
obo:OBI_0000011
A processual entity that realizes a plan which is the concretization of a plan specification.
obo:OBI_0000011
'Plan' includes a future direction sense. That can be problematic if plans are changed during their execution. There are however implicit contingencies for protocols that an agent has in his mind that can be considered part of the plan, even if the agent didn't have them in mind before. Therefore, a planned process can diverge from what the agent would have said the plan was before executing it, by adjusting to problems encountered during execution (e.g. choosing another reagent with equivalent properties, if the originally planned one has run out.)
obo:OBI_0000011
We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some
objectives is a planned process.
obo:OBI_0000011
We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some
objectives is a planned process.
obo:OBI_0000011
Bjoern Peters
obo:OBI_0000011
branch derived
obo:OBI_0000011
6/11/9: Edited at workshop. Used to include: is initiated by an agent
obo:OBI_0000011
This class merges the previously separated objective driven process and planned process, as they the separation proved hard to maintain. (1/22/09, branch call)
obo:OBI_0000011
obo:dron.owl
obo:OBI_0000011
obo:envo.owl
obo:OBI_0000011
obo:ico.owl
obo:OBI_0000011
obo:oae.owl
obo:OBI_0000011
obo:obi.owl
obo:OBI_0000011
obo:omrse.owl
obo:OBI_0000011
obo:opmi.owl
obo:OBI_0000011
obo:vo.owl
obo:OBI_0000011
http://purl.obolibrary.org/obo/obi.owl
obo:OBI_0000011
planned process
obo:OBI_0000011
planned process
obo:OBI_0000066
investigation
obo:OBI_0000066
Lung cancer investigation using expression profiling, a stem cell transplant investigation, biobanking is not an investigation, though it may be part of an investigation
obo:OBI_0000066
obo:IAO_0000122
obo:OBI_0000066
a planned process that consists of parts: planning, study design execution, documentation and which produce conclusion(s).
obo:OBI_0000066
Bjoern Peters
obo:OBI_0000066
OBI branch derived
obo:OBI_0000066
Could add specific objective specification
obo:OBI_0000066
Following OBI call November 2012,26th: it was decided there was no need for adding "achieves objective of drawing conclusion" as existing relations were providing equivalent ability. this note closes the issue and validates the class definition to be part of the OBI core
editor = PRS
obo:OBI_0000066
obo:obi.owl
obo:OBI_0000066
obo:opmi.owl
obo:OBI_0000066
study
obo:OBI_0000066
investigation
obo:OBI_0000070
assay
obo:OBI_0000070
Assay the wavelength of light emitted by excited Neon atoms. Count of geese flying over a house.
obo:OBI_0000070
obo:IAO_0000122
obo:OBI_0000070
A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies.
obo:OBI_0000070
12/3/12: BP: the reference to the 'physical examination' is included to point out that a prediction is not an assay, as that does not require physical examiniation.
obo:OBI_0000070
PlanAndPlannedProcess Branch
obo:OBI_0000070
measuring
obo:OBI_0000070
scientific observation
obo:OBI_0000070
OBI branch derived
obo:OBI_0000070
obo:obi.owl
obo:OBI_0000070
study assay
obo:OBI_0000070
any method
obo:OBI_0000070
assay
obo:OBI_0000102
responsible party role
obo:OBI_0000102
he THERAPIST has the ability to print a separate statement for the patient and each responsible party. http://www.beaverlog.com/therapist/ez_support/billing/responsible_party_statements.htm
obo:OBI_0000102
obo:IAO_0000120
obo:OBI_0000102
a study personnel role played by a party who is accountable for the execution of a study component and can make decisions about the conduct of the study
obo:OBI_0000102
Person: Jennifer Fostel
obo:OBI_0000102
responsible party
obo:OBI_0000102
OBI
obo:OBI_0000102
obo:obi.owl
obo:OBI_0000102
responsible party role
obo:OBI_0000115
intervention design
obo:OBI_0000115
PMID: 18208636.Br J Nutr. 2008 Jan 22;:1-11.Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study.
obo:OBI_0000115
obo:IAO_0000125
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0000115
A description of the manner in which the clinical trial will be conducted.
obo:OBI_0000115
An intervention design is a study design in which a controlled process applied to the subjects (the intervention) serves as the independent variable manipulated by the experimentalist. The treatment (perturbation or intervention) defined can be defined as a combination of values taken by independent variable manipulated by the experimentalists are applied to the recruited subjects assigned (possibly by applying specific methods) to treatment groups. The specificity of intervention design is the fact that independent variables are being manipulated and a response of the biological system is evaluated via response variables as monitored by possibly a series of assays.
obo:OBI_0000115
Philppe Rocca-Serra
obo:OBI_0000115
OBI branch derived
obo:OBI_0000115
obo:obi.owl
obo:OBI_0000115
Interventional Study Design
obo:OBI_0000115
intervention model
obo:OBI_0000115
intervention design
obo:OBI_0000202
investigation agent role
obo:OBI_0000202
The person perform microarray experiments and submit microarray results (including raw data, processed data) with experiment description to ArrayExpress.
obo:OBI_0000202
obo:IAO_0000122
obo:OBI_0000202
A role borne by an entity and that is realized in a process that is part of an investigation in which an objective is achieved. These processes include, among others: planning, overseeing, funding, reviewing.
obo:OBI_0000202
Implementing a study means carrying out or performing the study and providing reagents or other materials used in the study and other tasks without which the study would not happen.
obo:OBI_0000202
Philly2013: Historically, this role would have been borne only by humans or organizations. However, we now also want to enable representing investigations run by robot scientists such as ADAM (King et al, Science, 2009)
obo:OBI_0000202
GROUP: Role Branch
obo:OBI_0000202
investigator
obo:OBI_0000202
OBI
obo:OBI_0000202
Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term.
obo:OBI_0000202
obo:obi.owl
obo:OBI_0000202
obo:opmi.owl
obo:OBI_0000202
study person role
obo:OBI_0000202
Philly2013: Historically, this role would have been borne only by humans or organizations. However, we now also want to enable investigations run by robot scientists such as ADAM (King et al, Science, 2009)
obo:OBI_0000202
investigation agent role
obo:OBI_0000243
sponsor role
obo:OBI_0000243
obo:IAO_0000120
obo:OBI_0000243
a responsible party role involved with any of the following activities: initiating, managing and funding a study
obo:OBI_0000243
Person: Jennifer Fostel
obo:OBI_0000243
sponsor
obo:OBI_0000243
CDISC definition: sponsor. 1. An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. 2. A corporation or agency whose employees conduct the investigation is considered a sponsor; employees are considered investigators
obo:OBI_0000243
obo:obi.owl
obo:OBI_0000243
obo:opmi.owl
obo:OBI_0000243
sponsor role
obo:OBI_0000245
organization
obo:OBI_0000245
PMID: 16353909.AAPS J. 2005 Sep 22;7(2):E274-80. Review. The joint food and agriculture organization of the United Nations/World Health Organization Expert Committee on Food Additives and its role in the evaluation of the safety of veterinary drug residues in foods.
obo:OBI_0000245
obo:IAO_0000122
obo:OBI_0000245
An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members.
obo:OBI_0000245
BP: The definition summarizes long email discussions on the OBI developer, roles, biomaterial and denrie branches. It leaves open if an organization is a material entity or a dependent continuant, as no consensus was reached on that. The current placement as material is therefore temporary, in order to move forward with development. Here is the entire email summary, on which the definition is based:
1) there are organization_member_roles (president, treasurer, branch
editor), with individual persons as bearers
2) there are organization_roles (employer, owner, vendor, patent holder)
3) an organization has a charter / rules / bylaws, which specify what roles
there are, how they should be realized, and how to modify the
charter/rules/bylaws themselves.
It is debatable what the organization itself is (some kind of dependent
continuant or an aggregate of people). This also determines who/what the
bearer of organization_roles' are. My personal favorite is still to define
organization as a kind of 'legal entity', but thinking it through leads to
all kinds of questions that are clearly outside the scope of OBI.
Interestingly enough, it does not seem to matter much where we place
organization itself, as long as we can subclass it (University, Corporation,
Government Agency, Hospital), instantiate it (Affymetrix, NCBI, NIH, ISO,
W3C, University of Oklahoma), and have it play roles.
This leads to my proposal: We define organization through the statements 1 -
3 above, but without an 'is a' statement for now. We can leave it in its
current place in the is_a hierarchy (material entity) or move it up to
'continuant'. We leave further clarifications to BFO, and close this issue
for now.
obo:OBI_0000245
PERSON: Alan Ruttenberg
obo:OBI_0000245
PERSON: Bjoern Peters
obo:OBI_0000245
PERSON: Philippe Rocca-Serra
obo:OBI_0000245
PERSON: Susanna Sansone
obo:OBI_0000245
GROUP: OBI
obo:OBI_0000245
obo:obi.owl
obo:OBI_0000245
organization
obo:OBI_0000272
protocol
obo:OBI_0000272
PCR protocol, has objective specification, amplify DNA fragment of interest, and has action specification describes the amounts of experimental reagents used (e..g. buffers, dNTPS, enzyme), and the temperature and cycle time settings for running the PCR.
obo:OBI_0000272
obo:IAO_0000122
obo:OBI_0000272
A plan specification which has sufficient level of detail and quantitative information to communicate it between investigation agents, so that different investigation agents will reliably be able to independently reproduce the process.
obo:OBI_0000272
PlanAndPlannedProcess Branch
obo:OBI_0000272
OBI branch derived + wikipedia (http://en.wikipedia.org/wiki/Protocol_%28natural_sciences%29)
obo:OBI_0000272
obo:obi.owl
obo:OBI_0000272
study protocol
obo:OBI_0000272
protocol
obo:OBI_0000293
has_specified_input
obo:OBI_0000810
informed consent process
obo:OBI_0000810
obo:IAO_0000122
obo:OBI_0000810
A planned process in which a person or their legal representative is informed about key facts about potential risks and benefits of a process and makes a documented decision as to whether the person in question will participate.
obo:OBI_0000810
09/28/2009 Alan Ruttenberg: This is made a subclass of the higher level processual entity in BFO because I don't want to take a stand on whether it is a process aggregate. Analogous to the situation with Material entity.
obo:OBI_0000810
Person:Alan Ruttenberg
obo:OBI_0000810
http://clinicaltrials.gov/ct2/info/glossary#informed
obo:OBI_0000810
2009/09/28 Alan Ruttenberg. Fucoidan-use-case
obo:OBI_0000810
obo:obi.owl
obo:OBI_0000810
informed consent process
obo:OBI_0000968
device
obo:OBI_0000968
A voltmeter is a measurement device which is intended to perform some measure function.
obo:OBI_0000968
An autoclave is a device that sterlizes instruments or contaminated waste by applying high temperature and pressure.
obo:OBI_0000968
obo:IAO_0000122
obo:OBI_0000968
A material entity that is designed to perform a function in a scientific investigation, but is not a reagent.
obo:OBI_0000968
2012-12-17 JAO: In common lab usage, there is a distinction made between devices and reagents that is difficult to model. Therefore we have chosen to specifically exclude reagents from the definition of "device", and are enumerating the types of roles that a reagent can perform.
2013-6-5 MHB: The following clarifications are outcomes of the May 2013 Philly Workshop. Reagents are distinguished from devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in some chemical interaction or reaction during the realization of their experimental role. By contrast, devices do not participate in such chemical reactions/interactions. Note that there are cases where devices use reagent components during their operation, where the reagent-device distinction is less clear. For example:
(1) An HPLC machine is considered a device, but has a column that holds a stationary phase resin as an operational component. This resin qualifies as a device if it participates purely in size exclusion, but bears a reagent role that is realized in the running of a column if it interacts electrostatically or chemically with the evaluant. The container the resin is in (“the column”) considered alone is a device. So the entire column as well as the entire HPLC machine are devices that have a reagent as an operating part.
(2) A pH meter is a device, but its electrode component bears a reagent role in virtue of its interacting directly with the evaluant in execution of an assay.
(3) A gel running box is a device that has a metallic lead as a component that participates in a chemical reaction with the running buffer when a charge is passed through it. This metallic lead is considered to have a reagent role as a component of this device realized in the running of a gel.
In the examples above, a reagent is an operational component of a device, but the device itself does not realize a reagent role (as bearing a reagent role is not transitive across the part_of relation). In this way, the asserted disjointness between a reagent and device holds, as both roles are never realized in the same bearer during execution of an assay.
obo:OBI_0000968
PERSON: Helen Parkinson
obo:OBI_0000968
instrument
obo:OBI_0000968
OBI development call 2012-12-17.
obo:OBI_0000968
obo:obi.owl
obo:OBI_0000968
device
obo:OBI_0001627
country name
obo:OBI_0001627
obo:IAO_0000120
obo:OBI_0001627
A textual entity that denotes a geographic location that is a site or part of a site that is identified as a country in the political geography.
obo:OBI_0001627
Person: Chris Stoeckert, Jie Zheng
obo:OBI_0001627
NIAID GSCID-BRC metadata working group
obo:OBI_0001627
Website: http://en.wikipedia.org/wiki/Country
obo:OBI_0001627
obo:obi.owl
obo:OBI_0001627
Specimen Collection Location - Country
obo:OBI_0001627
NIAID GSCID-BRC
obo:OBI_0001627
country name
obo:OBI_0001755
selection criterion
obo:OBI_0001755
rats should be aged between 6 and 8 weeks and weight between 180-250grams
obo:OBI_0001755
obo:IAO_0000122
obo:OBI_0001755
A directive information entity which defines and states a principle of standard by which selection process may take place.
obo:OBI_0001755
Person: Philippe Rocca-Serra
obo:OBI_0001755
selection rule
obo:OBI_0001755
OBI discussion summarized under the following tracker item : http://sourceforge.net/p/obi/obi-terms/678/
obo:OBI_0001755
obo:obi.owl
obo:OBI_0001755
selection criterion
obo:OBI_0001847
ISA alternative term
obo:OBI_0001847
obo:IAO_0000122
obo:OBI_0001847
An alternative term used by the ISA tools project (http://isa-tools.org).
obo:OBI_0001847
Requested by Alejandra Gonzalez-Beltran
https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891&atid=886178
obo:OBI_0001847
Person: Alejandra Gonzalez-Beltran
obo:OBI_0001847
Person: Philippe Rocca-Serra
obo:OBI_0001847
ISA tools project (http://isa-tools.org)
obo:OBI_0001847
ISA alternative term
obo:OBI_0001886
NIAID GSCID-BRC alternative term
obo:OBI_0001886
obo:IAO_0000122
obo:OBI_0001886
An alternative term used by the National Institute of Allergy and Infectious Diseases (NIAID) Genomic Sequencing Centers for Infectious Diseases (GSCID) and Bioinformatics Resource Centers (BRC).
obo:OBI_0001886
PERSON: Chris Stoeckert, Jie Zheng
obo:OBI_0001886
NIAID GSCID-BRC metadata working group
obo:OBI_0001886
NIAID GSCID-BRC alternative term
obo:OBI_0001928
selection
obo:OBI_0001928
PMID: 24023800. In this study, a set of eleven genes (VATP16, 60 S, UQCC, SMD3, EF1α, UBQ, SAND, GAPDH, ACT, PsaB, PTB2) was evaluated to identify reference genes during the first hours of interaction (6, 12, 18 and 24 hpi) between two V. vinifera genotypes and P. viticola. Two analyses were used for the selection of reference genes: direct comparison of susceptible, Trincadeira, and resistant, Regent, V. vinifera cultivars at 0 h, 6, 12, 18 and 24 hours post inoculation with P. viticola (genotype effect); and comparison of each genotype with mock inoculated samples during inoculation time-course (biotic stress effect). Three statistical methods were used, GeNorm, NormFinder, and BestKeeper, allowing to identify UBQ, EF1α and GAPDH as the most stable genes for the genotype effect.
obo:OBI_0001928
obo:IAO_0000122
obo:OBI_0001928
A planned process which results in the creation of group of entity from a larger group by the application of predefined criteria.
obo:OBI_0001928
this term refers to a planned process and therefore is distinct from the notion of 'natural selection', a process covering the operation of natural causes by which those individuals of a species that are best adapted to the environment tend to be preserved and to transmit their characters, while those less adapted die out, so that in the course of generations the degree of adaptation to the environment tends progressively to increase. (as defined by Oxford English Dictionary)
obo:OBI_0001928
Person: Philippe Rocca-Serra
obo:OBI_0001928
selection process
obo:OBI_0001928
OBI
obo:OBI_0001928
obo:obi.owl
obo:OBI_0001928
selection
obo:OBI_0001933
value specification
obo:OBI_0001933
The value of 'positive' in a classification scheme of "positive or negative"; the value of '20g' on the quantitative scale of mass.
obo:OBI_0001933
obo:IAO_0000122
obo:OBI_0001933
An information content entity that specifies a value within a classification scheme or on a quantitative scale.
obo:OBI_0001933
This term is currently a descendant of 'information content entity', which requires that it 'is about' something. A value specification of '20g' for a measurement data item of the mass of a particular mouse 'is about' the mass of that mouse. However there are cases where a value specification is not clearly about any particular. In the future we may change 'value specification' to remove the 'is about' requirement.
obo:OBI_0001933
PERSON:Bjoern Peters
obo:OBI_0001933
obo:obi.owl
obo:OBI_0001933
value specification
obo:OBI_0002555
age group inclusion criterion
obo:OBI_0002555
"18-33 years old"
obo:OBI_0002555
obo:IAO_0000123
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:OBI_0002555
A type of eligibility criteria that indicates the age a person must be to participate in a clinical study. This may be indicated by a specific age or the following age groups. The age groups are: Child (birth-17), Adult (18-64), Older Adult (65+).
obo:OBI_0002555
An inclusion criterion that defines and states an age bracket which, if met, makes an entity suitable for a given task or participation in a given process.
obo:OBI_0002555
Mathias Brochhausen
obo:OBI_0002555
#839
obo:OBI_0002555
obo:obi.owl
obo:OBI_0002555
ages eligible for study
obo:OBI_0002555
age group inclusion criterion
obo:OBI_0002555
https://www.who.int/ictrp/network/trds/en/
obo:OBI_0002556
minimum age value specification
obo:OBI_0002556
obo:IAO_0000123
obo:OBI_0002556
A value specifcation that specifies the youngest age when specifying an age range.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0002556
The numerical value, if any, for the minimum age a potential participant must meet to be eligible for the clinical study.
obo:OBI_0002556
Mathias Brochhausen
obo:OBI_0002556
obo:obi.owl
obo:OBI_0002556
minimum age
obo:OBI_0002556
minimum age value specification
obo:OBI_0002557
maximum age value specification
obo:OBI_0002557
obo:IAO_0000123
obo:OBI_0002557
A value specifcation that specifies the oldest age when specifying an age range.
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0002557
The numerical value, if any, for the maximum age a potential participant can be to be eligible for the clinical study.
obo:OBI_0002557
Mathias Brochhausen
obo:OBI_0002557
obo:obi.owl
obo:OBI_0002557
maximum age
obo:OBI_0002557
maximum age value specification
obo:OBI_0002561
sex inclusion criterion
obo:OBI_0002561
"included males and females", "included male patients"
obo:OBI_0002561
obo:IAO_0000123
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:OBI_0002561
A type of eligibility criteria that indicates the sex of people who may participate in a clinical study (all, female, male). Sex is a person's classification as female or male based on biological distinctions. Sex is distinct from gender-based eligibility.
obo:OBI_0002561
An inclusion criterion that defines and states one or more sexes which, if met, makes an entity suitable for a given task or participation in a given process.
obo:OBI_0002561
Mathias Brochhausen
obo:OBI_0002561
obo:obi.owl
obo:OBI_0002561
sexes eligible for study
obo:OBI_0002561
sex inclusion criterion
obo:OBI_0002561
https://www.who.int/ictrp/network/trds/en/
obo:OBI_0002624
case-control study design
obo:OBI_0002624
obo:IAO_0000120
obo:OBI_0002624
A study design that entails the creation of two types of roles, such that each participant under investigation bears one or the other. What distinguishes the two types of roles is an 'outcome', which is associated with participants that have the case role but not associated with participants that have the control role. A case-control study examines the hypothesis that the presence of the outcome in case participants is associated with an 'exposure' that is not associated with control participants.
obo:OBI_0002624
John Judkins, Bjoern Peters
obo:OBI_0002624
Wikipedia, OBI
obo:OBI_0002624
obo:obi.owl
obo:OBI_0002624
case-control study design
obo:OBI_0300311
observation design
obo:OBI_0300311
PMID: 12387964.Lancet. 2002 Oct 12;360(9340):1144-9.Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.
obo:OBI_0300311
obo:IAO_0000125
obo:OBI_0300311
observation design is a study design in which subjects are monitored in the absence of any active intervention by experimentalists.
obo:OBI_0300311
Philippe Rocca-Serra
obo:OBI_0300311
OBI branch derived
obo:OBI_0300311
obo:obi.owl
obo:OBI_0300311
observation design
obo:OBI_0300311
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0500000
study design
obo:OBI_0500000
a matched pairs study design describes criteria by which subjects are identified as pairs which then undergo the same protocols, and the data generated is analyzed by comparing the differences between the paired subjects, which constitute the results of the executed study design.
obo:OBI_0500000
obo:IAO_0000122
obo:OBI_0500000
A plan specification comprised of protocols (which may specify how and what kinds of data will be gathered) that are executed as part of an investigation and is realized during a study design execution.
obo:OBI_0500000
Editor note: there is at least an implicit restriction on the kind of data transformations that can be done based on the measured data available.
obo:OBI_0500000
PERSON: Chris Stoeckert
obo:OBI_0500000
experimental design
obo:OBI_0500000
rediscussed at length (MC/JF/BP). 12/9/08). The definition was clarified to differentiate it from protocol.
obo:OBI_0500000
obo:obi.owl
obo:OBI_0500000
obo:omiabis.owl
obo:OBI_0500000
study design
obo:OBI_0500000
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0500000
https://www.who.int/ictrp/network/trds/en/
obo:OBI_0500002
repeated measure design
obo:OBI_0500002
PMID: 10959922.J Biopharm Stat. 2000 Aug;10(3):433-45.Equivalence in test assay method comparisons for the repeated-measure, matched-pair design in medical device studies: statistical considerations.
obo:OBI_0500002
obo:IAO_0000120
obo:OBI_0500002
a study design which use the same individuals and exposure them to a set of conditions. The effect of order and practice can be confounding factor in such designs
obo:OBI_0500002
PlanAndPlannedProcess Branch
obo:OBI_0500002
http://www.holah.karoo.net/experimentaldesigns.htm
obo:OBI_0500002
obo:obi.owl
obo:OBI_0500002
repeated measure design
obo:OBI_0500003
cross over design
obo:OBI_0500003
PMID: 17601993-Objective: HIV-infected patients with lipodystrophy (HIV-lipodystrophy) are insulin resistant and have elevated plasma free fatty acid (FFA) concentrations. We aimed to explore the mechanisms underlying FFA-induced insulin resistance in patients with HIV-lipodystrophy. Research Design and Methods: Using a randomized placebo-controlled cross-over design, we studied the effects of an overnight acipimox-induced suppression of FFA on glucose and FFA metabolism by using stable isotope labelled tracer techniques during basal conditions and a two-stage euglycemic, hyperinsulinemic clamp (20 mU insulin/m(2)/min; 50 mU insulin/m(2)/min) in nine patients with nondiabetic HIV-lipodystrophy. All patients received antiretroviral therapy. Biopsies from the vastus lateralis muscle were obtained during each stage of the clamp. Results: Acipimox treatment reduced basal FFA rate of appearance by 68.9% (52.6%-79.5%) and decreased plasma FFA concentration by 51.6 % (42.0%-58.9%), (both, P < 0.0001). Endogenous glucose production was not influenced by acipimox. During the clamp the increase in glucose-uptake was significantly greater after acipimox treatment compared to placebo (acipimox: 26.85 (18.09-39.86) vs placebo: 20.30 (13.67-30.13) mumol/kg/min; P < 0.01). Insulin increased phosphorylation of Akt (Thr(308)) and GSK-3beta (Ser(9)), decreased phosphorylation of glycogen synthase (GS) site 3a+b and increased GS-activity (I-form) in skeletal muscle (P < 0.01). Acipimox decreased phosphorylation of GS (site 3a+b) (P < 0.02) and increased GS-activity (P < 0.01) in muscle. Conclusion: The present study provides direct evidence that suppression of lipolysis in patients with HIV-lipodystrophy improves insulin-stimulated peripheral glucose-uptake. The increased glucose-uptake may in part be explained by increased dephosphorylation of GS (site 3a+b) resulting in increased GS activity.
obo:OBI_0500003
obo:IAO_0000120
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0500003
Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study
obo:OBI_0500003
a repeated measure design which ensures that experimental units receive, in sequence, the treatment (or the control), and then, after a specified time interval (aka *wash-out periods*), switch to the control (or treatment). In this design, subjects (patients in human context) serve as their own controls, and randomization may be used to determine the ordering which a subject receives the treatment and control
obo:OBI_0500003
Philippe Rocca-Serra
obo:OBI_0500003
(source: http://www.sbu.se/Filer/Content0/publikationer/1/literaturesearching_1993/glossary.html)
obo:OBI_0500003
obo:obi.owl
obo:OBI_0500003
cross over design
obo:OBI_0500004
n-to-1 design
obo:OBI_0500004
obo:IAO_0000125
obo:OBI_0500004
N-of-1 design is a cross-over design in which the same patient is repeatedly randomised to receive either the experimental treatment or its control (Senn, 1993).
obo:OBI_0500004
Philippe Rocca-Serra
obo:OBI_0500004
Adapted from http://www.childrens-mercy.org/stats/definitions/crossover.htm and source:http://symptomresearch.nih.gov/chapter_6/sec1/csss1pg1.htm)
obo:OBI_0500004
obo:obi.owl
obo:OBI_0500004
n-to-1 design
obo:OBI_0500006
parallel group design
obo:OBI_0500006
PMID: 17408389-Purpose: Proliferative vitreoretinopathy (PVR) is the most important reason for blindness following retinal detachment. Presently, vitreous tamponades such as gas or silicone oil cannot contact the lower part of the retina. A heavier-than-water tamponade displaces the inflammatory and PVR-stimulating environment from the inferior area of the retina. The Heavy Silicone Oil versus Standard Silicone Oil Study (HSO Study) is designed to answer the question of whether a heavier-than-water tamponade improves the prognosis of eyes with PVR of the lower retina. Methods: The HSO Study is a multicentre, randomized, prospective controlled clinical trial comparing two endotamponades within a two-arm parallel group design. Patients with inferiorly and posteriorly located PVR are randomized to either heavy silicone oil or standard silicone oil as a tamponading agent. Three hundred and fifty consecutive patients are recruited per group. After intraoperative re-attachment, patients are randomized to either standard silicone oil (1000 cSt or 5000 cSt) or Densiron((R)) as a tamponading agent. The main endpoint criteria are complete retinal attachment at 12 months and change of visual acuity (VA) 12 months postoperatively compared with the preoperative VA. Secondary endpoints include complete retinal attachment before endotamponade removal, quality of life analysis and the number of retina affecting re-operation within 1 year of follow-up. Results: The design and early recruitment phase of the study are described. Conclusions: The results of this study will uncover whether or not heavy silicone oil improves the prognosis of eyes with PVR.
obo:OBI_0500006
obo:IAO_0000125
obo:OBI_0500006
A parallel group design or independent measure design is a study design which uses unique experimental unit each experimental group, in other word no two individuals are shared between experimental groups, hence also known as parallel group design. Subjects of a treatment group receive a unique combination of independent variable values making up a treatment
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0500006
Participants are assigned to one of two or more groups in parallel for the duration of the study
obo:OBI_0500006
Philippe Rocca-Serra
obo:OBI_0500006
independent measure design
obo:OBI_0500006
http://www.holah.karoo.net/experimentaldesigns.htm
obo:OBI_0500006
obo:obi.owl
obo:OBI_0500006
parallel group design
obo:OBI_0500014
factorial design
obo:OBI_0500014
PMID: 17582121-Our objective was to examine the effects of dietary cation-anion difference (DCAD) with different concentrations of dietary crude protein (CP) on performance and acid-base status in early lactation cows. Six lactating Holstein cows averaging 44 d in milk were used in a 6 x 6 Latin square design with a 2 x 3 factorial arrangement of treatments: DCAD of -3, 22, or 47 milliequivalents (Na + K - Cl - S)/100 g of dry matter (DM), and 16 or 19% CP on a DM basis. Linear increases with DCAD occurred in DM intake, milk fat percentage, 4% fat-corrected milk production, milk true protein, milk lactose, and milk solids-not-fat. Milk production itself was unaffected by DCAD. Jugular venous blood pH, base excess and HCO3(-) concentration, and urine pH increased, but jugular venous blood Cl- concentration, urine titratable acidity, and net acid excretion decreased linearly with increasing DCAD. An elevated ratio of coccygeal venous plasma essential AA to nonessential AA with increasing DCAD indicated that N metabolism in the rumen was affected, probably resulting in more microbial protein flowing to the small intestine. Cows fed 16% CP had lower urea N in milk than cows fed 19% CP; the same was true for urea N in coccygeal venous plasma and urine. Dry matter intake, milk production, milk composition, and acid-base status did not differ between the 16 and 19% CP treatments. It was concluded that DCAD affected DM intake and performance of dairy cows in early lactation. Feeding 16% dietary CP to cows in early lactation, compared with 19% CP, maintained lactation performance while reducing urea N excretion in milk and urine.
obo:OBI_0500014
obo:IAO_0000125
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0500014
Two or more interventions, each alone and in combination, are evaluated in parallel against a control group
obo:OBI_0500014
factorial design is_a study design which is used to evaluate two or more factors simultaneously. The treatments are combinations of levels of the factors. The advantages of factorial designs over one-factor-at-a-time experiments is that they are more efficient and they allow interactions to be detected. In statistics, a factorial design experiment is an experiment whose design consists of two or more factors, each with discrete possible values or levels, and whose experimental units take on all possible combinations of these levels across all such factors. Such an experiment allows studying the effect of each factor on the response variable, as well as the effects of interactions between factors on the response variable.
obo:OBI_0500014
Philippe Rocca-Serra
obo:OBI_0500014
http://www.stats.gla.ac.uk/steps/glossary/anova.html#facdes And from wikipedia (01/03/2007): http://en.wikipedia.org/wiki/Factorial_experiment)
obo:OBI_0500014
obo:obi.owl
obo:OBI_0500014
factorial design
obo:OBI_0500026
eligibility criterion
obo:OBI_0500026
PMID: 17579629 -Eligibility criteria included: untreated ED-SCLC; age >/=70 and performance status 0-2, or age <70 and PS 3.
obo:OBI_0500026
obo:IAO_0000122
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OBI_0500026
A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest.
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:OBI_0500026
The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex
obo:OBI_0500026
an eligibility criterion (rule) is_a selection criterion which
defines and states the requirements (positive or negative) for an entity to be considered as suitable for a given task or participation in a process.
obo:OBI_0500026
Person: Philippe Rocca-Serra
obo:OBI_0500026
eligibility rule
obo:OBI_0500026
Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group
obo:OBI_0500026
obo:obi.owl
obo:OBI_0500026
eligibility criterion
obo:OBI_0500027
inclusion criterion
obo:OBI_0500027
PMID: 23979341-The major inclusion criterion was patients in whom severe cerebral embolism was diagnosed at age 75 or younger (more than 9 in the NIHSS score on day 7 after the onset of stroke) .
obo:OBI_0500027
obo:IAO_0000125
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:OBI_0500027
A type of eligibility criteria. These are the reasons that a person is allowed to participate in a clinical study.
obo:OBI_0500027
an inclusion criterion (rule) is_a *eligibility criterion* which defines and states a condition which, if met, makes an entity suitable for a given task or participation in a given process. For instance, in a study protocol, inclusion criteria indicate the conditions that prospective subjects MUST meet to be eligible for participation in a study.
obo:OBI_0500027
Person: Philippe Rocca-Serra
obo:OBI_0500027
inclusion condition
obo:OBI_0500027
inclusion rule
obo:OBI_0500027
Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group
obo:OBI_0500027
obo:obi.owl
http://www.icmje.org/recommendations/
https://www.who.int/ictrp/network/trds/en/
obo:OBI_0500027
key inclusion criteria
obo:OBI_0500027
inclusion criterion
obo:OBI_0500028
exclusion rule
obo:OBI_0500028
PMID: 17600285-Exclusion criteria included the use of any topical ophthalmic or topical oral medication and/or history of ocular or oral surgery within the past six months.
obo:OBI_0500028
obo:IAO_0000125
https://clinicaltrials.gov/ct2/about-studies/glossary
obo:OBI_0500028
A type of eligibility criteria. These are reasons that a person is not allowed to participate in a clinical study.
obo:OBI_0500028
an exclusion criterion (rule) is_a *eligibility criterion* which defines and states a condition which, if met, makes an entity unsuitable for a given task or participation in a given process. For instance, in a study protocol, exclusion criteria indicate the conditions that prospective subjects SHOULD NOT meet to be eligible for participation in a study
obo:OBI_0500028
Person: Philippe Rocca-Serra
obo:OBI_0500028
Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group
obo:OBI_0500028
obo:obi.owl
http://www.icmje.org/recommendations/
https://www.who.int/ictrp/network/trds/en/
obo:OBI_0500028
key exclusion criteria
obo:OBI_0500028
exclusion criterion
obo:OBI_0600004
human subject enrollment
obo:OBI_0600004
enlisting familiy members of HIV patients into a study
obo:OBI_0600004
obo:IAO_0000122
obo:OBI_0600004
A planned process with the objective to obtain a population of human subjects to participate in an investigation by determining eligibility of subjects and obtaining informed consent.
obo:OBI_0600004
As with group assignment, should the specified output here be an organism which bears a role
obo:OBI_0600004
Bjoern Peters
obo:OBI_0600004
IEDB
obo:OBI_0600004
criteria come from plan / clinical trial branch
obo:OBI_0600004
obo:obi.owl
obo:OBI_0600004
human subject enrollment
obo:OBI_9991118
IEDB alternative term
obo:OBI_9991118
obo:IAO_0000122
obo:OBI_9991118
An alternative term used by the IEDB.
obo:OBI_9991118
PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters
obo:OBI_9991118
IEDB
obo:OBI_9991118
IEDB alternative term
obo:OGMS_0000014
A representation that is either the output of a clinical history taking or a physical examination or an image finding, or some combination thereof.
obo:OGMS_0000014
Albert Goldfain
obo:OGMS_0000014
http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf
obo:OGMS_0000014
creation date: 2010-07-19T10:18:02Z
obo:OGMS_0000014
obo:ogms.owl
obo:OGMS_0000014
clinical finding
obo:OGMS_0000015
A series of statements representing health-relevant qualities of a patient and of a patient's family.
obo:OGMS_0000015
Albert Goldfain
obo:OGMS_0000015
http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf
obo:OGMS_0000015
creation date: 2010-07-19T10:18:59Z
obo:OGMS_0000015
obo:ogms.owl
obo:OGMS_0000015
clinical history
obo:OGMS_0000019
A representation of a quality of a patient that is (1) recorded by a clinician because the quality is hypothesized to be of clinical significance and (2) refers to qualities obtaining in the patient prior to their becoming detectable in a clinical history taking or physical examination.
obo:OGMS_0000019
Albert Goldfain
obo:OGMS_0000019
http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf
obo:OGMS_0000019
creation date: 2009-06-23T10:22:44Z
obo:OGMS_0000019
obo:ogms.owl
obo:OGMS_0000019
preclinical finding
obo:OGMS_0000031
A disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism.
obo:OGMS_0000031
Albert Goldfain
obo:OGMS_0000031
http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf
obo:OGMS_0000031
creation date: 2009-06-23T11:21:20Z
obo:OGMS_0000031
obo:ogms.owl
obo:OGMS_0000031
disease
obo:OGMS_0000060
Albert Goldfain
obo:OGMS_0000060
creation date: 2009-06-23T11:53:49Z
obo:OGMS_0000060
obo:oae.owl
obo:OGMS_0000060
obo:ogms.owl
obo:OGMS_0000060
bodily process
obo:OGMS_0000061
A bodily process that is clinically abnormal.
obo:OGMS_0000061
Albert Goldfain
obo:OGMS_0000061
http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf
obo:OGMS_0000061
creation date: 2009-06-23T11:54:29Z
obo:OGMS_0000061
obo:oae.owl
obo:OGMS_0000061
obo:ogms.owl
obo:OGMS_0000061
pathological bodily process
https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf
obo:OGMS_0000073
1. the determination of the nature of a case of disease.
2. the art of distinguishing one disease from another.
obo:OGMS_0000073
The representation of a conclusion of a diagnostic process.
obo:OGMS_0000073
Albert Goldfain
obo:OGMS_0000073
http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf
obo:OGMS_0000073
creation date: 2009-06-23T12:42:23Z
obo:OGMS_0000073
obo:ogms.owl
obo:OGMS_0000073
diagnosis
obo:OMIABIS_0001019
A study design that involves repeated observations of the same entity over time. In the biobank context, longitudinal studies sample a group of people in a given time period, and study them at intervals by the acquisition and analyses of data and/or samples over time.
obo:OMIABIS_0001019
Alice Nzinga
obo:OMIABIS_0001019
obo:omiabis.owl
obo:OMIABIS_0001019
longitudinal study design
obo:OMIABIS_0001020
A longitudinal study that aims to study a case-defined population who presently have a certain condition or recepient of a particular treatment that are followed over time and are compared with a similar group who do not have condition.
obo:OMIABIS_0001020
obo:omiabis.owl
obo:OMIABIS_0001020
cohort study design
obo:OMRSE_00000024
A role inhering in an entity realized by social interactions in human society.
obo:OMRSE_00000024
Mathias Brochhausen
obo:OMRSE_00000024
obo:omrse.owl
obo:OMRSE_00000024
Previous definition: A role played by an entity in human social processes.
obo:OMRSE_00000024
role in human social processes
obo:OMRSE_00000038
A role borne by a human individual or by a collection of humans regarded as possessing rights and duties enforeable at law.
obo:OMRSE_00000038
Mathias Brochhausen
obo:OMRSE_00000038
Malcolm N. Shaw: International Law. Cambridge University Press, Cambridge, 2008.
obo:OMRSE_00000038
obo:omrse.owl
obo:OMRSE_00000038
We are aware of the fact that Wikipedia's definition differs from ours by saying that "Legal personality (...) is the characteristic of a non-living entity regarded by law to have the status of personhood" (http://en.wikipedia.org/wiki/Legal_personality)
However, Shaw explicates:
"In any legal system, certain entities, whether they be individuals or companies, will be regarded as possessing rights and duties enforceable at law. Thus an individual may prosecute or be prosecuted for assault and a company can sue for breach of contract. They are able to do this because the law recognises them as 'legal persons' possessing the capacity to have and to maintain certain rights, and being subject to perform specific duties. (...) In municipal law individuals, limited companies and public corporations are recognized as each possessing a distinct legal personality, the terms of which are circumscribed by the relevant legislation" (Shaw MN: International Law. Sixth Edition. Cambridge University Press, Cambridge, 2008). We hold that Shaw's position is ontological more prolific since it not only allows to explain how groups of individuals become recognized as unities at law, but also how different individuals can hold different legal personality roles (always against the context of one legal system). The latter will proof useful when dealing with the representing comatous patients or minorsat law in ontologies.
obo:OMRSE_00000038
legal person role
obo:OPMI_0000112
A telephone number is a sequence of digits assigned to a fixed-line telephone subscriber station connected to a telephone line or to a wireless electronic telephony device, such as a radio telephone or a mobile telephone, or to other devices for data transmission via the public switched telephone network (PSTN) or other public and private networks.
obo:OPMI_0000112
Oliver He
obo:OPMI_0000112
phone number
obo:OPMI_0000112
https://en.wikipedia.org/wiki/Telephone_number
obo:OPMI_0000112
obo:opmi.owl
obo:OPMI_0000112
telephone number
obo:OPMI_0000223
The textual name of the contact person or organization
obo:OPMI_0000223
obo:opmi.owl
obo:OPMI_0000223
contact name
obo:OPMI_0000282
The medical state or condition of a patient
obo:OPMI_0000282
Oliver He, Edison Ong
obo:OPMI_0000282
medical state
obo:OPMI_0000282
https://en.wikipedia.org/wiki/Medical_state
obo:OPMI_0000282
obo:opmi.owl
obo:OPMI_0000282
medical condition
obo:OPMI_0000293
A person who performs an investigation task and takes the role of an investigator role.
obo:OPMI_0000293
obo:opmi.owl
obo:OPMI_0000293
investigator
obo:OPMI_0000294
An investigator who is involved in a clinical trial and is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator's care; and for the control of drugs under investigation.
obo:OPMI_0000294
Oliver He
obo:OPMI_0000294
https://en.wikipedia.org/wiki/Clinical_investigator
obo:OPMI_0000294
obo:opmi.owl
obo:OPMI_0000294
clinical investigator
obo:OPMI_0000296
The (estimated) date on which the clinical study is open for recruitment of participants, or the actual date on which the first participant is enrolled.
obo:OPMI_0000296
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000296
obo:opmi.owl
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:OPMI_0000296
date of first enrollment
obo:OPMI_0000296
study start
obo:OPMI_0000296
clinical trial start date
obo:OPMI_0000297
The date on which a study completes
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000297
The date the final participant was examined or received an intervention for purposes of final collection of data for the primary and secondary outcome measures and adverse events (for example, last participant’s last visit), whether the clinical study concluded according to the pre-specified protocol or was terminated.
obo:OPMI_0000297
Oliver He
obo:OPMI_0000297
obo:opmi.owl
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:OPMI_0000297
Completion Date
obo:OPMI_0000297
study completion
obo:OPMI_0000297
study completion date
https://www.clinicaltrials.gov/ct2/about-studies/glossary
obo:OPMI_0000302
The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
obo:OPMI_0000302
a date when a registration occurs
obo:OPMI_0000302
obo:opmi.owl
obo:OPMI_0000302
First submitted
https://www.who.int/ictrp/network/trds/en/
obo:OPMI_0000302
date of registration in primary registry
obo:OPMI_0000302
date of registration
obo:OPMI_0000304
The current stage of a clinical study and whether it is or will be open for enrollment
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000304
The recruitment status for the clinical study as a whole, based upon the status of the individual sites. If at least one facility in a multi-site clinical study has an Individual Site Status of "Recruiting," then the Overall Recruitment Status for the study must be "Recruiting."
obo:OPMI_0000304
Oliver He
obo:OPMI_0000304
https://clinicaltrials.gov/ct2/help/glossary/recruitment-status
obo:OPMI_0000304
obo:opmi.owl
obo:OPMI_0000304
recruitment status
obo:OPMI_0000304
http://www.icmje.org/recommendations/
http://www.who.int/ictrp/network/trds/en/index.html
obo:OPMI_0000326
Oliver He, Edison Ong
obo:OPMI_0000326
obo:opmi.owl
obo:OPMI_0000326
status
obo:OPMI_0000327
The current stage of a clinical study and whether it is or will be open for enrollment
obo:OPMI_0000327
Oliver He
obo:OPMI_0000327
https://clinicaltrials.gov/ct2/help/glossary/recruitment-status
obo:OPMI_0000327
obo:opmi.owl
obo:OPMI_0000327
study status
obo:OPMI_0000364
An annotation property that refers to a code defined by NCIT
obo:OPMI_0000364
NCIT code
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000365
Combining a drug and device, a biological product and device; a drug and biological product; or a drug, biological product, and device
obo:OPMI_0000365
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000365
obo:opmi.owl
obo:OPMI_0000365
combinational intervention
obo:OPMI_0000366
has process quality
obo:OPMI_0000376
A medical intervention that involves a behavioral process to control, prevent, or treat a behavior problem.
obo:OPMI_0000376
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000376
https://www.understood.org/en/learning-attention-issues/treatments-approaches/educational-strategies/behavior-intervention-plans-what-you-need-to-know
obo:OPMI_0000376
obo:opmi.owl
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000376
behavioral
obo:OPMI_0000376
behavioral intervention
obo:OPMI_0000381
obo:opmi.owl
obo:OPMI_0000381
human subject
obo:OPMI_0000383
In clinicaltrials.gov, contact information character limits:
First Name: 62 characters
Last Name: 62 characters
Degree: 30 characters
Phone: 30 characters
Phone Ext: 14 characters
Email: 254 characters
Citation: https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials
obo:OPMI_0000383
A person who serves as a contact role and has disclosed specified information to be reached. Usually the contact information, such as email and phone number, is provided.,
obo:OPMI_0000383
Leon, Asiyah, Oliver: Since each contact needs to provide some contact information, we may need to define the contact information.
obo:OPMI_0000383
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000383
https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials
obo:OPMI_0000383
obo:opmi.owl
obo:OPMI_0000383
contact person
obo:OPMI_0000384
A contact person for each facility participating in a study.
obo:OPMI_0000384
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000384
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000384
obo:opmi.owl
obo:OPMI_0000384
facility contact
obo:OPMI_0000389
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000389
https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials
obo:OPMI_0000389
obo:opmi.owl
obo:OPMI_0000389
contact of scientific queries
obo:OPMI_0000390
An investigation agent role that is taken by a human individual
obo:OPMI_0000390
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000390
human investigator role
obo:OPMI_0000390
obo:opmi.owl
obo:OPMI_0000390
investigator role
obo:OPMI_0000391
a role taken by a person who serves as a contact for some process.
obo:OPMI_0000391
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000391
obo:opmi.owl
obo:OPMI_0000391
contact person role
obo:OPMI_0000393
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000393
https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials
obo:OPMI_0000393
obo:opmi.owl
obo:OPMI_0000393
contact for public queries
obo:OPMI_0000395
A person to whom questions concerning enrollment at any location of the study can be addressed.
obo:OPMI_0000395
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000395
central contact person
obo:OPMI_0000395
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000395
obo:opmi.owl
obo:OPMI_0000395
central contact person of study
obo:OPMI_0000397
information content entity about a contact person
obo:OPMI_0000397
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000397
obo:opmi.owl
obo:OPMI_0000397
contact person information
obo:OPMI_0000398
A sponsor role taken by an individual, organization, group or other legal entity which takes responsibility for initiating, managing and/or financing a study. The Primary Sponsor is responsible for ensuring that the trial is properly registered. The Primary Sponsor may or may not be the main funder.
obo:OPMI_0000398
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000398
https://www.who.int/ictrp/network/trds/en/
obo:OPMI_0000398
obo:opmi.owl
obo:OPMI_0000398
primary sponsor role
obo:OPMI_0000399
A sponsor role taken by an additional individual, organization or another legal person, if any, that has agreed with the primary sponsor to take on responsibilities of sponsorship.
obo:OPMI_0000399
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000399
collaborator role
obo:OPMI_0000399
https://www.who.int/ictrp/network/trds/en/
obo:OPMI_0000399
obo:opmi.owl
obo:OPMI_0000399
A secondary sponsor may have agreed to:
- take on all the responsibilities of sponsorship jointly with the primary sponsor; or
- form a group with the Primary Sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or
- act as the Primary Sponsor’s legal representative in relation to some or all of the trial sites.
by WHO (https://www.who.int/ictrp/network/trds/en/)
obo:OPMI_0000399
In clinicaltrials.gov, the secondary sponsor role can be taken by a project collaborator (Reference: https://prsinfo.clinicaltrials.gov/trainTrainer/WHO-ICMJE-ClinTrialsgov-Cross-Ref.pdf). However, a secondary sponsor may serve as a collaborator role, but a collaborator may not serve as a secondary sponsor role.
obo:OPMI_0000399
secondary sponsor role
obo:OPMI_0000400
An investigator role taken by an individual who is designated as responsible party by the sponsor
obo:OPMI_0000400
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000400
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000400
obo:opmi.owl
obo:OPMI_0000400
principal investigator role
obo:OPMI_0000401
An investigator role taken by an individual who both initiates and conducts the study
obo:OPMI_0000401
Leon Li, Asiyah Lin, Oliver He
obo:OPMI_0000401
https://prsinfo.clinicaltrials.gov/definitions.html
obo:OPMI_0000401
obo:opmi.owl
obo:OPMI_0000401
sponsor investigator role
obo:OPMI_0000402
An investigation agent role taken by an agent (an individual, organization, group or another legal entity) who provides support to an investigation. The support may include funding, design, implementation, data analysis or reporting. The responsible party is responsible for confirming all collaborators before listing them.
obo:OPMI_0000402
Leon Li, Asiyah Li, Oliver He
obo:OPMI_0000402
collaborator role
obo:OPMI_0000402
https://prsinfo.clinicaltrials.gov/definitions.html#Collaborators
obo:OPMI_0000402
https://www.who.int/ictrp/network/trds/en/
obo:OPMI_0000402
obo:opmi.owl
obo:OPMI_0000402
A secondary sponsor may serve as a collaborator role. However, a collaborator may not serve as a secondary sponsor role.
obo:OPMI_0000402
investigation collaborator role
obo:OPMI_0000418
A systematic, scientific investigation that can be either interventional or observational and involves human beings as research subjects. Human subject research can be either medical (clinical) research or non-medical (e.g., social science) research.
obo:OPMI_0000418
Oliver He
obo:OPMI_0000418
human investigation
obo:OPMI_0000418
human study
obo:OPMI_0000418
https://en.wikipedia.org/wiki/Human_subject_research
obo:OPMI_0000418
obo:opmi.owl
obo:OPMI_0000418
human subject study
obo:PATO_0000047
An organismal quality inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved.
obo:PATO_0000047
obo:pato.owl
obo:PATO_0000047
quality
obo:PATO_0000047
PATO:0000047
obo:PATO_0000047
http://purl.oboInOwllibrary.org/oboInOwl/pato#attribute_slim
obo:PATO_0000047
biological sex
obo:PATO_0000383
A biological sex quality inhering in an individual or a population that only produces gametes that can be fertilised by male gametes.
obo:PATO_0000383
obo:pato.owl
obo:PATO_0000383
quality
obo:PATO_0000383
PATO:0000383
obo:PATO_0000383
http://purl.oboInOwllibrary.org/oboInOwl/pato#mpath_slim
obo:PATO_0000383
http://purl.oboInOwllibrary.org/oboInOwl/pato#value_slim
obo:PATO_0000383
female
obo:PATO_0000384
A biological sex quality inhering in an individual or a population whose sex organs contain only male gametes.
obo:PATO_0000384
obo:pato.owl
obo:PATO_0000384
quality
obo:PATO_0000384
PATO:0000384
obo:PATO_0000384
http://purl.oboInOwllibrary.org/oboInOwl/pato#mpath_slim
obo:PATO_0000384
http://purl.oboInOwllibrary.org/oboInOwl/pato#value_slim
obo:PATO_0000384
male
obo:PATO_0001236
A quality which inheres in an process.
obo:PATO_0001236
obo:pato.owl
obo:PATO_0001236
PATO:0001239
obo:PATO_0001236
PATO:0001240
obo:PATO_0001236
quality of a process
obo:PATO_0001236
quality of occurrent
obo:PATO_0001236
quality of process
obo:PATO_0001236
relational quality of occurrent
obo:PATO_0001236
quality
obo:PATO_0001236
PATO:0001236
obo:PATO_0001236
See comments of relational quality of a physical entity.
obo:PATO_0001236
process quality
obo:PATO_0001241
A quality which inheres in a continuant.
obo:PATO_0001241
obo:pato.owl
obo:PATO_0001241
PATO:0001237
obo:PATO_0001241
PATO:0001238
obo:PATO_0001241
snap:Quality
obo:PATO_0001241
monadic quality of a continuant
obo:PATO_0001241
multiply inhering quality of a physical entity
obo:PATO_0001241
quality of a continuant
obo:PATO_0001241
quality of a single physical entity
obo:PATO_0001241
quality of an object
obo:PATO_0001241
quality of continuant
obo:PATO_0001241
monadic quality of an object
obo:PATO_0001241
monadic quality of continuant
obo:PATO_0001241
quality
obo:PATO_0001241
PATO:0001241
obo:PATO_0001241
Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles.
obo:PATO_0001241
physical object quality
obo:PATO_0001894
An organismal quality inhering in a bearer by virtue of the bearer's physical expression of sexual characteristics.
obo:PATO_0001894
obo:pato.owl
obo:PATO_0001894
quality
obo:PATO_0001894
PATO:0001894
obo:PATO_0001894
http://purl.oboInOwllibrary.org/oboInOwl/pato#attribute_slim
obo:PATO_0001894
phenotypic sex
obo:PATO_0001995
A quality that inheres in an entire organism or part of an organism.
obo:PATO_0001995
obo:pato.owl
obo:PATO_0001995
quality
obo:PATO_0001995
PATO:0001995
obo:PATO_0001995
organismal quality
obo:PDRO_0000129
obo:IAO_0000123
obo:PDRO_0000129
An information content entity that describes some relationships between some entities and whose truthfullness is a prerequisite for something.
obo:PDRO_0000129
Une entité de contenu informationnel qui décrit des relations entre certaines entités et dont la véracité est un prérequis pour quelque chose.
obo:PDRO_0000129
obo:pdro.owl
obo:PDRO_0000129
condition
obo:PDRO_0000129
condition
obo:RO_0000057
has participant
obo:RO_0000059
concretizes
obo:RO_0000087
has role
obo:RO_0002248
Any portion of roundup 'has active ingredient' some glyphosate
obo:RO_0002248
A relationship that holds between a substance and a chemical entity, if the chemical entity is part of the substance, and the chemical entity forms the biologically active component of the substance.
obo:RO_0002248
obo:ro.owl
obo:RO_0002248
has active substance
obo:RO_0002248
has active pharmaceutical ingredient
obo:RO_0002248
has active ingredient
obo:RO_0002249
active ingredient in
obo:VO_0000002
a medical intervention that involves in adding vaccine into a host (e.g., human, mouse) in vivo with the intent to invoke an adaptive immune response.
obo:VO_0000002
obo:oae.owl
obo:VO_0000002
obo:vo.owl
obo:VO_0000002
vaccination
obo:VO_0000002
https://prsinfo.clinicaltrials.gov/definitions.html
obo:VO_0000427
A vaccine clinical trial that investigates the safety profile of a vaccine in a small group (10-50) of healthy volunteers.
obo:VO_0000427
YH
obo:VO_0000427
obo:vo.owl
obo:VO_0000427
phase 1 vaccine trial
obo:VO_0000428
A vaccine clinical trial that studies vaccine efficacy with a target population (numbering 50-100). Different dosage levels will also be explored at this stage to determine the optimum dose.
obo:VO_0000428
YH
obo:VO_0000428
obo:vo.owl
obo:VO_0000428
phase 2 vaccine trial
obo:VO_0000429
A vaccine clinical trial that takes the trial to a large-scale safety and efficacy study in a relevant patient population, usually in excess of 3,000.
obo:VO_0000429
YH
obo:VO_0000429
obo:vo.owl
obo:VO_0000429
phase 3 vaccine trial
obo:VO_0000430
The final stage of vaccine clinical evaluation. Phase IV occurs after a vaccine or therapy is licensed and is being used by large numbers of people. These studies are not always required or completed.
obo:VO_0000430
YH
obo:VO_0000430
obo:vo.owl
obo:VO_0000430
phase 4 vaccine trial
obo:VO_0000596
A processual entity by which a vaccine is tested clinically for safety and effectiveness. Clinical trials are conducted in phases. Classically, clinical trials unfold in three phases in order to gather data and information about a vaccine and its performance. This will form the basis of a dossier submitted to regulatory authorities by way of an application for licensure. After a vaccine is licensed and is being used by large numbers of people, a Phase IV study may or may not be taken for vaccine clinical evaluation.
obo:VO_0000596
Most vaccines against a pathogen (e.g., HIV) are not tested by vaccinating people and then deliberately exposing them to virulent pathogen (e.g., HIV). This strategy is never for a vaccine against a disease as serious as HIV.
The best way to determine if a vaccine is effective is to test it in a randomized, controlled, double-blind clinical trial. This type of trial is often referred to as the gold standard in medical research and provides the strongest evidence for the efficacy of a vaccine.
obo:VO_0000596
YH
obo:VO_0000596
obo:vo.owl
obo:VO_0000596
vaccine clinical trial
obo:omrse.owl
The Ontology of Medically Related Social Entities
http://purl.obolibrary.org/obo/ncbitaxon#has_rank
A metadata relation between a class and its taxonomic rank (eg species, family)
http://purl.obolibrary.org/obo/ncbitaxon#has_rank
ncbi_taxonomy
http://purl.obolibrary.org/obo/ncbitaxon#has_rank
has_rank
dc:description
Description may include but is not limited to: an abstract,
table of contents, reference to a graphical representation
of content or a free-text account of the content.
dc:description
An account of the content of the resource.
dc:description
dc:
dc:description
Description
dc:description
Description
dc:source
The present resource may be derived from the Source resource
in whole or in part. Recommended best practice is to reference
the resource by means of a string or number conforming to a
formal identification system.
dc:source
A reference to a resource from which the present resource
is derived.
dc:source
dc:
dc:source
Source
dc:source
Source
https://prsinfo.clinicaltrials.gov/definitions.html
http://purl.org/net/OCRe/research.owl#Case_control_study
Group of individuals with specific characteristics (for example, conditions or exposures) compared to group(s) with different characteristics, but otherwise similar.
https://prsinfo.clinicaltrials.gov/definitions.html
http://purl.org/net/OCRe/research.owl#Case_crossover_study
Characteristics of case immediately prior to disease onset (sometimes called the hazard period) compared to characteristics of same case at a prior time (that is, control period).
https://prsinfo.clinicaltrials.gov/definitions.html
http://purl.org/net/OCRe/research.owl#Cohort_study
Group of individuals, initially defined and composed, with common characteristics (for example, condition, birth year), who are examined or traced over a given time period.
https://prsinfo.clinicaltrials.gov/definitions.html
http://purl.org/net/OCRe/research.owl#Parallel_group_study
Participants are assigned to one of two or more groups in parallel for the duration of the study
https://prsinfo.clinicaltrials.gov/definitions.html
http://purl.org/net/OCRe/study_design.owl#Crossover_study
Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study
https://prsinfo.clinicaltrials.gov/definitions.html
http://purl.org/net/OCRe/study_design.owl#Single_group_study
Clinical trials with a single arm
oboInOwl:hasAlternativeId
has_alternative_id
oboInOwl:hasDbXref
database_cross_reference
oboInOwl:hasExactSynonym
A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software.
oboInOwl:hasExactSynonym
Fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software.
oboInOwl:hasExactSynonym
FULL_SYN
oboInOwl:hasExactSynonym
Synonym with Source Data
oboInOwl:hasExactSynonym
has exact synonym
oboInOwl:hasExactSynonym
has_exact_synonym
oboInOwl:hasNarrowSynonym
has_narrow_synonym
oboInOwl:hasOBONamespace
has_obo_namespace
oboInOwl:hasRelatedSynonym
has_related_synonym
oboInOwl:inSubset
An association that connects the concept defining a particular terminology subset with concepts that belong to this subset.
oboInOwl:inSubset
Used to associate the concept defining a particular terminology subset with concepts that belong to this subset.
oboInOwl:inSubset
Concept_In_Subset
oboInOwl:inSubset
in subset
oboInOwl:inSubset
in_subset
oboInOwl:shorthand
shorthand
rdfs:label
label
rdfs:label
label
rdfs:label
label
rdfs:subClassOf
obo:gaz.owl
rdfs:subClassOf
obo:opmi.owl
obo:CTO_0000021
A centrally registered identifier that is assigned for a specific clinical trial registered in the Korean Clinical Research Information Service (CRIS). The format for the registry number is “KCT” followed by a 7-digit number, e.g., KCT0004537.
obo:CTO_0000021
CRIS identifier
obo:CTO_0000021
Korean clinical trial registry identifier
obo:CTO_0000021
http://cris.nih.go.kr/cris/en/use_guide/cris_introduce.jsp
obo:CTO_0000027
A centrally registered identifier that is assigned for a specific clinical trial registered in the Sri Lanka clinical trials registry (SLCTR ). The format for the registry number is “SLCTR /” followed by a 4-digit number, followed by a slash, followed a 3-digit number, e.g., SLCTR/2020/010
obo:CTO_0000027
SLCTR identifier
obo:CTO_0000027
Sri Lanka clinical trials registry identifier
obo:CTO_0000027
https://slctr.lk/
obo:CTO_0000029
The jRTC (Japan Registry of Clinical Trials) clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000029
Japan Registry of Clinical Trials
obo:CTO_0000029
jRTC
obo:CTO_0000029
jRTC clinical trials register
obo:CTO_0000029
https://jrct.niph.go.jp/
obo:CTO_0000029
https://rctportal.niph.go.jp/en/
obo:CTO_0000042
The international standard randomised controlled trial register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.
obo:CTO_0000042
ISRCTN
obo:CTO_0000042
International standard randomised controlled trial register
obo:CTO_0000042
http://www.isrctn.com/
obo:obi.owl
obo:omrse.owl
xsd:boolean
xsd:anyURI
xsd:string
obo:NCIT_Semantic_Type-enum
xsd:string
xsd:string
xsd:string
xsd:string
obo:NCIT_Contributing_Source-enum
obo:NCIT_textArea
xsd:string
xsd:string
obo:NCIT_textArea
xsd:string